id	sid	tid	token	lemma	pos
ajlm-933	1	1	abstract	abstract	ADJ
ajlm-933	1	2	introduction	introduction	NOUN
ajlm-933	1	3	methods	method	NOUN
ajlm-933	1	4	results	result	VERB
ajlm-933	1	5	discussion	discussion	NOUN
ajlm-933	1	6	acknowledgements	acknowledgement	NOUN
ajlm-933	1	7	references	reference	NOUN
ajlm-933	1	8	about	about	ADP
ajlm-933	1	9	the	the	DET
ajlm-933	1	10	author(s	author(s	PROPN
ajlm-933	1	11	)	)	PUNCT
ajlm-933	1	12	samson	samson	PROPN
ajlm-933	1	13	m.	m.	PROPN
ajlm-933	1	14	haumba	haumba	PROPN
ajlm-933	1	15	university	university	PROPN
ajlm-933	1	16	research	research	PROPN
ajlm-933	1	17	co.	co.	PROPN
ajlm-933	1	18	,	,	PUNCT
ajlm-933	1	19	llc	llc	PROPN
ajlm-933	1	20	,	,	PUNCT
ajlm-933	1	21	mbabane	mbabane	NOUN
ajlm-933	1	22	,	,	PUNCT
ajlm-933	1	23	eswatini	eswatini	PROPN
ajlm-933	1	24	mitsuru	mitsuru	PROPN
ajlm-933	1	25	toda	toda	PROPN
ajlm-933	1	26	epidemic	epidemic	PROPN
ajlm-933	1	27	intelligence	intelligence	PROPN
ajlm-933	1	28	service	service	NOUN
ajlm-933	1	29	(	(	PUNCT
ajlm-933	1	30	eis	eis	PROPN
ajlm-933	1	31	)	)	PUNCT
ajlm-933	1	32	,	,	PUNCT
ajlm-933	1	33	division	division	NOUN
ajlm-933	1	34	of	of	ADP
ajlm-933	1	35	scientific	scientific	ADJ
ajlm-933	1	36	education	education	NOUN
ajlm-933	1	37	and	and	CCONJ
ajlm-933	1	38	professional	professional	ADJ
ajlm-933	1	39	development	development	NOUN
ajlm-933	1	40	,	,	PUNCT
ajlm-933	1	41	center	center	NOUN
ajlm-933	1	42	for	for	ADP
ajlm-933	1	43	surveillance	surveillance	NOUN
ajlm-933	1	44	,	,	PUNCT
ajlm-933	1	45	epidemiology	epidemiology	NOUN
ajlm-933	1	46	,	,	PUNCT
ajlm-933	1	47	and	and	CCONJ
ajlm-933	1	48	laboratory	laboratory	NOUN
ajlm-933	1	49	services	service	NOUN
ajlm-933	1	50	(	(	PUNCT
ajlm-933	1	51	csels	csel	NOUN
ajlm-933	1	52	)	)	PUNCT
ajlm-933	1	53	,	,	PUNCT
ajlm-933	1	54	centers	center	NOUN
ajlm-933	1	55	for	for	ADP
ajlm-933	1	56	disease	disease	NOUN
ajlm-933	1	57	control	control	NOUN
ajlm-933	1	58	and	and	CCONJ
ajlm-933	1	59	prevention	prevention	NOUN
ajlm-933	1	60	(	(	PUNCT
ajlm-933	1	61	cdc	cdc	PROPN
ajlm-933	1	62	)	)	PUNCT
ajlm-933	1	63	,	,	PUNCT
ajlm-933	1	64	atlanta	atlanta	PROPN
ajlm-933	1	65	,	,	PUNCT
ajlm-933	1	66	georgia	georgia	PROPN
ajlm-933	1	67	,	,	PUNCT
ajlm-933	1	68	united	united	PROPN
ajlm-933	1	69	states	states	PROPN
ajlm-933	1	70	mycotic	mycotic	ADJ
ajlm-933	1	71	diseases	disease	NOUN
ajlm-933	1	72	branch	branch	NOUN
ajlm-933	1	73	(	(	PUNCT
ajlm-933	1	74	mdb	mdb	PROPN
ajlm-933	1	75	)	)	PUNCT
ajlm-933	1	76	,	,	PUNCT
ajlm-933	1	77	division	division	NOUN
ajlm-933	1	78	of	of	ADP
ajlm-933	1	79	foodborne	foodborne	ADJ
ajlm-933	1	80	,	,	PUNCT
ajlm-933	1	81	waterborne	waterborne	NOUN
ajlm-933	1	82	,	,	PUNCT
ajlm-933	1	83	and	and	CCONJ
ajlm-933	1	84	environmental	environmental	ADJ
ajlm-933	1	85	disease	disease	NOUN
ajlm-933	1	86	(	(	PUNCT
ajlm-933	1	87	dfwed	dfwe	VERB
ajlm-933	1	88	)	)	PUNCT
ajlm-933	1	89	,	,	PUNCT
ajlm-933	1	90	national	national	ADJ
ajlm-933	1	91	center	center	NOUN
ajlm-933	1	92	for	for	ADP
ajlm-933	1	93	emerging	emerge	VERB
ajlm-933	1	94	and	and	CCONJ
ajlm-933	1	95	zoonotic	zoonotic	ADJ
ajlm-933	1	96	infectious	infectious	ADJ
ajlm-933	1	97	diseases	disease	NOUN
ajlm-933	1	98	(	(	PUNCT
ajlm-933	1	99	ncezid	ncezid	PROPN
ajlm-933	1	100	)	)	PUNCT
ajlm-933	1	101	,	,	PUNCT
ajlm-933	1	102	centers	center	NOUN
ajlm-933	1	103	for	for	ADP
ajlm-933	1	104	disease	disease	NOUN
ajlm-933	1	105	control	control	NOUN
ajlm-933	1	106	and	and	CCONJ
ajlm-933	1	107	prevention	prevention	NOUN
ajlm-933	1	108	(	(	PUNCT
ajlm-933	1	109	cdc	cdc	PROPN
ajlm-933	1	110	)	)	PUNCT
ajlm-933	1	111	,	,	PUNCT
ajlm-933	1	112	atlanta	atlanta	PROPN
ajlm-933	1	113	,	,	PUNCT
ajlm-933	1	114	georgia	georgia	PROPN
ajlm-933	1	115	,	,	PUNCT
ajlm-933	1	116	united	united	PROPN
ajlm-933	1	117	states	states	PROPN
ajlm-933	1	118	rossana	rossana	PROPN
ajlm-933	1	119	jeffries	jeffries	PROPN
ajlm-933	1	120	university	university	PROPN
ajlm-933	1	121	research	research	PROPN
ajlm-933	1	122	co.	co.	PROPN
ajlm-933	1	123	,	,	PUNCT
ajlm-933	1	124	llc	llc	PROPN
ajlm-933	1	125	,	,	PUNCT
ajlm-933	1	126	mbabane	mbabane	NOUN
ajlm-933	1	127	,	,	PUNCT
ajlm-933	1	128	eswatini	eswatini	VERB
ajlm-933	1	129	peter	peter	PROPN
ajlm-933	1	130	ehrenkranz	ehrenkranz	PROPN
ajlm-933	1	131	global	global	PROPN
ajlm-933	1	132	development	development	PROPN
ajlm-933	1	133	,	,	PUNCT
ajlm-933	1	134	bill	bill	NOUN
ajlm-933	1	135	and	and	CCONJ
ajlm-933	1	136	melinda	melinda	PROPN
ajlm-933	1	137	gates	gates	PROPN
ajlm-933	1	138	foundation	foundation	PROPN
ajlm-933	1	139	,	,	PUNCT
ajlm-933	1	140	seattle	seattle	PROPN
ajlm-933	1	141	,	,	PUNCT
ajlm-933	1	142	washington	washington	PROPN
ajlm-933	1	143	,	,	PUNCT
ajlm-933	1	144	united	united	PROPN
ajlm-933	1	145	states	states	PROPN
ajlm-933	1	146	munyaradzi	munyaradzi	PROPN
ajlm-933	1	147	pasipamire	pasipamire	PROPN
ajlm-933	1	148	ministry	ministry	PROPN
ajlm-933	1	149	of	of	ADP
ajlm-933	1	150	health	health	PROPN
ajlm-933	1	151	eswatini	eswatini	PROPN
ajlm-933	1	152	national	national	PROPN
ajlm-933	1	153	aids	aids	PROPN
ajlm-933	1	154	programme	programme	NOUN
ajlm-933	1	155	(	(	PUNCT
ajlm-933	1	156	enap	enap	ADJ
ajlm-933	1	157	)	)	PUNCT
ajlm-933	1	158	,	,	PUNCT
ajlm-933	1	159	mbabane	mbabane	NOUN
ajlm-933	1	160	,	,	PUNCT
ajlm-933	1	161	eswatini	eswatini	PROPN
ajlm-933	1	162	trong	trong	PROPN
ajlm-933	1	163	ao	ao	PROPN
ajlm-933	1	164	centers	center	NOUN
ajlm-933	1	165	for	for	ADP
ajlm-933	1	166	disease	disease	NOUN
ajlm-933	1	167	control	control	NOUN
ajlm-933	1	168	and	and	CCONJ
ajlm-933	1	169	prevention	prevention	NOUN
ajlm-933	1	170	(	(	PUNCT
ajlm-933	1	171	cdc	cdc	PROPN
ajlm-933	1	172	)	)	PUNCT
ajlm-933	1	173	,	,	PUNCT
ajlm-933	1	174	mbabane	mbabane	NOUN
ajlm-933	1	175	,	,	PUNCT
ajlm-933	1	176	eswatini	eswatini	PROPN
ajlm-933	1	177	nomthandazo	nomthandazo	PROPN
ajlm-933	1	178	lukhele	lukhele	PROPN
ajlm-933	1	179	ministry	ministry	PROPN
ajlm-933	1	180	of	of	ADP
ajlm-933	1	181	health	health	PROPN
ajlm-933	1	182	eswatini	eswatini	PROPN
ajlm-933	1	183	national	national	PROPN
ajlm-933	1	184	aids	aids	PROPN
ajlm-933	1	185	programme	programme	NOUN
ajlm-933	1	186	(	(	PUNCT
ajlm-933	1	187	enap	enap	ADJ
ajlm-933	1	188	)	)	PUNCT
ajlm-933	1	189	,	,	PUNCT
ajlm-933	1	190	mbabane	mbabane	NOUN
ajlm-933	1	191	,	,	PUNCT
ajlm-933	1	192	eswatini	eswatini	VERB
ajlm-933	1	193	sikhathele	sikhathele	PROPN
ajlm-933	1	194	mazibuko	mazibuko	PROPN
ajlm-933	1	195	ministry	ministry	PROPN
ajlm-933	1	196	of	of	ADP
ajlm-933	1	197	health	health	PROPN
ajlm-933	1	198	eswatini	eswatini	PROPN
ajlm-933	1	199	national	national	PROPN
ajlm-933	1	200	aids	aids	PROPN
ajlm-933	1	201	programme	programme	NOUN
ajlm-933	1	202	(	(	PUNCT
ajlm-933	1	203	enap	enap	ADJ
ajlm-933	1	204	)	)	PUNCT
ajlm-933	1	205	,	,	PUNCT
ajlm-933	1	206	mbabane	mbabane	NOUN
ajlm-933	1	207	,	,	PUNCT
ajlm-933	1	208	eswatini	eswatini	X
ajlm-933	1	209	mandzisi	mandzisi	VERB
ajlm-933	1	210	mkhontfo	mkhontfo	PROPN
ajlm-933	1	211	university	university	PROPN
ajlm-933	1	212	research	research	PROPN
ajlm-933	1	213	co.	co.	PROPN
ajlm-933	1	214	,	,	PUNCT
ajlm-933	1	215	llc	llc	PROPN
ajlm-933	1	216	,	,	PUNCT
ajlm-933	1	217	mbabane	mbabane	NOUN
ajlm-933	1	218	,	,	PUNCT
ajlm-933	1	219	eswatini	eswatini	PROPN
ajlm-933	1	220	rachel	rachel	PROPN
ajlm-933	1	221	m.	m.	PROPN
ajlm-933	1	222	smith	smith	PROPN
ajlm-933	1	223	mycotic	mycotic	PROPN
ajlm-933	1	224	diseases	disease	NOUN
ajlm-933	1	225	branch	branch	NOUN
ajlm-933	1	226	(	(	PUNCT
ajlm-933	1	227	mdb	mdb	PROPN
ajlm-933	1	228	)	)	PUNCT
ajlm-933	1	229	,	,	PUNCT
ajlm-933	1	230	division	division	NOUN
ajlm-933	1	231	of	of	ADP
ajlm-933	1	232	foodborne	foodborne	ADJ
ajlm-933	1	233	,	,	PUNCT
ajlm-933	1	234	waterborne	waterborne	NOUN
ajlm-933	1	235	,	,	PUNCT
ajlm-933	1	236	and	and	CCONJ
ajlm-933	1	237	environmental	environmental	ADJ
ajlm-933	1	238	disease	disease	NOUN
ajlm-933	1	239	(	(	PUNCT
ajlm-933	1	240	dfwed	dfwe	VERB
ajlm-933	1	241	)	)	PUNCT
ajlm-933	1	242	,	,	PUNCT
ajlm-933	1	243	national	national	ADJ
ajlm-933	1	244	center	center	NOUN
ajlm-933	1	245	for	for	ADP
ajlm-933	1	246	emerging	emerge	VERB
ajlm-933	1	247	and	and	CCONJ
ajlm-933	1	248	zoonotic	zoonotic	ADJ
ajlm-933	1	249	infectious	infectious	ADJ
ajlm-933	1	250	diseases	disease	NOUN
ajlm-933	1	251	(	(	PUNCT
ajlm-933	1	252	ncezid	ncezid	PROPN
ajlm-933	1	253	)	)	PUNCT
ajlm-933	1	254	,	,	PUNCT
ajlm-933	1	255	centers	center	NOUN
ajlm-933	1	256	for	for	ADP
ajlm-933	1	257	disease	disease	NOUN
ajlm-933	1	258	control	control	NOUN
ajlm-933	1	259	and	and	CCONJ
ajlm-933	1	260	prevention	prevention	NOUN
ajlm-933	1	261	(	(	PUNCT
ajlm-933	1	262	cdc	cdc	PROPN
ajlm-933	1	263	)	)	PUNCT
ajlm-933	1	264	,	,	PUNCT
ajlm-933	1	265	atlanta	atlanta	PROPN
ajlm-933	1	266	,	,	PUNCT
ajlm-933	1	267	georgia	georgia	PROPN
ajlm-933	1	268	,	,	PUNCT
ajlm-933	1	269	united	united	PROPN
ajlm-933	1	270	states	states	PROPN
ajlm-933	1	271	tom	tom	PROPN
ajlm-933	1	272	chiller	chiller	NOUN
ajlm-933	1	273	mycotic	mycotic	ADJ
ajlm-933	1	274	diseases	disease	NOUN
ajlm-933	1	275	branch	branch	NOUN
ajlm-933	1	276	(	(	PUNCT
ajlm-933	1	277	mdb	mdb	PROPN
ajlm-933	1	278	)	)	PUNCT
ajlm-933	1	279	,	,	PUNCT
ajlm-933	1	280	division	division	NOUN
ajlm-933	1	281	of	of	ADP
ajlm-933	1	282	foodborne	foodborne	ADJ
ajlm-933	1	283	,	,	PUNCT
ajlm-933	1	284	waterborne	waterborne	NOUN
ajlm-933	1	285	,	,	PUNCT
ajlm-933	1	286	and	and	CCONJ
ajlm-933	1	287	environmental	environmental	ADJ
ajlm-933	1	288	disease	disease	NOUN
ajlm-933	1	289	(	(	PUNCT
ajlm-933	1	290	dfwed	dfwe	VERB
ajlm-933	1	291	)	)	PUNCT
ajlm-933	1	292	,	,	PUNCT
ajlm-933	1	293	national	national	ADJ
ajlm-933	1	294	center	center	NOUN
ajlm-933	1	295	for	for	ADP
ajlm-933	1	296	emerging	emerge	VERB
ajlm-933	1	297	and	and	CCONJ
ajlm-933	1	298	zoonotic	zoonotic	ADJ
ajlm-933	1	299	infectious	infectious	ADJ
ajlm-933	1	300	diseases	disease	NOUN
ajlm-933	1	301	(	(	PUNCT
ajlm-933	1	302	ncezid	ncezid	PROPN
ajlm-933	1	303	)	)	PUNCT
ajlm-933	1	304	,	,	PUNCT
ajlm-933	1	305	centers	center	NOUN
ajlm-933	1	306	for	for	ADP
ajlm-933	1	307	disease	disease	NOUN
ajlm-933	1	308	control	control	NOUN
ajlm-933	1	309	and	and	CCONJ
ajlm-933	1	310	prevention	prevention	NOUN
ajlm-933	1	311	(	(	PUNCT
ajlm-933	1	312	cdc	cdc	PROPN
ajlm-933	1	313	)	)	PUNCT
ajlm-933	1	314	,	,	PUNCT
ajlm-933	1	315	atlanta	atlanta	PROPN
ajlm-933	1	316	,	,	PUNCT
ajlm-933	1	317	georgia	georgia	PROPN
ajlm-933	1	318	,	,	PUNCT
ajlm-933	1	319	united	united	PROPN
ajlm-933	1	320	states	states	PROPN
ajlm-933	1	321	citation	citation	PROPN
ajlm-933	1	322	haumba	haumba	PROPN
ajlm-933	2	1	sm	sm	PROPN
ajlm-933	2	2	,	,	PUNCT
ajlm-933	2	3	toda	toda	PROPN
ajlm-933	2	4	m	m	PROPN
ajlm-933	2	5	,	,	PUNCT
ajlm-933	2	6	jeffries	jeffries	PROPN
ajlm-933	2	7	r	r	NOUN
ajlm-933	2	8	,	,	PUNCT
ajlm-933	2	9	et	et	PROPN
ajlm-933	2	10	al	al	PROPN
ajlm-933	2	11	.	.	PUNCT
ajlm-933	2	12	prevalence	prevalence	NOUN
ajlm-933	2	13	of	of	ADP
ajlm-933	2	14	cryptococcal	cryptococcal	ADJ
ajlm-933	2	15	antigen	antigen	NOUN
ajlm-933	2	16	(	(	PUNCT
ajlm-933	2	17	crag	crag	NOUN
ajlm-933	2	18	)	)	PUNCT
ajlm-933	2	19	among	among	ADP
ajlm-933	2	20	hiv	hiv	PROPN
ajlm-933	2	21	-	-	PUNCT
ajlm-933	2	22	positive	positive	ADJ
ajlm-933	2	23	patients	patient	NOUN
ajlm-933	2	24	in	in	ADP
ajlm-933	2	25	eswatini	eswatini	NOUN
ajlm-933	2	26	,	,	PUNCT
ajlm-933	2	27	2014–2015	2014–2015	NUM
ajlm-933	2	28	.	.	PUNCT
ajlm-933	3	1	afr	afr	PROPN
ajlm-933	3	2	j	j	PROPN
ajlm-933	3	3	lab	lab	PROPN
ajlm-933	3	4	med	me	VERB
ajlm-933	3	5	.	.	PUNCT
ajlm-933	3	6	2020;9(1	2020;9(1	NUM
ajlm-933	3	7	)	)	PUNCT
ajlm-933	3	8	,	,	PUNCT
ajlm-933	3	9	a933	a933	PROPN
ajlm-933	3	10	https://doi.org/10.4102/ajlm.v9i1.933	https://doi.org/10.4102/ajlm.v9i1.933	NOUN
ajlm-933	3	11	original	original	ADJ
ajlm-933	3	12	research	research	NOUN
ajlm-933	3	13	prevalence	prevalence	NOUN
ajlm-933	3	14	of	of	ADP
ajlm-933	3	15	cryptococcal	cryptococcal	ADJ
ajlm-933	3	16	antigen	antigen	NOUN
ajlm-933	3	17	(	(	PUNCT
ajlm-933	3	18	crag	crag	NOUN
ajlm-933	3	19	)	)	PUNCT
ajlm-933	3	20	among	among	ADP
ajlm-933	3	21	hiv	hiv	PROPN
ajlm-933	3	22	-	-	PUNCT
ajlm-933	3	23	positive	positive	ADJ
ajlm-933	3	24	patients	patient	NOUN
ajlm-933	3	25	in	in	ADP
ajlm-933	3	26	eswatini	eswatini	NOUN
ajlm-933	3	27	,	,	PUNCT
ajlm-933	3	28	2014–2015	2014–2015	NUM
ajlm-933	3	29	samson	samson	PROPN
ajlm-933	3	30	m.	m.	NOUN
ajlm-933	3	31	haumba	haumba	PROPN
ajlm-933	3	32	,	,	PUNCT
ajlm-933	3	33	mitsuru	mitsuru	PROPN
ajlm-933	3	34	toda	toda	PROPN
ajlm-933	3	35	,	,	PUNCT
ajlm-933	3	36	rossana	rossana	PROPN
ajlm-933	3	37	jeffries	jeffries	PROPN
ajlm-933	3	38	,	,	PUNCT
ajlm-933	3	39	peter	peter	PROPN
ajlm-933	3	40	ehrenkranz	ehrenkranz	PROPN
ajlm-933	3	41	,	,	PUNCT
ajlm-933	3	42	munyaradzi	munyaradzi	NOUN
ajlm-933	3	43	pasipamire	pasipamire	NOUN
ajlm-933	3	44	,	,	PUNCT
ajlm-933	3	45	trong	trong	PROPN
ajlm-933	3	46	ao	ao	PROPN
ajlm-933	3	47	,	,	PUNCT
ajlm-933	3	48	nomthandazo	nomthandazo	ADJ
ajlm-933	3	49	lukhele	lukhele	PROPN
ajlm-933	3	50	,	,	PUNCT
ajlm-933	3	51	sikhathele	sikhathele	PROPN
ajlm-933	3	52	mazibuko	mazibuko	PROPN
ajlm-933	3	53	,	,	PUNCT
ajlm-933	3	54	mandzisi	mandzisi	ADJ
ajlm-933	3	55	mkhontfo	mkhontfo	VERB
ajlm-933	3	56	,	,	PUNCT
ajlm-933	3	57	rachel	rachel	PROPN
ajlm-933	3	58	m.	m.	PROPN
ajlm-933	3	59	smith	smith	PROPN
ajlm-933	3	60	,	,	PUNCT
ajlm-933	3	61	tom	tom	PROPN
ajlm-933	3	62	chiller	chiller	PROPN
ajlm-933	3	63	received	receive	VERB
ajlm-933	3	64	:	:	PUNCT
ajlm-933	3	65	05	05	NUM
ajlm-933	3	66	nov	nov	PROPN
ajlm-933	3	67	.	.	PROPN
ajlm-933	3	68	2018	2018	NUM
ajlm-933	3	69	;	;	PUNCT
ajlm-933	3	70	accepted	accept	VERB
ajlm-933	3	71	:	:	PUNCT
ajlm-933	3	72	07	07	NUM
ajlm-933	3	73	apr	apr	NOUN
ajlm-933	3	74	.	.	PUNCT
ajlm-933	4	1	2020	2020	NUM
ajlm-933	4	2	;	;	PUNCT
ajlm-933	4	3	published	publish	VERB
ajlm-933	4	4	:	:	PUNCT
ajlm-933	4	5	29	29	NUM
ajlm-933	4	6	july	july	NOUN
ajlm-933	4	7	2020	2020	NUM
ajlm-933	4	8	copyright	copyright	NOUN
ajlm-933	4	9	:	:	PUNCT
ajlm-933	5	1	©	©	PROPN
ajlm-933	5	2	2020	2020	NUM
ajlm-933	5	3	.	.	PUNCT
ajlm-933	6	1	the	the	DET
ajlm-933	6	2	author(s	author(s	PROPN
ajlm-933	6	3	)	)	PUNCT
ajlm-933	6	4	.	.	PUNCT
ajlm-933	7	1	licensee	licensee	NOUN
ajlm-933	7	2	:	:	PUNCT
ajlm-933	7	3	aosis	aosis	NOUN
ajlm-933	7	4	.	.	PUNCT
ajlm-933	8	1	this	this	PRON
ajlm-933	8	2	is	be	AUX
ajlm-933	8	3	an	an	DET
ajlm-933	8	4	open	open	ADJ
ajlm-933	8	5	access	access	NOUN
ajlm-933	8	6	article	article	NOUN
ajlm-933	8	7	distributed	distribute	VERB
ajlm-933	8	8	under	under	ADP
ajlm-933	8	9	the	the	DET
ajlm-933	8	10	terms	term	NOUN
ajlm-933	8	11	of	of	ADP
ajlm-933	8	12	the	the	DET
ajlm-933	8	13	creative	creative	ADJ
ajlm-933	8	14	commons	common	NOUN
ajlm-933	8	15	attribution	attribution	NOUN
ajlm-933	8	16	license	license	NOUN
ajlm-933	8	17	,	,	PUNCT
ajlm-933	8	18	which	which	PRON
ajlm-933	8	19	permits	permit	VERB
ajlm-933	8	20	unrestricted	unrestricted	ADJ
ajlm-933	8	21	use	use	NOUN
ajlm-933	8	22	,	,	PUNCT
ajlm-933	8	23	distribution	distribution	NOUN
ajlm-933	8	24	,	,	PUNCT
ajlm-933	8	25	and	and	CCONJ
ajlm-933	8	26	reproduction	reproduction	NOUN
ajlm-933	8	27	in	in	ADP
ajlm-933	8	28	any	any	DET
ajlm-933	8	29	medium	medium	NOUN
ajlm-933	8	30	,	,	PUNCT
ajlm-933	8	31	provided	provide	VERB
ajlm-933	8	32	the	the	DET
ajlm-933	8	33	original	original	ADJ
ajlm-933	8	34	work	work	NOUN
ajlm-933	8	35	is	be	AUX
ajlm-933	8	36	properly	properly	ADV
ajlm-933	8	37	cited	cite	VERB
ajlm-933	8	38	.	.	PUNCT
ajlm-933	9	1	abstract	abstract	ADJ
ajlm-933	9	2	background	background	NOUN
ajlm-933	9	3	:	:	PUNCT
ajlm-933	9	4	cryptococcal	cryptococcal	ADJ
ajlm-933	9	5	meningitis	meningitis	NOUN
ajlm-933	9	6	is	be	AUX
ajlm-933	9	7	a	a	DET
ajlm-933	9	8	leading	lead	VERB
ajlm-933	9	9	cause	cause	NOUN
ajlm-933	9	10	of	of	ADP
ajlm-933	9	11	death	death	NOUN
ajlm-933	9	12	amongst	amongst	ADP
ajlm-933	9	13	people	people	NOUN
ajlm-933	9	14	living	live	VERB
ajlm-933	9	15	with	with	ADP
ajlm-933	9	16	hiv	hiv	PROPN
ajlm-933	9	17	.	.	PUNCT
ajlm-933	10	1	however	however	ADV
ajlm-933	10	2	,	,	PUNCT
ajlm-933	10	3	routine	routine	ADJ
ajlm-933	10	4	cryptococcal	cryptococcal	ADJ
ajlm-933	10	5	antigen	antigen	NOUN
ajlm-933	10	6	(	(	PUNCT
ajlm-933	10	7	crag	crag	NOUN
ajlm-933	10	8	)	)	PUNCT
ajlm-933	10	9	screening	screening	NOUN
ajlm-933	10	10	was	be	AUX
ajlm-933	10	11	not	not	PART
ajlm-933	10	12	in	in	ADP
ajlm-933	10	13	the	the	DET
ajlm-933	10	14	national	national	ADJ
ajlm-933	10	15	guidelines	guideline	NOUN
ajlm-933	10	16	in	in	ADP
ajlm-933	10	17	eswatini	eswatini	NOUN
ajlm-933	10	18	.	.	PUNCT
ajlm-933	11	1	objectives	objective	NOUN
ajlm-933	11	2	:	:	PUNCT
ajlm-933	11	3	a	a	DET
ajlm-933	11	4	cross	cross	ADJ
ajlm-933	11	5	-	-	ADJ
ajlm-933	11	6	sectional	sectional	ADJ
ajlm-933	11	7	study	study	NOUN
ajlm-933	11	8	was	be	AUX
ajlm-933	11	9	conducted	conduct	VERB
ajlm-933	11	10	between	between	ADP
ajlm-933	11	11	august	august	PROPN
ajlm-933	11	12	2014	2014	NUM
ajlm-933	11	13	and	and	CCONJ
ajlm-933	11	14	march	march	PROPN
ajlm-933	11	15	2015	2015	NUM
ajlm-933	11	16	to	to	PART
ajlm-933	11	17	examine	examine	VERB
ajlm-933	11	18	crag	crag	NOUN
ajlm-933	11	19	prevalence	prevalence	NOUN
ajlm-933	11	20	at	at	ADP
ajlm-933	11	21	mbabane	mbabane	NOUN
ajlm-933	11	22	government	government	NOUN
ajlm-933	11	23	hospital	hospital	NOUN
ajlm-933	11	24	in	in	ADP
ajlm-933	11	25	eswatini	eswatini	NOUN
ajlm-933	11	26	.	.	PUNCT
ajlm-933	12	1	methods	method	NOUN
ajlm-933	12	2	:	:	PUNCT
ajlm-933	12	3	we	we	PRON
ajlm-933	12	4	collected	collect	VERB
ajlm-933	12	5	urine	urine	NOUN
ajlm-933	12	6	and	and	CCONJ
ajlm-933	12	7	whole	whole	ADJ
ajlm-933	12	8	blood	blood	NOUN
ajlm-933	12	9	from	from	ADP
ajlm-933	12	10	antiretroviral	antiretroviral	ADJ
ajlm-933	12	11	-	-	PUNCT
ajlm-933	12	12	therapy	therapy	NOUN
ajlm-933	12	13	-	-	PUNCT
ajlm-933	12	14	naïve	naïve	ADJ
ajlm-933	12	15	patients	patient	NOUN
ajlm-933	12	16	with	with	ADP
ajlm-933	12	17	hiv	hiv	PROPN
ajlm-933	12	18	and	and	CCONJ
ajlm-933	12	19	a	a	DET
ajlm-933	12	20	cluster	cluster	NOUN
ajlm-933	12	21	of	of	ADP
ajlm-933	12	22	differentiation	differentiation	NOUN
ajlm-933	12	23	4	4	NUM
ajlm-933	12	24	(	(	PUNCT
ajlm-933	12	25	cd4	cd4	PROPN
ajlm-933	12	26	)	)	PUNCT
ajlm-933	12	27	counts	count	VERB
ajlm-933	12	28	<	<	X
ajlm-933	12	29	200	200	NUM
ajlm-933	12	30	cells	cell	NOUN
ajlm-933	12	31	/	/	SYM
ajlm-933	12	32	mm3	mm3	NOUN
ajlm-933	12	33	for	for	ADP
ajlm-933	12	34	plasma	plasma	NOUN
ajlm-933	12	35	and	and	CCONJ
ajlm-933	12	36	urine	urine	NOUN
ajlm-933	12	37	crag	crag	NOUN
ajlm-933	12	38	lateral	lateral	ADJ
ajlm-933	12	39	flow	flow	NOUN
ajlm-933	12	40	assay	assay	NOUN
ajlm-933	12	41	(	(	PUNCT
ajlm-933	12	42	lfa	lfa	PROPN
ajlm-933	12	43	)	)	PUNCT
ajlm-933	12	44	screening	screening	NOUN
ajlm-933	12	45	at	at	ADP
ajlm-933	12	46	the	the	DET
ajlm-933	12	47	national	national	PROPN
ajlm-933	12	48	hiv	hiv	PROPN
ajlm-933	12	49	reference	reference	PROPN
ajlm-933	12	50	laboratory	laboratory	NOUN
ajlm-933	12	51	.	.	PUNCT
ajlm-933	13	1	two	two	NUM
ajlm-933	13	2	cd4	cd4	PROPN
ajlm-933	13	3	cut	cut	VERB
ajlm-933	13	4	-	-	PUNCT
ajlm-933	13	5	off	off	ADP
ajlm-933	13	6	points	point	NOUN
ajlm-933	13	7	were	be	AUX
ajlm-933	13	8	used	use	VERB
ajlm-933	13	9	to	to	PART
ajlm-933	13	10	estimate	estimate	VERB
ajlm-933	13	11	crag	crag	NOUN
ajlm-933	13	12	prevalence	prevalence	NOUN
ajlm-933	13	13	:	:	PUNCT
ajlm-933	14	1	cd4	cd4	PROPN
ajlm-933	14	2	<	<	X
ajlm-933	14	3	100	100	NUM
ajlm-933	14	4	and	and	CCONJ
ajlm-933	14	5	<	<	X
ajlm-933	14	6	200	200	NUM
ajlm-933	14	7	cells	cell	NOUN
ajlm-933	14	8	/	/	SYM
ajlm-933	14	9	mm3	mm3	NOUN
ajlm-933	14	10	.	.	PUNCT
ajlm-933	14	11	sensitivity	sensitivity	NOUN
ajlm-933	14	12	and	and	CCONJ
ajlm-933	14	13	specificity	specificity	NOUN
ajlm-933	14	14	of	of	ADP
ajlm-933	14	15	urine	urine	NOUN
ajlm-933	14	16	crag	crag	NOUN
ajlm-933	14	17	lfa	lfa	PROPN
ajlm-933	14	18	was	be	AUX
ajlm-933	14	19	compared	compare	VERB
ajlm-933	14	20	to	to	ADP
ajlm-933	14	21	plasma	plasma	NOUN
ajlm-933	14	22	crag	crag	PROPN
ajlm-933	14	23	lfa	lfa	PROPN
ajlm-933	14	24	.	.	PROPN
ajlm-933	15	1	results	result	NOUN
ajlm-933	15	2	:	:	PUNCT
ajlm-933	15	3	plasma	plasma	NOUN
ajlm-933	15	4	crag	crag	NOUN
ajlm-933	15	5	prevalence	prevalence	NOUN
ajlm-933	15	6	was	be	AUX
ajlm-933	15	7	4	4	NUM
ajlm-933	15	8	%	%	NOUN
ajlm-933	15	9	(	(	PUNCT
ajlm-933	15	10	8/182	8/182	NUM
ajlm-933	15	11	,	,	PUNCT
ajlm-933	15	12	95	95	NUM
ajlm-933	15	13	%	%	NOUN
ajlm-933	15	14	confidence	confidence	NOUN
ajlm-933	15	15	interval	interval	NOUN
ajlm-933	16	1	[	[	X
ajlm-933	16	2	ci	ci	X
ajlm-933	16	3	]	]	X
ajlm-933	16	4	:	:	PUNCT
ajlm-933	16	5	2–8	2–8	NUM
ajlm-933	16	6	)	)	PUNCT
ajlm-933	16	7	amongst	amongst	ADP
ajlm-933	16	8	patients	patient	NOUN
ajlm-933	16	9	with	with	ADP
ajlm-933	16	10	cd4	cd4	PROPN
ajlm-933	16	11	counts	count	NOUN
ajlm-933	16	12	of	of	ADP
ajlm-933	16	13	<	<	X
ajlm-933	16	14	200	200	NUM
ajlm-933	16	15	cells	cell	NOUN
ajlm-933	16	16	/	/	SYM
ajlm-933	16	17	mm3	mm3	ADJ
ajlm-933	16	18	,	,	PUNCT
ajlm-933	16	19	and	and	CCONJ
ajlm-933	16	20	8	8	NUM
ajlm-933	16	21	%	%	NOUN
ajlm-933	16	22	(	(	PUNCT
ajlm-933	16	23	8/102	8/102	NUM
ajlm-933	16	24	,	,	PUNCT
ajlm-933	16	25	95	95	NUM
ajlm-933	16	26	%	%	NOUN
ajlm-933	16	27	ci	ci	NOUN
ajlm-933	16	28	:	:	PUNCT
ajlm-933	16	29	3–15	3–15	ADJ
ajlm-933	16	30	)	)	PUNCT
ajlm-933	16	31	amongst	amongst	ADP
ajlm-933	16	32	patients	patient	NOUN
ajlm-933	16	33	with	with	ADP
ajlm-933	16	34	cd4	cd4	PROPN
ajlm-933	16	35	counts	count	NOUN
ajlm-933	16	36	of	of	ADP
ajlm-933	16	37	<	<	X
ajlm-933	16	38	100	100	NUM
ajlm-933	16	39	cells	cell	NOUN
ajlm-933	16	40	/	/	SYM
ajlm-933	17	1	mm3	mm3	NOUN
ajlm-933	17	2	.	.	PUNCT
ajlm-933	17	3	urine	urine	PROPN
ajlm-933	17	4	crag	crag	NOUN
ajlm-933	17	5	lfa	lfa	PROPN
ajlm-933	17	6	had	have	VERB
ajlm-933	17	7	a	a	DET
ajlm-933	17	8	sensitivity	sensitivity	NOUN
ajlm-933	17	9	of	of	ADP
ajlm-933	17	10	100	100	NUM
ajlm-933	17	11	%	%	NOUN
ajlm-933	17	12	(	(	PUNCT
ajlm-933	17	13	95	95	NUM
ajlm-933	17	14	%	%	NOUN
ajlm-933	17	15	ci	ci	NOUN
ajlm-933	17	16	:	:	PUNCT
ajlm-933	17	17	59–100	59–100	NUM
ajlm-933	17	18	)	)	PUNCT
ajlm-933	17	19	and	and	CCONJ
ajlm-933	17	20	a	a	DET
ajlm-933	17	21	specificity	specificity	NOUN
ajlm-933	17	22	of	of	ADP
ajlm-933	17	23	80	80	NUM
ajlm-933	17	24	%	%	NOUN
ajlm-933	17	25	(	(	PUNCT
ajlm-933	17	26	95	95	NUM
ajlm-933	17	27	%	%	NOUN
ajlm-933	17	28	ci	ci	NOUN
ajlm-933	17	29	:	:	PUNCT
ajlm-933	17	30	72–86	72–86	NUM
ajlm-933	17	31	)	)	PUNCT
ajlm-933	17	32	compared	compare	VERB
ajlm-933	17	33	with	with	ADP
ajlm-933	17	34	plasma	plasma	NOUN
ajlm-933	17	35	crag	crag	NOUN
ajlm-933	17	36	lfa	lfa	PROPN
ajlm-933	17	37	tests	test	VERB
ajlm-933	17	38	for	for	ADP
ajlm-933	17	39	patients	patient	NOUN
ajlm-933	17	40	with	with	ADP
ajlm-933	17	41	cd4	cd4	PROPN
ajlm-933	17	42	<	<	X
ajlm-933	17	43	200	200	NUM
ajlm-933	17	44	cells	cell	NOUN
ajlm-933	17	45	/	/	SYM
ajlm-933	17	46	mm3	mm3	NOUN
ajlm-933	17	47	.	.	PUNCT
ajlm-933	18	1	forty	forty	NUM
ajlm-933	18	2	-	-	PUNCT
ajlm-933	18	3	three	three	NUM
ajlm-933	18	4	per	per	ADP
ajlm-933	18	5	cent	cent	NOUN
ajlm-933	18	6	of	of	ADP
ajlm-933	18	7	99	99	NUM
ajlm-933	18	8	patients	patient	NOUN
ajlm-933	18	9	with	with	ADP
ajlm-933	18	10	cd4	cd4	PROPN
ajlm-933	18	11	<	<	X
ajlm-933	18	12	100	100	NUM
ajlm-933	18	13	were	be	AUX
ajlm-933	18	14	at	at	ADP
ajlm-933	18	15	world	world	PROPN
ajlm-933	18	16	health	health	NOUN
ajlm-933	18	17	organization	organization	NOUN
ajlm-933	18	18	clinical	clinical	ADJ
ajlm-933	18	19	stages	stage	NOUN
ajlm-933	18	20	i	i	PRON
ajlm-933	18	21	or	or	CCONJ
ajlm-933	18	22	ii	ii	PROPN
ajlm-933	18	23	.	.	PUNCT
ajlm-933	19	1	conclusion	conclusion	NOUN
ajlm-933	19	2	:	:	PUNCT
ajlm-933	19	3	the	the	DET
ajlm-933	19	4	prevalence	prevalence	NOUN
ajlm-933	19	5	of	of	ADP
ajlm-933	19	6	crag	crag	NOUN
ajlm-933	19	7	in	in	ADP
ajlm-933	19	8	eswatini	eswatini	PROPN
ajlm-933	19	9	was	be	AUX
ajlm-933	19	10	higher	high	ADJ
ajlm-933	19	11	than	than	ADP
ajlm-933	19	12	the	the	DET
ajlm-933	19	13	current	current	ADJ
ajlm-933	19	14	global	global	ADJ
ajlm-933	19	15	estimate	estimate	NOUN
ajlm-933	19	16	of	of	ADP
ajlm-933	19	17	6	6	NUM
ajlm-933	19	18	%	%	NOUN
ajlm-933	19	19	amongst	amongst	ADP
ajlm-933	19	20	hiv	hiv	PROPN
ajlm-933	19	21	-	-	PUNCT
ajlm-933	19	22	positive	positive	ADJ
ajlm-933	19	23	people	people	NOUN
ajlm-933	19	24	with	with	ADP
ajlm-933	19	25	cd4	cd4	PROPN
ajlm-933	19	26	<	<	X
ajlm-933	19	27	100	100	NUM
ajlm-933	19	28	cell	cell	NOUN
ajlm-933	19	29	/	/	SYM
ajlm-933	19	30	mm3	mm3	NOUN
ajlm-933	19	31	,	,	PUNCT
ajlm-933	19	32	indicating	indicate	VERB
ajlm-933	19	33	the	the	DET
ajlm-933	19	34	importance	importance	NOUN
ajlm-933	19	35	of	of	ADP
ajlm-933	19	36	initiating	initiate	VERB
ajlm-933	19	37	a	a	DET
ajlm-933	19	38	national	national	ADJ
ajlm-933	19	39	screening	screening	NOUN
ajlm-933	19	40	programme	programme	NOUN
ajlm-933	19	41	.	.	PUNCT
ajlm-933	20	1	mechanisms	mechanism	NOUN
ajlm-933	20	2	for	for	ADP
ajlm-933	20	3	crag	crag	NOUN
ajlm-933	20	4	testing	testing	NOUN
ajlm-933	20	5	,	,	PUNCT
ajlm-933	20	6	training	training	NOUN
ajlm-933	20	7	,	,	PUNCT
ajlm-933	20	8	reporting	reporting	NOUN
ajlm-933	20	9	,	,	PUNCT
ajlm-933	20	10	and	and	CCONJ
ajlm-933	20	11	drug	drug	NOUN
ajlm-933	20	12	and	and	CCONJ
ajlm-933	20	13	commodity	commodity	NOUN
ajlm-933	20	14	supply	supply	NOUN
ajlm-933	20	15	issues	issue	NOUN
ajlm-933	20	16	are	be	AUX
ajlm-933	20	17	important	important	ADJ
ajlm-933	20	18	considerations	consideration	NOUN
ajlm-933	20	19	before	before	ADP
ajlm-933	20	20	national	national	ADJ
ajlm-933	20	21	implementation	implementation	NOUN
ajlm-933	20	22	.	.	PUNCT
ajlm-933	21	1	keywords	keyword	NOUN
ajlm-933	21	2	:	:	PUNCT
ajlm-933	21	3	cryptococcal	cryptococcal	ADJ
ajlm-933	21	4	antigenaemia	antigenaemia	PROPN
ajlm-933	21	5	screening	screening	NOUN
ajlm-933	21	6	;	;	PUNCT
ajlm-933	21	7	prevalence	prevalence	NOUN
ajlm-933	21	8	;	;	PUNCT
ajlm-933	21	9	people	people	NOUN
ajlm-933	21	10	living	live	VERB
ajlm-933	21	11	with	with	ADP
ajlm-933	21	12	hiv	hiv	PROPN
ajlm-933	21	13	;	;	PUNCT
ajlm-933	21	14	cryptococcal	cryptococcal	ADJ
ajlm-933	21	15	meningitis	meningitis	NOUN
ajlm-933	21	16	;	;	PUNCT
ajlm-933	21	17	advanced	advanced	ADJ
ajlm-933	21	18	hiv	hiv	PROPN
ajlm-933	21	19	disease	disease	NOUN
ajlm-933	21	20	package	package	NOUN
ajlm-933	21	21	;	;	PUNCT
ajlm-933	21	22	eswatini	eswatini	NOUN
ajlm-933	21	23	.	.	PUNCT
ajlm-933	22	1	introduction	introduction	NOUN
ajlm-933	22	2	cryptococcosis	cryptococcosis	NOUN
ajlm-933	22	3	,	,	PUNCT
ajlm-933	22	4	caused	cause	VERB
ajlm-933	22	5	by	by	ADP
ajlm-933	22	6	cryptococcus	cryptococcus	PROPN
ajlm-933	22	7	neoformans	neoformans	PROPN
ajlm-933	22	8	or	or	CCONJ
ajlm-933	22	9	cryptococcus	cryptococcus	PROPN
ajlm-933	22	10	gattii	gattii	PROPN
ajlm-933	22	11	,	,	PUNCT
ajlm-933	22	12	is	be	AUX
ajlm-933	22	13	an	an	DET
ajlm-933	22	14	invasive	invasive	ADJ
ajlm-933	22	15	and	and	CCONJ
ajlm-933	22	16	life	life	NOUN
ajlm-933	22	17	-	-	PUNCT
ajlm-933	22	18	threatening	threaten	VERB
ajlm-933	22	19	fungal	fungal	ADJ
ajlm-933	22	20	infection	infection	NOUN
ajlm-933	22	21	,	,	PUNCT
ajlm-933	22	22	often	often	ADV
ajlm-933	22	23	affecting	affect	VERB
ajlm-933	22	24	immunocompromised	immunocompromise	VERB
ajlm-933	22	25	patients	patient	NOUN
ajlm-933	22	26	.	.	PUNCT
ajlm-933	23	1	cryptococcal	cryptococcal	ADJ
ajlm-933	23	2	meningitis	meningitis	PROPN
ajlm-933	23	3	,	,	PUNCT
ajlm-933	23	4	a	a	DET
ajlm-933	23	5	type	type	NOUN
ajlm-933	23	6	of	of	ADP
ajlm-933	23	7	cryptococcosis	cryptococcosis	NOUN
ajlm-933	23	8	affecting	affect	VERB
ajlm-933	23	9	the	the	DET
ajlm-933	23	10	brain	brain	NOUN
ajlm-933	23	11	meninges	meninge	NOUN
ajlm-933	23	12	,	,	PUNCT
ajlm-933	23	13	is	be	AUX
ajlm-933	23	14	one	one	NUM
ajlm-933	23	15	of	of	ADP
ajlm-933	23	16	the	the	DET
ajlm-933	23	17	leading	lead	VERB
ajlm-933	23	18	opportunistic	opportunistic	ADJ
ajlm-933	23	19	infections	infection	NOUN
ajlm-933	23	20	and	and	CCONJ
ajlm-933	23	21	causes	cause	NOUN
ajlm-933	23	22	of	of	ADP
ajlm-933	23	23	death	death	NOUN
ajlm-933	23	24	amongst	amongst	ADP
ajlm-933	23	25	people	people	NOUN
ajlm-933	23	26	living	live	VERB
ajlm-933	23	27	with	with	ADP
ajlm-933	23	28	hiv	hiv	PROPN
ajlm-933	23	29	.	.	PUNCT
ajlm-933	24	1	it	it	PRON
ajlm-933	24	2	especially	especially	ADV
ajlm-933	24	3	affects	affect	VERB
ajlm-933	24	4	patients	patient	NOUN
ajlm-933	24	5	with	with	ADP
ajlm-933	24	6	advanced	advanced	ADJ
ajlm-933	24	7	hiv	hiv	PROPN
ajlm-933	24	8	who	who	PRON
ajlm-933	24	9	have	have	VERB
ajlm-933	24	10	a	a	DET
ajlm-933	24	11	cluster	cluster	NOUN
ajlm-933	24	12	of	of	ADP
ajlm-933	24	13	differentiation	differentiation	NOUN
ajlm-933	24	14	4	4	NUM
ajlm-933	24	15	(	(	PUNCT
ajlm-933	24	16	cd4	cd4	PROPN
ajlm-933	24	17	)	)	PUNCT
ajlm-933	24	18	count	count	NOUN
ajlm-933	24	19	<	<	X
ajlm-933	24	20	200	200	NUM
ajlm-933	24	21	cells	cell	NOUN
ajlm-933	24	22	/	/	SYM
ajlm-933	24	23	mm3	mm3	NOUN
ajlm-933	24	24	or	or	CCONJ
ajlm-933	24	25	who	who	PRON
ajlm-933	24	26	are	be	AUX
ajlm-933	24	27	at	at	ADP
ajlm-933	24	28	stages	stage	NOUN
ajlm-933	24	29	iii	iii	NUM
ajlm-933	24	30	or	or	CCONJ
ajlm-933	24	31	iv	iv	NUM
ajlm-933	24	32	of	of	ADP
ajlm-933	24	33	the	the	DET
ajlm-933	24	34	world	world	PROPN
ajlm-933	24	35	health	health	NOUN
ajlm-933	24	36	organization	organization	NOUN
ajlm-933	24	37	(	(	PUNCT
ajlm-933	24	38	who	who	PRON
ajlm-933	24	39	)	)	PUNCT
ajlm-933	24	40	hiv	hiv	PROPN
ajlm-933	24	41	infection	infection	NOUN
ajlm-933	24	42	clinical	clinical	VERB
ajlm-933	24	43	stages.1	stages.1	NOUN
ajlm-933	24	44	in	in	ADP
ajlm-933	24	45	2014	2014	NUM
ajlm-933	24	46	,	,	PUNCT
ajlm-933	24	47	globally	globally	ADV
ajlm-933	24	48	,	,	PUNCT
ajlm-933	24	49	the	the	DET
ajlm-933	24	50	cryptococcal	cryptococcal	ADJ
ajlm-933	24	51	antigenaemia	antigenaemia	PROPN
ajlm-933	24	52	prevalence	prevalence	NOUN
ajlm-933	24	53	was	be	AUX
ajlm-933	24	54	estimated	estimate	VERB
ajlm-933	24	55	at	at	ADP
ajlm-933	24	56	6	6	NUM
ajlm-933	24	57	%	%	NOUN
ajlm-933	24	58	(	(	PUNCT
ajlm-933	24	59	278	278	NUM
ajlm-933	24	60	000	000	NUM
ajlm-933	24	61	)	)	PUNCT
ajlm-933	24	62	amongst	amongst	ADP
ajlm-933	24	63	patients	patient	NOUN
ajlm-933	24	64	with	with	ADP
ajlm-933	24	65	cd4	cd4	PROPN
ajlm-933	24	66	<	<	X
ajlm-933	24	67	100	100	NUM
ajlm-933	24	68	cells	cell	NOUN
ajlm-933	24	69	/	/	SYM
ajlm-933	24	70	mm3	mm3	PROPN
ajlm-933	24	71	,	,	PUNCT
ajlm-933	24	72	with	with	ADP
ajlm-933	24	73	approximately	approximately	ADV
ajlm-933	24	74	223	223	NUM
ajlm-933	24	75	100	100	NUM
ajlm-933	24	76	cryptococcal	cryptococcal	ADJ
ajlm-933	24	77	meningitis	meningitis	NOUN
ajlm-933	24	78	cases	case	NOUN
ajlm-933	24	79	occurring	occur	VERB
ajlm-933	24	80	annually.2	annually.2	NOUN
ajlm-933	24	81	in	in	ADP
ajlm-933	24	82	the	the	DET
ajlm-933	24	83	same	same	ADJ
ajlm-933	24	84	year	year	NOUN
ajlm-933	24	85	,	,	PUNCT
ajlm-933	24	86	2014	2014	NUM
ajlm-933	24	87	,	,	PUNCT
ajlm-933	24	88	the	the	DET
ajlm-933	24	89	annual	annual	ADJ
ajlm-933	24	90	deaths	death	NOUN
ajlm-933	24	91	due	due	ADP
ajlm-933	24	92	to	to	ADP
ajlm-933	24	93	cryptococcal	cryptococcal	ADJ
ajlm-933	24	94	meningitis	meningitis	NOUN
ajlm-933	24	95	were	be	AUX
ajlm-933	24	96	estimated	estimate	VERB
ajlm-933	24	97	at	at	ADP
ajlm-933	24	98	181	181	NUM
ajlm-933	24	99	100	100	NUM
ajlm-933	24	100	,	,	PUNCT
ajlm-933	24	101	with	with	ADP
ajlm-933	24	102	75	75	NUM
ajlm-933	24	103	%	%	NOUN
ajlm-933	24	104	(	(	PUNCT
ajlm-933	24	105	135	135	NUM
ajlm-933	24	106	900	900	NUM
ajlm-933	24	107	)	)	PUNCT
ajlm-933	24	108	of	of	ADP
ajlm-933	24	109	deaths	death	NOUN
ajlm-933	24	110	occurring	occur	VERB
ajlm-933	24	111	in	in	ADP
ajlm-933	24	112	sub	sub	ADJ
ajlm-933	24	113	-	-	ADJ
ajlm-933	24	114	saharan	saharan	ADJ
ajlm-933	24	115	africa.2	africa.2	PROPN
ajlm-933	24	116	the	the	PRON
ajlm-933	24	117	who	who	PRON
ajlm-933	24	118	recommends	recommend	VERB
ajlm-933	24	119	targeted	target	VERB
ajlm-933	24	120	screening	screening	NOUN
ajlm-933	24	121	of	of	ADP
ajlm-933	24	122	hiv	hiv	PROPN
ajlm-933	24	123	-	-	PUNCT
ajlm-933	24	124	positive	positive	ADJ
ajlm-933	24	125	patients	patient	NOUN
ajlm-933	24	126	to	to	PART
ajlm-933	24	127	enable	enable	VERB
ajlm-933	24	128	early	early	ADJ
ajlm-933	24	129	detection	detection	NOUN
ajlm-933	24	130	and	and	CCONJ
ajlm-933	24	131	pre	pre	ADJ
ajlm-933	24	132	-	-	ADJ
ajlm-933	24	133	emptive	emptive	ADJ
ajlm-933	24	134	treatment	treatment	NOUN
ajlm-933	24	135	of	of	ADP
ajlm-933	24	136	cryptococcal	cryptococcal	ADJ
ajlm-933	24	137	infection.1	infection.1	PROPN
ajlm-933	24	138	pre	pre	ADJ
ajlm-933	24	139	-	-	ADJ
ajlm-933	24	140	emptive	emptive	ADJ
ajlm-933	24	141	antifungal	antifungal	ADJ
ajlm-933	24	142	therapy	therapy	NOUN
ajlm-933	24	143	can	can	AUX
ajlm-933	24	144	prevent	prevent	VERB
ajlm-933	24	145	cryptococcal	cryptococcal	ADJ
ajlm-933	24	146	meningitis	meningitis	NOUN
ajlm-933	24	147	-	-	PUNCT
ajlm-933	24	148	related	relate	VERB
ajlm-933	24	149	mortality	mortality	NOUN
ajlm-933	24	150	and	and	CCONJ
ajlm-933	24	151	morbidity	morbidity	NOUN
ajlm-933	24	152	in	in	ADP
ajlm-933	24	153	cryptococcal	cryptococcal	ADJ
ajlm-933	24	154	antigen	antigen	NOUN
ajlm-933	24	155	(	(	PUNCT
ajlm-933	24	156	crag)-positive	crag)-positive	ADJ
ajlm-933	24	157	antiretroviral	antiretroviral	ADJ
ajlm-933	24	158	therapy	therapy	NOUN
ajlm-933	24	159	(	(	PUNCT
ajlm-933	24	160	art)-naïve	art)-naïve	ADJ
ajlm-933	24	161	patients.3	patients.3	VERB
ajlm-933	24	162	the	the	DET
ajlm-933	24	163	crag	crag	NOUN
ajlm-933	24	164	lateral	lateral	ADJ
ajlm-933	24	165	flow	flow	NOUN
ajlm-933	24	166	assay	assay	NOUN
ajlm-933	24	167	(	(	PUNCT
ajlm-933	24	168	lfa	lfa	PROPN
ajlm-933	24	169	)	)	PUNCT
ajlm-933	24	170	is	be	AUX
ajlm-933	24	171	an	an	DET
ajlm-933	24	172	affordable,4	affordable,4	ADJ
ajlm-933	24	173	cost	cost	NOUN
ajlm-933	24	174	-	-	PUNCT
ajlm-933	24	175	effective,5	effective,5	NOUN
ajlm-933	24	176	and	and	CCONJ
ajlm-933	24	177	simple	simple	ADJ
ajlm-933	24	178	point	point	NOUN
ajlm-933	24	179	-	-	PUNCT
ajlm-933	24	180	of	of	ADP
ajlm-933	24	181	-	-	PUNCT
ajlm-933	24	182	care	care	NOUN
ajlm-933	24	183	assay	assay	NOUN
ajlm-933	24	184	for	for	ADP
ajlm-933	24	185	crag	crag	NOUN
ajlm-933	24	186	testing	testing	NOUN
ajlm-933	24	187	in	in	ADP
ajlm-933	24	188	blood	blood	NOUN
ajlm-933	24	189	and	and	CCONJ
ajlm-933	24	190	cerebrospinal	cerebrospinal	ADJ
ajlm-933	24	191	fluid	fluid	NOUN
ajlm-933	24	192	(	(	PUNCT
ajlm-933	24	193	csf	csf	NOUN
ajlm-933	24	194	)	)	PUNCT
ajlm-933	24	195	.	.	PUNCT
ajlm-933	25	1	crag	crag	NOUN
ajlm-933	25	2	can	can	AUX
ajlm-933	25	3	be	be	AUX
ajlm-933	25	4	detected	detect	VERB
ajlm-933	25	5	a	a	DET
ajlm-933	25	6	median	median	NOUN
ajlm-933	25	7	of	of	ADP
ajlm-933	25	8	three	three	NUM
ajlm-933	25	9	weeks	week	NOUN
ajlm-933	25	10	before	before	ADP
ajlm-933	25	11	clinical	clinical	ADJ
ajlm-933	25	12	evidence	evidence	NOUN
ajlm-933	25	13	of	of	ADP
ajlm-933	25	14	cryptococcal	cryptococcal	ADJ
ajlm-933	25	15	meningitis.6	meningitis.6	PROPN
ajlm-933	25	16	the	the	DET
ajlm-933	25	17	prevalence	prevalence	NOUN
ajlm-933	25	18	of	of	ADP
ajlm-933	25	19	hiv	hiv	PROPN
ajlm-933	25	20	in	in	ADP
ajlm-933	25	21	eswatini	eswatini	PROPN
ajlm-933	25	22	(	(	PUNCT
ajlm-933	25	23	formerly	formerly	ADV
ajlm-933	25	24	swaziland	swaziland	NOUN
ajlm-933	25	25	)	)	PUNCT
ajlm-933	25	26	is	be	AUX
ajlm-933	25	27	amongst	amongst	ADP
ajlm-933	25	28	the	the	DET
ajlm-933	25	29	highest	high	ADJ
ajlm-933	25	30	in	in	ADP
ajlm-933	25	31	the	the	DET
ajlm-933	25	32	world.7	world.7	PROPN
ajlm-933	25	33	despite	despite	SCONJ
ajlm-933	25	34	the	the	DET
ajlm-933	25	35	high	high	ADJ
ajlm-933	25	36	hiv	hiv	PROPN
ajlm-933	25	37	prevalence	prevalence	NOUN
ajlm-933	25	38	and	and	CCONJ
ajlm-933	25	39	known	know	VERB
ajlm-933	25	40	risk	risk	NOUN
ajlm-933	25	41	of	of	ADP
ajlm-933	25	42	cryptococcal	cryptococcal	ADJ
ajlm-933	25	43	meningitis	meningitis	NOUN
ajlm-933	25	44	,	,	PUNCT
ajlm-933	25	45	crag	crag	NOUN
ajlm-933	25	46	prevalence	prevalence	NOUN
ajlm-933	25	47	amongst	amongst	ADP
ajlm-933	25	48	people	people	NOUN
ajlm-933	25	49	with	with	ADP
ajlm-933	25	50	advanced	advanced	ADJ
ajlm-933	25	51	hiv	hiv	PROPN
ajlm-933	25	52	disease	disease	NOUN
ajlm-933	25	53	,	,	PUNCT
ajlm-933	25	54	or	or	CCONJ
ajlm-933	25	55	cd4	cd4	PROPN
ajlm-933	25	56	<	<	X
ajlm-933	25	57	200	200	NUM
ajlm-933	25	58	cells	cell	NOUN
ajlm-933	25	59	/	/	SYM
ajlm-933	25	60	mm3	mm3	PROPN
ajlm-933	25	61	,	,	PUNCT
ajlm-933	25	62	is	be	AUX
ajlm-933	25	63	unknown	unknown	ADJ
ajlm-933	25	64	in	in	ADP
ajlm-933	25	65	eswatini	eswatini	NOUN
ajlm-933	25	66	.	.	PUNCT
ajlm-933	26	1	at	at	ADP
ajlm-933	26	2	the	the	DET
ajlm-933	26	3	time	time	NOUN
ajlm-933	26	4	of	of	ADP
ajlm-933	26	5	this	this	DET
ajlm-933	26	6	study	study	NOUN
ajlm-933	26	7	,	,	PUNCT
ajlm-933	26	8	routine	routine	ADJ
ajlm-933	26	9	crag	crag	NOUN
ajlm-933	26	10	screening	screening	NOUN
ajlm-933	26	11	was	be	AUX
ajlm-933	26	12	not	not	PART
ajlm-933	26	13	included	include	VERB
ajlm-933	26	14	in	in	ADP
ajlm-933	26	15	the	the	DET
ajlm-933	26	16	national	national	ADJ
ajlm-933	26	17	guidelines	guideline	NOUN
ajlm-933	26	18	and	and	CCONJ
ajlm-933	26	19	its	its	PRON
ajlm-933	26	20	clinical	clinical	ADJ
ajlm-933	26	21	utility	utility	NOUN
ajlm-933	26	22	was	be	AUX
ajlm-933	26	23	unknown	unknown	ADJ
ajlm-933	26	24	.	.	PUNCT
ajlm-933	27	1	we	we	PRON
ajlm-933	27	2	conducted	conduct	VERB
ajlm-933	27	3	a	a	DET
ajlm-933	27	4	cross	cross	ADJ
ajlm-933	27	5	-	-	ADJ
ajlm-933	27	6	sectional	sectional	ADJ
ajlm-933	27	7	study	study	NOUN
ajlm-933	27	8	to	to	PART
ajlm-933	27	9	examine	examine	VERB
ajlm-933	27	10	crag	crag	NOUN
ajlm-933	27	11	prevalence	prevalence	NOUN
ajlm-933	27	12	at	at	ADP
ajlm-933	27	13	a	a	DET
ajlm-933	27	14	national	national	ADJ
ajlm-933	27	15	hospital	hospital	NOUN
ajlm-933	27	16	in	in	ADP
ajlm-933	27	17	eswatini	eswatini	NOUN
ajlm-933	27	18	.	.	PUNCT
ajlm-933	28	1	we	we	PRON
ajlm-933	28	2	also	also	ADV
ajlm-933	28	3	compared	compare	VERB
ajlm-933	28	4	sensitivity	sensitivity	NOUN
ajlm-933	28	5	and	and	CCONJ
ajlm-933	28	6	specificity	specificity	NOUN
ajlm-933	28	7	of	of	ADP
ajlm-933	28	8	urine	urine	NOUN
ajlm-933	28	9	crag	crag	NOUN
ajlm-933	28	10	lfa	lfa	PROPN
ajlm-933	28	11	relative	relative	ADJ
ajlm-933	28	12	to	to	ADP
ajlm-933	28	13	plasma	plasma	NOUN
ajlm-933	28	14	crag	crag	PROPN
ajlm-933	28	15	lfa	lfa	PROPN
ajlm-933	28	16	.	.	PUNCT
ajlm-933	29	1	methods	method	NOUN
ajlm-933	29	2	ethical	ethical	ADJ
ajlm-933	29	3	considerations	consideration	NOUN
ajlm-933	29	4	the	the	DET
ajlm-933	29	5	swaziland	swaziland	PROPN
ajlm-933	29	6	scientific	scientific	ADJ
ajlm-933	29	7	and	and	CCONJ
ajlm-933	29	8	ethics	ethic	NOUN
ajlm-933	29	9	committee	committee	NOUN
ajlm-933	29	10	(	(	PUNCT
ajlm-933	29	11	mh/599c/	mh/599c/	X
ajlm-933	29	12	fwa	fwa	X
ajlm-933	29	13	000	000	NUM
ajlm-933	29	14	15267	15267	NUM
ajlm-933	29	15	)	)	PUNCT
ajlm-933	29	16	,	,	PUNCT
ajlm-933	29	17	and	and	CCONJ
ajlm-933	29	18	the	the	DET
ajlm-933	29	19	centers	center	NOUN
ajlm-933	29	20	for	for	ADP
ajlm-933	29	21	disease	disease	NOUN
ajlm-933	29	22	control	control	NOUN
ajlm-933	29	23	and	and	CCONJ
ajlm-933	29	24	prevention	prevention	NOUN
ajlm-933	29	25	institutional	institutional	ADJ
ajlm-933	29	26	review	review	NOUN
ajlm-933	29	27	board	board	NOUN
ajlm-933	29	28	reviewed	review	VERB
ajlm-933	29	29	and	and	CCONJ
ajlm-933	29	30	approved	approve	VERB
ajlm-933	29	31	the	the	DET
ajlm-933	29	32	study	study	NOUN
ajlm-933	29	33	protocol	protocol	NOUN
ajlm-933	29	34	(	(	PUNCT
ajlm-933	29	35	cgh	cgh	PROPN
ajlm-933	29	36	hsr	hsr	ADV
ajlm-933	29	37	tracking	track	VERB
ajlm-933	29	38	#	#	SYM
ajlm-933	29	39	2014	2014	NUM
ajlm-933	29	40	-	-	SYM
ajlm-933	29	41	139	139	NUM
ajlm-933	29	42	)	)	PUNCT
ajlm-933	29	43	.	.	PUNCT
ajlm-933	30	1	study	study	NOUN
ajlm-933	30	2	nurses	nurse	NOUN
ajlm-933	30	3	obtained	obtain	VERB
ajlm-933	30	4	verbal	verbal	ADJ
ajlm-933	30	5	informed	inform	VERB
ajlm-933	30	6	consent	consent	NOUN
ajlm-933	30	7	from	from	ADP
ajlm-933	30	8	all	all	DET
ajlm-933	30	9	participants	participant	NOUN
ajlm-933	30	10	.	.	PUNCT
ajlm-933	31	1	study	study	NOUN
ajlm-933	31	2	location	location	NOUN
ajlm-933	31	3	and	and	CCONJ
ajlm-933	31	4	population	population	NOUN
ajlm-933	31	5	a	a	DET
ajlm-933	31	6	cross	cross	ADJ
ajlm-933	31	7	-	-	ADJ
ajlm-933	31	8	sectional	sectional	ADJ
ajlm-933	31	9	study	study	NOUN
ajlm-933	31	10	was	be	AUX
ajlm-933	31	11	implemented	implement	VERB
ajlm-933	31	12	at	at	ADP
ajlm-933	31	13	mbabane	mbabane	NOUN
ajlm-933	31	14	government	government	NOUN
ajlm-933	31	15	hospital	hospital	NOUN
ajlm-933	31	16	,	,	PUNCT
ajlm-933	31	17	a	a	DET
ajlm-933	31	18	national	national	ADJ
ajlm-933	31	19	hospital	hospital	NOUN
ajlm-933	31	20	,	,	PUNCT
ajlm-933	31	21	in	in	ADP
ajlm-933	31	22	eswatini	eswatini	NOUN
ajlm-933	31	23	.	.	PUNCT
ajlm-933	32	1	mbabane	mbabane	NOUN
ajlm-933	32	2	government	government	NOUN
ajlm-933	32	3	hospital	hospital	NOUN
ajlm-933	32	4	is	be	AUX
ajlm-933	32	5	a	a	DET
ajlm-933	32	6	public	public	ADJ
ajlm-933	32	7	hospital	hospital	NOUN
ajlm-933	32	8	with	with	ADP
ajlm-933	32	9	a	a	DET
ajlm-933	32	10	500	500	NUM
ajlm-933	32	11	bed	bed	NOUN
ajlm-933	32	12	capacity	capacity	NOUN
ajlm-933	32	13	.	.	PUNCT
ajlm-933	33	1	it	it	PRON
ajlm-933	33	2	is	be	AUX
ajlm-933	33	3	the	the	DET
ajlm-933	33	4	largest	large	ADJ
ajlm-933	33	5	hiv	hiv	NOUN
ajlm-933	33	6	treatment	treatment	NOUN
ajlm-933	33	7	and	and	CCONJ
ajlm-933	33	8	care	care	NOUN
ajlm-933	33	9	centre	centre	NOUN
ajlm-933	33	10	in	in	ADP
ajlm-933	33	11	eswatini	eswatini	NOUN
ajlm-933	33	12	and	and	CCONJ
ajlm-933	33	13	serves	serve	VERB
ajlm-933	33	14	the	the	DET
ajlm-933	33	15	population	population	NOUN
ajlm-933	33	16	of	of	ADP
ajlm-933	33	17	the	the	DET
ajlm-933	33	18	hhohho	hhohho	PROPN
ajlm-933	33	19	region	region	NOUN
ajlm-933	33	20	(	(	PUNCT
ajlm-933	33	21	320	320	NUM
ajlm-933	33	22	651	651	NUM
ajlm-933	33	23	)	)	PUNCT
ajlm-933	33	24	,	,	PUNCT
ajlm-933	33	25	as	as	ADV
ajlm-933	33	26	well	well	ADV
ajlm-933	33	27	as	as	ADP
ajlm-933	33	28	the	the	DET
ajlm-933	33	29	population	population	NOUN
ajlm-933	33	30	of	of	ADP
ajlm-933	33	31	the	the	DET
ajlm-933	33	32	nation	nation	NOUN
ajlm-933	33	33	at	at	ADP
ajlm-933	33	34	large	large	ADJ
ajlm-933	33	35	(	(	PUNCT
ajlm-933	33	36	1	1	NUM
ajlm-933	33	37	093	093	NUM
ajlm-933	33	38	2381	2381	NUM
ajlm-933	33	39	million).8	million).8	NOUN
ajlm-933	33	40	we	we	PRON
ajlm-933	33	41	assessed	assess	VERB
ajlm-933	33	42	eligibility	eligibility	NOUN
ajlm-933	33	43	of	of	ADP
ajlm-933	33	44	art	art	NOUN
ajlm-933	33	45	-	-	PUNCT
ajlm-933	33	46	naïve	naïve	ADJ
ajlm-933	33	47	adults	adult	NOUN
ajlm-933	33	48	≥	≥	NOUN
ajlm-933	33	49	18	18	NUM
ajlm-933	33	50	years	year	NOUN
ajlm-933	33	51	old	old	ADJ
ajlm-933	33	52	in	in	ADP
ajlm-933	33	53	the	the	DET
ajlm-933	33	54	study	study	NOUN
ajlm-933	33	55	who	who	PRON
ajlm-933	33	56	attended	attend	VERB
ajlm-933	33	57	the	the	DET
ajlm-933	33	58	voluntary	voluntary	ADJ
ajlm-933	33	59	counseling	counseling	NOUN
ajlm-933	33	60	and	and	CCONJ
ajlm-933	33	61	testing	testing	NOUN
ajlm-933	33	62	clinic	clinic	NOUN
ajlm-933	33	63	,	,	PUNCT
ajlm-933	33	64	as	as	ADV
ajlm-933	33	65	well	well	ADV
ajlm-933	33	66	as	as	ADP
ajlm-933	33	67	hospitalised	hospitalised	ADJ
ajlm-933	33	68	patients	patient	NOUN
ajlm-933	33	69	,	,	PUNCT
ajlm-933	33	70	by	by	ADP
ajlm-933	33	71	determining	determine	VERB
ajlm-933	33	72	their	their	PRON
ajlm-933	33	73	cd4	cd4	PROPN
ajlm-933	33	74	levels	level	NOUN
ajlm-933	33	75	using	use	VERB
ajlm-933	33	76	alere	alere	ADJ
ajlm-933	33	77	pimatm	pimatm	NOUN
ajlm-933	33	78	(	(	PUNCT
ajlm-933	33	79	abbott	abbott	PROPN
ajlm-933	33	80	laboratories	laboratories	PROPN
ajlm-933	33	81	,	,	PUNCT
ajlm-933	33	82	chicago	chicago	PROPN
ajlm-933	33	83	,	,	PUNCT
ajlm-933	33	84	illinois	illinois	PROPN
ajlm-933	33	85	,	,	PUNCT
ajlm-933	33	86	united	united	PROPN
ajlm-933	33	87	states	states	PROPN
ajlm-933	33	88	)	)	PUNCT
ajlm-933	33	89	.	.	PUNCT
ajlm-933	34	1	for	for	ADP
ajlm-933	34	2	hiv	hiv	PROPN
ajlm-933	34	3	-	-	PUNCT
ajlm-933	34	4	positive	positive	ADJ
ajlm-933	34	5	patients	patient	NOUN
ajlm-933	34	6	with	with	ADP
ajlm-933	34	7	cd4	cd4	PROPN
ajlm-933	34	8	≤	≤	ADV
ajlm-933	34	9	350	350	NUM
ajlm-933	34	10	cells	cell	NOUN
ajlm-933	34	11	/	/	SYM
ajlm-933	34	12	mm3	mm3	NOUN
ajlm-933	34	13	by	by	ADP
ajlm-933	34	14	the	the	DET
ajlm-933	34	15	alere	alere	ADJ
ajlm-933	34	16	pimatm	pimatm	PROPN
ajlm-933	34	17	cd4	cd4	PROPN
ajlm-933	34	18	test	test	NOUN
ajlm-933	34	19	,	,	PUNCT
ajlm-933	34	20	a	a	DET
ajlm-933	34	21	confirmatory	confirmatory	NOUN
ajlm-933	34	22	test	test	NOUN
ajlm-933	34	23	was	be	AUX
ajlm-933	34	24	completed	complete	VERB
ajlm-933	34	25	using	use	VERB
ajlm-933	34	26	bd	bd	PROPN
ajlm-933	34	27	facscaliburtm	facscaliburtm	PROPN
ajlm-933	34	28	(	(	PUNCT
ajlm-933	34	29	beckton	beckton	PROPN
ajlm-933	34	30	dickinson	dickinson	PROPN
ajlm-933	34	31	,	,	PUNCT
ajlm-933	34	32	san	san	PROPN
ajlm-933	34	33	jose	jose	PROPN
ajlm-933	34	34	,	,	PUNCT
ajlm-933	34	35	california	california	PROPN
ajlm-933	34	36	,	,	PUNCT
ajlm-933	34	37	united	united	PROPN
ajlm-933	34	38	states	states	PROPN
ajlm-933	34	39	)	)	PUNCT
ajlm-933	34	40	flow	flow	NOUN
ajlm-933	34	41	cytometry	cytometry	NOUN
ajlm-933	34	42	.	.	PUNCT
ajlm-933	35	1	patients	patient	NOUN
ajlm-933	35	2	with	with	ADP
ajlm-933	35	3	cd4	cd4	PROPN
ajlm-933	35	4	<	<	X
ajlm-933	35	5	200	200	NUM
ajlm-933	35	6	cells	cell	NOUN
ajlm-933	35	7	/	/	SYM
ajlm-933	35	8	mm3	mm3	NOUN
ajlm-933	35	9	on	on	ADP
ajlm-933	35	10	bd	bd	PROPN
ajlm-933	35	11	facscaliburtm	facscaliburtm	PROPN
ajlm-933	35	12	were	be	AUX
ajlm-933	35	13	enrolled	enrol	VERB
ajlm-933	35	14	in	in	ADP
ajlm-933	35	15	the	the	DET
ajlm-933	35	16	study	study	NOUN
ajlm-933	35	17	.	.	PUNCT
ajlm-933	36	1	enrolment	enrolment	PROPN
ajlm-933	36	2	occurred	occur	VERB
ajlm-933	36	3	from	from	ADP
ajlm-933	36	4	18	18	NUM
ajlm-933	36	5	august	august	PROPN
ajlm-933	36	6	2014	2014	NUM
ajlm-933	36	7	to	to	ADP
ajlm-933	36	8	19	19	NUM
ajlm-933	36	9	march	march	PROPN
ajlm-933	36	10	2015	2015	NUM
ajlm-933	36	11	.	.	PUNCT
ajlm-933	37	1	we	we	PRON
ajlm-933	37	2	excluded	exclude	VERB
ajlm-933	37	3	pregnant	pregnant	ADJ
ajlm-933	37	4	women	woman	NOUN
ajlm-933	37	5	,	,	PUNCT
ajlm-933	37	6	patients	patient	NOUN
ajlm-933	37	7	with	with	ADP
ajlm-933	37	8	a	a	DET
ajlm-933	37	9	previous	previous	ADJ
ajlm-933	37	10	diagnosis	diagnosis	NOUN
ajlm-933	37	11	or	or	CCONJ
ajlm-933	37	12	treatment	treatment	NOUN
ajlm-933	37	13	for	for	ADP
ajlm-933	37	14	cryptococcal	cryptococcal	ADJ
ajlm-933	37	15	meningitis	meningitis	NOUN
ajlm-933	37	16	,	,	PUNCT
ajlm-933	37	17	and	and	CCONJ
ajlm-933	37	18	patients	patient	NOUN
ajlm-933	37	19	who	who	PRON
ajlm-933	37	20	had	have	AUX
ajlm-933	37	21	ever	ever	ADV
ajlm-933	37	22	received	receive	VERB
ajlm-933	37	23	fluconazole	fluconazole	NOUN
ajlm-933	37	24	for	for	ADP
ajlm-933	37	25	<	<	X
ajlm-933	37	26	5	5	NUM
ajlm-933	37	27	days	day	NOUN
ajlm-933	37	28	before	before	ADP
ajlm-933	37	29	study	study	NOUN
ajlm-933	37	30	enrolment	enrolment	NOUN
ajlm-933	37	31	.	.	PUNCT
ajlm-933	38	1	blood	blood	NOUN
ajlm-933	38	2	and	and	CCONJ
ajlm-933	38	3	urine	urine	NOUN
ajlm-933	38	4	samples	sample	NOUN
ajlm-933	38	5	were	be	AUX
ajlm-933	38	6	obtained	obtain	VERB
ajlm-933	38	7	during	during	ADP
ajlm-933	38	8	the	the	DET
ajlm-933	38	9	patient	patient	NOUN
ajlm-933	38	10	’s	’s	PART
ajlm-933	38	11	first	first	ADJ
ajlm-933	38	12	visit	visit	NOUN
ajlm-933	38	13	to	to	ADP
ajlm-933	38	14	the	the	DET
ajlm-933	38	15	hiv	hiv	PROPN
ajlm-933	38	16	testing	testing	NOUN
ajlm-933	38	17	clinic	clinic	NOUN
ajlm-933	38	18	or	or	CCONJ
ajlm-933	38	19	soon	soon	ADV
ajlm-933	38	20	after	after	ADP
ajlm-933	38	21	hiv	hiv	PROPN
ajlm-933	38	22	testing	testing	NOUN
ajlm-933	38	23	,	,	PUNCT
ajlm-933	38	24	if	if	SCONJ
ajlm-933	38	25	an	an	DET
ajlm-933	38	26	inpatient	inpatient	NOUN
ajlm-933	38	27	.	.	PUNCT
ajlm-933	39	1	plasma	plasma	NOUN
ajlm-933	39	2	and	and	CCONJ
ajlm-933	39	3	urine	urine	NOUN
ajlm-933	39	4	crag	crag	NOUN
ajlm-933	39	5	screening	screening	NOUN
ajlm-933	39	6	were	be	AUX
ajlm-933	39	7	conducted	conduct	VERB
ajlm-933	39	8	using	use	VERB
ajlm-933	39	9	a	a	DET
ajlm-933	39	10	lfa	lfa	PROPN
ajlm-933	39	11	(	(	PUNCT
ajlm-933	39	12	immy	immy	PROPN
ajlm-933	39	13	,	,	PUNCT
ajlm-933	39	14	norman	norman	PROPN
ajlm-933	39	15	,	,	PUNCT
ajlm-933	39	16	oklahoma	oklahoma	PROPN
ajlm-933	39	17	,	,	PUNCT
ajlm-933	39	18	united	united	PROPN
ajlm-933	39	19	states	states	PROPN
ajlm-933	39	20	)	)	PUNCT
ajlm-933	39	21	at	at	ADP
ajlm-933	39	22	the	the	DET
ajlm-933	39	23	hospital	hospital	NOUN
ajlm-933	39	24	laboratory	laboratory	NOUN
ajlm-933	39	25	for	for	ADP
ajlm-933	39	26	patients	patient	NOUN
ajlm-933	39	27	both	both	CCONJ
ajlm-933	39	28	with	with	ADP
ajlm-933	39	29	and	and	CCONJ
ajlm-933	39	30	without	without	ADP
ajlm-933	39	31	signs	sign	NOUN
ajlm-933	39	32	of	of	ADP
ajlm-933	39	33	cryptococcal	cryptococcal	ADJ
ajlm-933	39	34	meningitis	meningitis	NOUN
ajlm-933	39	35	.	.	PUNCT
ajlm-933	40	1	data	datum	NOUN
ajlm-933	40	2	collection	collection	NOUN
ajlm-933	40	3	trained	train	VERB
ajlm-933	40	4	study	study	NOUN
ajlm-933	40	5	nurses	nurse	NOUN
ajlm-933	40	6	and	and	CCONJ
ajlm-933	40	7	research	research	NOUN
ajlm-933	40	8	assistants	assistant	NOUN
ajlm-933	40	9	conducted	conduct	VERB
ajlm-933	40	10	data	datum	NOUN
ajlm-933	40	11	collection	collection	NOUN
ajlm-933	40	12	.	.	PUNCT
ajlm-933	41	1	study	study	NOUN
ajlm-933	41	2	nurses	nurse	NOUN
ajlm-933	41	3	and	and	CCONJ
ajlm-933	41	4	research	research	NOUN
ajlm-933	41	5	assistants	assistant	NOUN
ajlm-933	41	6	gave	give	VERB
ajlm-933	41	7	a	a	DET
ajlm-933	41	8	communication	communication	NOUN
ajlm-933	41	9	leaflet	leaflet	NOUN
ajlm-933	41	10	providing	provide	VERB
ajlm-933	41	11	basic	basic	ADJ
ajlm-933	41	12	information	information	NOUN
ajlm-933	41	13	on	on	ADP
ajlm-933	41	14	cryptococcus	cryptococcus	PROPN
ajlm-933	41	15	spp	spp	PROPN
ajlm-933	41	16	.	.	PUNCT
ajlm-933	42	1	and	and	CCONJ
ajlm-933	42	2	hiv	hiv	PROPN
ajlm-933	42	3	infection	infection	NOUN
ajlm-933	42	4	as	as	ADV
ajlm-933	42	5	well	well	ADV
ajlm-933	42	6	as	as	ADP
ajlm-933	42	7	the	the	DET
ajlm-933	42	8	objectives	objective	NOUN
ajlm-933	42	9	of	of	ADP
ajlm-933	42	10	the	the	DET
ajlm-933	42	11	study	study	NOUN
ajlm-933	42	12	to	to	ADP
ajlm-933	42	13	eligible	eligible	ADJ
ajlm-933	42	14	patients	patient	NOUN
ajlm-933	42	15	.	.	PUNCT
ajlm-933	43	1	after	after	ADP
ajlm-933	43	2	the	the	DET
ajlm-933	43	3	informed	informed	ADJ
ajlm-933	43	4	consent	consent	NOUN
ajlm-933	43	5	process	process	NOUN
ajlm-933	43	6	,	,	PUNCT
ajlm-933	43	7	data	datum	NOUN
ajlm-933	43	8	on	on	ADP
ajlm-933	43	9	patient	patient	ADJ
ajlm-933	43	10	demographic	demographic	ADJ
ajlm-933	43	11	characteristics	characteristic	NOUN
ajlm-933	43	12	including	include	VERB
ajlm-933	43	13	age	age	NOUN
ajlm-933	43	14	,	,	PUNCT
ajlm-933	43	15	sex	sex	NOUN
ajlm-933	43	16	,	,	PUNCT
ajlm-933	43	17	marital	marital	ADJ
ajlm-933	43	18	status	status	NOUN
ajlm-933	43	19	,	,	PUNCT
ajlm-933	43	20	area	area	NOUN
ajlm-933	43	21	of	of	ADP
ajlm-933	43	22	residence	residence	NOUN
ajlm-933	43	23	(	(	PUNCT
ajlm-933	43	24	rural	rural	ADJ
ajlm-933	43	25	or	or	CCONJ
ajlm-933	43	26	urban	urban	ADJ
ajlm-933	43	27	)	)	PUNCT
ajlm-933	43	28	,	,	PUNCT
ajlm-933	43	29	level	level	NOUN
ajlm-933	43	30	of	of	ADP
ajlm-933	43	31	education	education	NOUN
ajlm-933	43	32	,	,	PUNCT
ajlm-933	43	33	and	and	CCONJ
ajlm-933	43	34	the	the	DET
ajlm-933	43	35	clinical	clinical	ADJ
ajlm-933	43	36	stage	stage	NOUN
ajlm-933	43	37	of	of	ADP
ajlm-933	43	38	hiv	hiv	PROPN
ajlm-933	43	39	infection9	infection9	PROPN
ajlm-933	43	40	were	be	AUX
ajlm-933	43	41	collected	collect	VERB
ajlm-933	43	42	.	.	PUNCT
ajlm-933	44	1	clinical	clinical	ADJ
ajlm-933	44	2	procedures	procedure	NOUN
ajlm-933	44	3	at	at	ADP
ajlm-933	44	4	enrolment	enrolment	NOUN
ajlm-933	44	5	,	,	PUNCT
ajlm-933	44	6	study	study	NOUN
ajlm-933	44	7	nurses	nurse	NOUN
ajlm-933	44	8	assessed	assess	VERB
ajlm-933	44	9	patients	patient	NOUN
ajlm-933	44	10	’	'	PUNCT
ajlm-933	44	11	clinical	clinical	ADJ
ajlm-933	44	12	signs	sign	NOUN
ajlm-933	44	13	and	and	CCONJ
ajlm-933	44	14	symptoms	symptom	NOUN
ajlm-933	44	15	of	of	ADP
ajlm-933	44	16	cryptococcal	cryptococcal	ADJ
ajlm-933	44	17	meningitis	meningiti	NOUN
ajlm-933	44	18	such	such	ADJ
ajlm-933	44	19	as	as	ADP
ajlm-933	44	20	fever	fever	NOUN
ajlm-933	44	21	,	,	PUNCT
ajlm-933	44	22	headache	headache	NOUN
ajlm-933	44	23	,	,	PUNCT
ajlm-933	44	24	neck	neck	NOUN
ajlm-933	44	25	stiffness	stiffness	NOUN
ajlm-933	44	26	,	,	PUNCT
ajlm-933	44	27	altered	alter	VERB
ajlm-933	44	28	mental	mental	ADJ
ajlm-933	44	29	status	status	NOUN
ajlm-933	44	30	,	,	PUNCT
ajlm-933	44	31	photophobia	photophobia	NOUN
ajlm-933	44	32	,	,	PUNCT
ajlm-933	44	33	nausea	nausea	NOUN
ajlm-933	44	34	,	,	PUNCT
ajlm-933	44	35	night	night	NOUN
ajlm-933	44	36	sweats	sweat	NOUN
ajlm-933	44	37	,	,	PUNCT
ajlm-933	44	38	cough	cough	NOUN
ajlm-933	44	39	,	,	PUNCT
ajlm-933	44	40	vomiting	vomiting	NOUN
ajlm-933	44	41	,	,	PUNCT
ajlm-933	44	42	shortness	shortness	NOUN
ajlm-933	44	43	of	of	ADP
ajlm-933	44	44	breath	breath	NOUN
ajlm-933	44	45	,	,	PUNCT
ajlm-933	44	46	skin	skin	NOUN
ajlm-933	44	47	papules	papule	NOUN
ajlm-933	44	48	,	,	PUNCT
ajlm-933	44	49	or	or	CCONJ
ajlm-933	44	50	kerning	kerning	NOUN
ajlm-933	44	51	sign	sign	NOUN
ajlm-933	44	52	.	.	PUNCT
ajlm-933	45	1	patients	patient	NOUN
ajlm-933	45	2	with	with	ADP
ajlm-933	45	3	positive	positive	ADJ
ajlm-933	45	4	plasma	plasma	NOUN
ajlm-933	45	5	crag	crag	NOUN
ajlm-933	45	6	results	result	NOUN
ajlm-933	45	7	and	and	CCONJ
ajlm-933	45	8	signs	sign	NOUN
ajlm-933	45	9	and	and	CCONJ
ajlm-933	45	10	symptoms	symptom	NOUN
ajlm-933	45	11	of	of	ADP
ajlm-933	45	12	cryptococcal	cryptococcal	ADJ
ajlm-933	45	13	meningitis	meningitis	NOUN
ajlm-933	45	14	underwent	undergo	VERB
ajlm-933	45	15	a	a	DET
ajlm-933	45	16	lumbar	lumbar	NOUN
ajlm-933	45	17	puncture	puncture	NOUN
ajlm-933	45	18	as	as	ADP
ajlm-933	45	19	part	part	NOUN
ajlm-933	45	20	of	of	ADP
ajlm-933	45	21	routine	routine	ADJ
ajlm-933	45	22	practice	practice	NOUN
ajlm-933	45	23	.	.	PUNCT
ajlm-933	46	1	csf	csf	ADJ
ajlm-933	46	2	samples	sample	NOUN
ajlm-933	46	3	obtained	obtain	VERB
ajlm-933	46	4	from	from	ADP
ajlm-933	46	5	the	the	DET
ajlm-933	46	6	lumbar	lumbar	NOUN
ajlm-933	46	7	puncture	puncture	NOUN
ajlm-933	46	8	were	be	AUX
ajlm-933	46	9	collected	collect	VERB
ajlm-933	46	10	for	for	ADP
ajlm-933	46	11	crag	crag	NOUN
ajlm-933	46	12	lfa	lfa	PROPN
ajlm-933	46	13	to	to	PART
ajlm-933	46	14	diagnose	diagnose	VERB
ajlm-933	46	15	cryptococcal	cryptococcal	ADJ
ajlm-933	46	16	meningitis	meningitis	NOUN
ajlm-933	46	17	.	.	PUNCT
ajlm-933	47	1	patients	patient	NOUN
ajlm-933	47	2	diagnosed	diagnose	VERB
ajlm-933	47	3	with	with	ADP
ajlm-933	47	4	cryptococcal	cryptococcal	ADJ
ajlm-933	47	5	meningitis	meningitis	NOUN
ajlm-933	47	6	were	be	AUX
ajlm-933	47	7	treated	treat	VERB
ajlm-933	47	8	according	accord	VERB
ajlm-933	47	9	to	to	ADP
ajlm-933	47	10	a	a	DET
ajlm-933	47	11	standard	standard	NOUN
ajlm-933	47	12	of	of	ADP
ajlm-933	47	13	care	care	NOUN
ajlm-933	47	14	based	base	VERB
ajlm-933	47	15	on	on	ADP
ajlm-933	47	16	who	who	PRON
ajlm-933	47	17	guidelines,3	guidelines,3	NOUN
ajlm-933	47	18	which	which	PRON
ajlm-933	47	19	included	include	VERB
ajlm-933	47	20	amphotericin	amphotericin	ADP
ajlm-933	47	21	b	b	SYM
ajlm-933	47	22	(	(	PUNCT
ajlm-933	47	23	0.7	0.7	NUM
ajlm-933	47	24	mg	mg	PROPN
ajlm-933	47	25	/	/	SYM
ajlm-933	47	26	kg	kg	PROPN
ajlm-933	47	27	/	/	SYM
ajlm-933	47	28	day	day	NOUN
ajlm-933	47	29	)	)	PUNCT
ajlm-933	47	30	and	and	CCONJ
ajlm-933	47	31	fluconazole	fluconazole	NOUN
ajlm-933	47	32	(	(	PUNCT
ajlm-933	47	33	800	800	NUM
ajlm-933	47	34	mg	mg	NOUN
ajlm-933	47	35	)	)	PUNCT
ajlm-933	47	36	for	for	ADP
ajlm-933	47	37	2	2	NUM
ajlm-933	47	38	weeks	week	NOUN
ajlm-933	47	39	followed	follow	VERB
ajlm-933	47	40	by	by	ADP
ajlm-933	47	41	400	400	NUM
ajlm-933	47	42	mg	mg	NOUN
ajlm-933	47	43	of	of	ADP
ajlm-933	47	44	fluconazole	fluconazole	NOUN
ajlm-933	47	45	for	for	ADP
ajlm-933	47	46	8	8	NUM
ajlm-933	47	47	weeks	week	NOUN
ajlm-933	47	48	and	and	CCONJ
ajlm-933	47	49	then	then	ADV
ajlm-933	47	50	maintained	maintain	VERB
ajlm-933	47	51	at	at	ADP
ajlm-933	47	52	200	200	NUM
ajlm-933	47	53	mg	mg	NOUN
ajlm-933	47	54	for	for	ADP
ajlm-933	47	55	secondary	secondary	ADJ
ajlm-933	47	56	prophylaxis	prophylaxis	NOUN
ajlm-933	47	57	.	.	PUNCT
ajlm-933	48	1	patients	patient	NOUN
ajlm-933	48	2	who	who	PRON
ajlm-933	48	3	refused	refuse	VERB
ajlm-933	48	4	a	a	DET
ajlm-933	48	5	lumbar	lumbar	NOUN
ajlm-933	48	6	puncture	puncture	NOUN
ajlm-933	48	7	but	but	CCONJ
ajlm-933	48	8	had	have	VERB
ajlm-933	48	9	positive	positive	ADJ
ajlm-933	48	10	plasma	plasma	NOUN
ajlm-933	48	11	crag	crag	NOUN
ajlm-933	48	12	results	result	NOUN
ajlm-933	48	13	were	be	AUX
ajlm-933	48	14	offered	offer	VERB
ajlm-933	48	15	pre	pre	ADJ
ajlm-933	48	16	-	-	ADJ
ajlm-933	48	17	emptive	emptive	ADJ
ajlm-933	48	18	therapy	therapy	NOUN
ajlm-933	48	19	which	which	PRON
ajlm-933	48	20	followed	follow	VERB
ajlm-933	48	21	who	who	PRON
ajlm-933	48	22	recommendations	recommendation	NOUN
ajlm-933	48	23	of	of	ADP
ajlm-933	48	24	fluconazole	fluconazole	NOUN
ajlm-933	48	25	800	800	NUM
ajlm-933	48	26	mg	mg	NUM
ajlm-933	48	27	/	/	SYM
ajlm-933	48	28	day	day	NOUN
ajlm-933	48	29	for	for	ADP
ajlm-933	48	30	the	the	DET
ajlm-933	48	31	first	first	ADJ
ajlm-933	48	32	2	2	NUM
ajlm-933	48	33	weeks	week	NOUN
ajlm-933	48	34	,	,	PUNCT
ajlm-933	48	35	followed	follow	VERB
ajlm-933	48	36	by	by	ADP
ajlm-933	48	37	8	8	NUM
ajlm-933	48	38	weeks	week	NOUN
ajlm-933	48	39	of	of	ADP
ajlm-933	48	40	400	400	NUM
ajlm-933	48	41	mg	mg	NUM
ajlm-933	48	42	/	/	SYM
ajlm-933	48	43	day	day	NOUN
ajlm-933	48	44	of	of	ADP
ajlm-933	48	45	fluconazole	fluconazole	NOUN
ajlm-933	48	46	daily	daily	ADV
ajlm-933	48	47	,	,	PUNCT
ajlm-933	48	48	and	and	CCONJ
ajlm-933	48	49	a	a	DET
ajlm-933	48	50	200	200	NUM
ajlm-933	48	51	mg	mg	NUM
ajlm-933	48	52	/	/	SYM
ajlm-933	48	53	day	day	NOUN
ajlm-933	48	54	fluconazole	fluconazole	NOUN
ajlm-933	48	55	maintenance	maintenance	NOUN
ajlm-933	48	56	dosage.3	dosage.3	PROPN
ajlm-933	48	57	the	the	DET
ajlm-933	48	58	south	south	ADJ
ajlm-933	48	59	african	african	ADJ
ajlm-933	48	60	clinical	clinical	ADJ
ajlm-933	48	61	guidelines	guideline	NOUN
ajlm-933	48	62	(	(	PUNCT
ajlm-933	48	63	2013	2013	NUM
ajlm-933	48	64	)	)	PUNCT
ajlm-933	48	65	were	be	AUX
ajlm-933	48	66	followed	follow	VERB
ajlm-933	48	67	for	for	ADP
ajlm-933	48	68	patients	patient	NOUN
ajlm-933	48	69	with	with	ADP
ajlm-933	48	70	positive	positive	ADJ
ajlm-933	48	71	plasma	plasma	NOUN
ajlm-933	48	72	crag	crag	NOUN
ajlm-933	48	73	and	and	CCONJ
ajlm-933	48	74	negative	negative	ADJ
ajlm-933	48	75	csf	csf	ADJ
ajlm-933	48	76	crag	crag	NOUN
ajlm-933	48	77	results.10	results.10	NOUN
ajlm-933	48	78	art	art	NOUN
ajlm-933	48	79	was	be	AUX
ajlm-933	48	80	delayed	delay	VERB
ajlm-933	48	81	for	for	ADP
ajlm-933	48	82	2	2	NUM
ajlm-933	48	83	weeks	week	NOUN
ajlm-933	48	84	to	to	PART
ajlm-933	48	85	decrease	decrease	VERB
ajlm-933	48	86	the	the	DET
ajlm-933	48	87	risk	risk	NOUN
ajlm-933	48	88	of	of	ADP
ajlm-933	48	89	immune	immune	ADJ
ajlm-933	48	90	reconstitution	reconstitution	NOUN
ajlm-933	48	91	inflammatory	inflammatory	ADJ
ajlm-933	48	92	syndrome	syndrome	NOUN
ajlm-933	48	93	,	,	PUNCT
ajlm-933	48	94	and	and	CCONJ
ajlm-933	48	95	they	they	PRON
ajlm-933	48	96	were	be	AUX
ajlm-933	48	97	prescribed	prescribe	VERB
ajlm-933	48	98	pre	pre	ADJ
ajlm-933	48	99	-	-	ADJ
ajlm-933	48	100	emptive	emptive	ADJ
ajlm-933	48	101	fluconazole	fluconazole	NOUN
ajlm-933	48	102	oral	oral	ADJ
ajlm-933	48	103	treatment	treatment	NOUN
ajlm-933	48	104	to	to	PART
ajlm-933	48	105	prevent	prevent	VERB
ajlm-933	48	106	the	the	DET
ajlm-933	48	107	development	development	NOUN
ajlm-933	48	108	of	of	ADP
ajlm-933	48	109	meningeal	meningeal	ADJ
ajlm-933	48	110	infection.10	infection.10	NOUN
ajlm-933	48	111	because	because	SCONJ
ajlm-933	48	112	of	of	ADP
ajlm-933	48	113	resource	resource	NOUN
ajlm-933	48	114	constraints	constraint	NOUN
ajlm-933	48	115	,	,	PUNCT
ajlm-933	48	116	patients	patient	NOUN
ajlm-933	48	117	’	'	PUNCT
ajlm-933	48	118	cryptococcal	cryptococcal	ADJ
ajlm-933	48	119	infections	infection	NOUN
ajlm-933	48	120	were	be	AUX
ajlm-933	48	121	not	not	PART
ajlm-933	48	122	verified	verify	VERB
ajlm-933	48	123	using	use	VERB
ajlm-933	48	124	x	x	NOUN
ajlm-933	48	125	-	-	NOUN
ajlm-933	48	126	ray	ray	NOUN
ajlm-933	48	127	or	or	CCONJ
ajlm-933	48	128	other	other	ADJ
ajlm-933	48	129	imaging	imaging	NOUN
ajlm-933	48	130	technology	technology	NOUN
ajlm-933	48	131	,	,	PUNCT
ajlm-933	48	132	and	and	CCONJ
ajlm-933	48	133	we	we	PRON
ajlm-933	48	134	did	do	AUX
ajlm-933	48	135	not	not	PART
ajlm-933	48	136	follow	follow	VERB
ajlm-933	48	137	the	the	DET
ajlm-933	48	138	individual	individual	ADJ
ajlm-933	48	139	patients	patient	NOUN
ajlm-933	48	140	’	'	PUNCT
ajlm-933	48	141	clinical	clinical	ADJ
ajlm-933	48	142	course	course	NOUN
ajlm-933	48	143	to	to	PART
ajlm-933	48	144	collect	collect	VERB
ajlm-933	48	145	outcome	outcome	NOUN
ajlm-933	48	146	measures	measure	NOUN
ajlm-933	48	147	for	for	ADP
ajlm-933	48	148	the	the	DET
ajlm-933	48	149	purposes	purpose	NOUN
ajlm-933	48	150	of	of	ADP
ajlm-933	48	151	this	this	DET
ajlm-933	48	152	study	study	NOUN
ajlm-933	48	153	.	.	PUNCT
ajlm-933	49	1	laboratory	laboratory	NOUN
ajlm-933	49	2	procedures	procedure	NOUN
ajlm-933	49	3	all	all	DET
ajlm-933	49	4	blood	blood	NOUN
ajlm-933	49	5	and	and	CCONJ
ajlm-933	49	6	urine	urine	NOUN
ajlm-933	49	7	specimens	specimen	NOUN
ajlm-933	49	8	were	be	AUX
ajlm-933	49	9	packaged	package	VERB
ajlm-933	49	10	according	accord	VERB
ajlm-933	49	11	to	to	ADP
ajlm-933	49	12	who	who	PRON
ajlm-933	49	13	standards	standard	NOUN
ajlm-933	49	14	.	.	PUNCT
ajlm-933	50	1	study	study	NOUN
ajlm-933	50	2	nurses	nurse	NOUN
ajlm-933	50	3	collected	collect	VERB
ajlm-933	50	4	fresh	fresh	ADJ
ajlm-933	50	5	urine	urine	NOUN
ajlm-933	50	6	samples	sample	NOUN
ajlm-933	50	7	and	and	CCONJ
ajlm-933	50	8	recorded	record	VERB
ajlm-933	50	9	urine	urine	NOUN
ajlm-933	50	10	crag	crag	NOUN
ajlm-933	50	11	lfa	lfa	PROPN
ajlm-933	50	12	positive	positive	ADJ
ajlm-933	50	13	results	result	NOUN
ajlm-933	50	14	.	.	PUNCT
ajlm-933	51	1	in	in	ADP
ajlm-933	51	2	addition	addition	NOUN
ajlm-933	51	3	,	,	PUNCT
ajlm-933	51	4	study	study	NOUN
ajlm-933	51	5	nurses	nurse	NOUN
ajlm-933	51	6	collected	collect	VERB
ajlm-933	51	7	whole	whole	ADJ
ajlm-933	51	8	blood	blood	NOUN
ajlm-933	51	9	in	in	ADP
ajlm-933	51	10	ethylene	ethylene	NOUN
ajlm-933	51	11	diamine	diamine	NOUN
ajlm-933	51	12	tetra	tetra	NOUN
ajlm-933	51	13	acetic	acetic	ADJ
ajlm-933	51	14	acid	acid	NOUN
ajlm-933	51	15	-	-	PUNCT
ajlm-933	51	16	treated	treat	VERB
ajlm-933	51	17	test	test	NOUN
ajlm-933	51	18	tubes	tube	NOUN
ajlm-933	51	19	and	and	CCONJ
ajlm-933	51	20	stored	store	VERB
ajlm-933	51	21	it	it	PRON
ajlm-933	51	22	at	at	ADP
ajlm-933	51	23	room	room	NOUN
ajlm-933	51	24	temperature	temperature	NOUN
ajlm-933	51	25	.	.	PUNCT
ajlm-933	52	1	the	the	DET
ajlm-933	52	2	blood	blood	NOUN
ajlm-933	52	3	was	be	AUX
ajlm-933	52	4	centrifuged	centrifuge	VERB
ajlm-933	52	5	for	for	ADP
ajlm-933	52	6	5	5	NUM
ajlm-933	52	7	min	min	NOUN
ajlm-933	52	8	at	at	ADP
ajlm-933	52	9	300	300	NUM
ajlm-933	52	10	revolutions	revolution	NOUN
ajlm-933	52	11	per	per	ADP
ajlm-933	52	12	minute	minute	NOUN
ajlm-933	52	13	to	to	PART
ajlm-933	52	14	obtain	obtain	VERB
ajlm-933	52	15	plasma	plasma	NOUN
ajlm-933	52	16	samples	sample	NOUN
ajlm-933	52	17	on	on	ADP
ajlm-933	52	18	the	the	DET
ajlm-933	52	19	same	same	ADJ
ajlm-933	52	20	day	day	NOUN
ajlm-933	52	21	that	that	PRON
ajlm-933	52	22	blood	blood	NOUN
ajlm-933	52	23	was	be	AUX
ajlm-933	52	24	collected	collect	VERB
ajlm-933	52	25	.	.	PUNCT
ajlm-933	53	1	plasma	plasma	NOUN
ajlm-933	53	2	and	and	CCONJ
ajlm-933	53	3	urine	urine	NOUN
ajlm-933	53	4	samples	sample	NOUN
ajlm-933	53	5	were	be	AUX
ajlm-933	53	6	stored	store	VERB
ajlm-933	53	7	at	at	ADP
ajlm-933	53	8	2	2	NUM
ajlm-933	53	9	°	°	ADP
ajlm-933	53	10	c	c	NOUN
ajlm-933	53	11	–	–	PUNCT
ajlm-933	53	12	8	8	NUM
ajlm-933	53	13	°	°	NUM
ajlm-933	53	14	c	c	NOUN
ajlm-933	53	15	for	for	ADP
ajlm-933	53	16	up	up	ADP
ajlm-933	53	17	to	to	PART
ajlm-933	53	18	72	72	NUM
ajlm-933	53	19	h.	h.	NOUN
ajlm-933	53	20	cd4	cd4	PROPN
ajlm-933	53	21	retesting	reteste	VERB
ajlm-933	53	22	was	be	AUX
ajlm-933	53	23	completed	complete	VERB
ajlm-933	53	24	using	use	VERB
ajlm-933	53	25	facscaliburtm	facscaliburtm	NOUN
ajlm-933	53	26	and	and	CCONJ
ajlm-933	53	27	research	research	NOUN
ajlm-933	53	28	assistants	assistant	NOUN
ajlm-933	53	29	conducted	conduct	VERB
ajlm-933	53	30	crag	crag	NOUN
ajlm-933	53	31	testing	testing	NOUN
ajlm-933	53	32	at	at	ADP
ajlm-933	53	33	the	the	DET
ajlm-933	53	34	laboratory	laboratory	NOUN
ajlm-933	53	35	the	the	DET
ajlm-933	53	36	next	next	ADJ
ajlm-933	53	37	day	day	NOUN
ajlm-933	53	38	using	use	VERB
ajlm-933	53	39	crag	crag	NOUN
ajlm-933	53	40	lfa	lfa	PROPN
ajlm-933	53	41	on	on	ADP
ajlm-933	53	42	samples	sample	NOUN
ajlm-933	53	43	from	from	ADP
ajlm-933	53	44	patients	patient	NOUN
ajlm-933	53	45	with	with	ADP
ajlm-933	53	46	cd4	cd4	PROPN
ajlm-933	53	47	<	<	X
ajlm-933	53	48	200	200	NUM
ajlm-933	53	49	cells	cell	NOUN
ajlm-933	53	50	/	/	SYM
ajlm-933	53	51	mm3	mm3	NOUN
ajlm-933	53	52	.	.	PUNCT
ajlm-933	54	1	in	in	ADP
ajlm-933	54	2	addition	addition	NOUN
ajlm-933	54	3	,	,	PUNCT
ajlm-933	54	4	research	research	NOUN
ajlm-933	54	5	assistants	assistant	NOUN
ajlm-933	54	6	performed	perform	VERB
ajlm-933	54	7	daily	daily	ADV
ajlm-933	54	8	positive	positive	ADJ
ajlm-933	54	9	and	and	CCONJ
ajlm-933	54	10	negative	negative	ADJ
ajlm-933	54	11	control	control	NOUN
ajlm-933	54	12	lfa	lfa	PROPN
ajlm-933	54	13	testing	testing	NOUN
ajlm-933	54	14	as	as	ADV
ajlm-933	54	15	well	well	ADV
ajlm-933	54	16	as	as	ADP
ajlm-933	54	17	lot	lot	NOUN
ajlm-933	54	18	-	-	PUNCT
ajlm-933	54	19	to	to	ADP
ajlm-933	54	20	-	-	PUNCT
ajlm-933	54	21	lot	lot	NOUN
ajlm-933	54	22	testing	testing	NOUN
ajlm-933	54	23	to	to	PART
ajlm-933	54	24	ensure	ensure	VERB
ajlm-933	54	25	the	the	DET
ajlm-933	54	26	quality	quality	NOUN
ajlm-933	54	27	of	of	ADP
ajlm-933	54	28	reagents	reagent	NOUN
ajlm-933	54	29	.	.	PUNCT
ajlm-933	55	1	research	research	NOUN
ajlm-933	55	2	assistants	assistant	NOUN
ajlm-933	55	3	communicated	communicate	VERB
ajlm-933	55	4	all	all	DET
ajlm-933	55	5	laboratory	laboratory	NOUN
ajlm-933	55	6	results	result	NOUN
ajlm-933	55	7	to	to	ADP
ajlm-933	55	8	physicians	physician	NOUN
ajlm-933	55	9	for	for	ADP
ajlm-933	55	10	clinical	clinical	ADJ
ajlm-933	55	11	management	management	NOUN
ajlm-933	55	12	,	,	PUNCT
ajlm-933	55	13	and	and	CCONJ
ajlm-933	55	14	clinicians	clinician	NOUN
ajlm-933	55	15	informed	inform	VERB
ajlm-933	55	16	the	the	DET
ajlm-933	55	17	participants	participant	NOUN
ajlm-933	55	18	of	of	ADP
ajlm-933	55	19	their	their	PRON
ajlm-933	55	20	results	result	NOUN
ajlm-933	55	21	.	.	PUNCT
ajlm-933	56	1	sensitivity	sensitivity	NOUN
ajlm-933	56	2	and	and	CCONJ
ajlm-933	56	3	specificity	specificity	NOUN
ajlm-933	56	4	analyses	analyse	VERB
ajlm-933	56	5	we	we	PRON
ajlm-933	56	6	compared	compare	VERB
ajlm-933	56	7	urine	urine	NOUN
ajlm-933	56	8	and	and	CCONJ
ajlm-933	56	9	plasma	plasma	NOUN
ajlm-933	56	10	crag	crag	NOUN
ajlm-933	56	11	lfa	lfa	PROPN
ajlm-933	56	12	results	result	VERB
ajlm-933	56	13	using	use	VERB
ajlm-933	56	14	plasma	plasma	NOUN
ajlm-933	56	15	lfa	lfa	PROPN
ajlm-933	56	16	as	as	ADP
ajlm-933	56	17	the	the	DET
ajlm-933	56	18	gold	gold	NOUN
ajlm-933	56	19	standard	standard	NOUN
ajlm-933	56	20	.	.	PUNCT
ajlm-933	57	1	records	record	NOUN
ajlm-933	57	2	were	be	AUX
ajlm-933	57	3	retained	retain	VERB
ajlm-933	57	4	for	for	ADP
ajlm-933	57	5	study	study	NOUN
ajlm-933	57	6	purposes	purpose	NOUN
ajlm-933	57	7	and	and	CCONJ
ajlm-933	57	8	not	not	PART
ajlm-933	57	9	for	for	ADP
ajlm-933	57	10	clinical	clinical	ADJ
ajlm-933	57	11	diagnosis	diagnosis	NOUN
ajlm-933	57	12	or	or	CCONJ
ajlm-933	57	13	treatment	treatment	NOUN
ajlm-933	57	14	purposes	purpose	NOUN
ajlm-933	57	15	,	,	PUNCT
ajlm-933	57	16	and	and	CCONJ
ajlm-933	57	17	our	our	PRON
ajlm-933	57	18	specificity	specificity	NOUN
ajlm-933	57	19	and	and	CCONJ
ajlm-933	57	20	sensitivity	sensitivity	NOUN
ajlm-933	57	21	analyses	analysis	NOUN
ajlm-933	57	22	did	do	AUX
ajlm-933	57	23	not	not	PART
ajlm-933	57	24	take	take	VERB
ajlm-933	57	25	into	into	ADP
ajlm-933	57	26	account	account	NOUN
ajlm-933	57	27	clinical	clinical	ADJ
ajlm-933	57	28	or	or	CCONJ
ajlm-933	57	29	radiological	radiological	ADJ
ajlm-933	57	30	findings	finding	NOUN
ajlm-933	57	31	.	.	PUNCT
ajlm-933	58	1	analyses	analysis	NOUN
ajlm-933	58	2	data	datum	NOUN
ajlm-933	58	3	were	be	AUX
ajlm-933	58	4	double	double	ADV
ajlm-933	58	5	entered	enter	VERB
ajlm-933	58	6	using	use	VERB
ajlm-933	58	7	epidata	epidata	NOUN
ajlm-933	58	8	(	(	PUNCT
ajlm-933	58	9	epidata	epidata	NOUN
ajlm-933	58	10	association	association	PROPN
ajlm-933	58	11	,	,	PUNCT
ajlm-933	58	12	odense	odense	PROPN
ajlm-933	58	13	,	,	PUNCT
ajlm-933	58	14	denmark	denmark	PROPN
ajlm-933	58	15	)	)	PUNCT
ajlm-933	58	16	.	.	PUNCT
ajlm-933	59	1	the	the	DET
ajlm-933	59	2	descriptive	descriptive	ADJ
ajlm-933	59	3	analyses	analysis	NOUN
ajlm-933	59	4	and	and	CCONJ
ajlm-933	59	5	calculation	calculation	NOUN
ajlm-933	59	6	of	of	ADP
ajlm-933	59	7	wilson	wilson	PROPN
ajlm-933	59	8	scores	score	NOUN
ajlm-933	59	9	on	on	ADP
ajlm-933	59	10	95	95	NUM
ajlm-933	59	11	%	%	NOUN
ajlm-933	59	12	confidence	confidence	NOUN
ajlm-933	59	13	intervals	interval	NOUN
ajlm-933	59	14	(	(	PUNCT
ajlm-933	59	15	ci	ci	NOUN
ajlm-933	59	16	)	)	PUNCT
ajlm-933	59	17	on	on	ADP
ajlm-933	59	18	the	the	DET
ajlm-933	59	19	crag	crag	NOUN
ajlm-933	59	20	prevalence	prevalence	NOUN
ajlm-933	59	21	were	be	AUX
ajlm-933	59	22	conducted	conduct	VERB
ajlm-933	59	23	using	use	VERB
ajlm-933	59	24	stata	stata	PROPN
ajlm-933	59	25	15	15	NUM
ajlm-933	59	26	(	(	PUNCT
ajlm-933	59	27	statacorp	statacorp	PROPN
ajlm-933	59	28	,	,	PUNCT
ajlm-933	59	29	college	college	NOUN
ajlm-933	59	30	station	station	NOUN
ajlm-933	59	31	,	,	PUNCT
ajlm-933	59	32	texas	texas	PROPN
ajlm-933	59	33	,	,	PUNCT
ajlm-933	59	34	united	united	PROPN
ajlm-933	59	35	states	states	PROPN
ajlm-933	59	36	)	)	PUNCT
ajlm-933	59	37	.	.	PUNCT
ajlm-933	60	1	results	result	NOUN
ajlm-933	60	2	of	of	ADP
ajlm-933	60	3	313	313	NUM
ajlm-933	60	4	patients	patient	NOUN
ajlm-933	60	5	initially	initially	ADV
ajlm-933	60	6	screened	screen	VERB
ajlm-933	60	7	for	for	ADP
ajlm-933	60	8	eligibility	eligibility	NOUN
ajlm-933	60	9	,	,	PUNCT
ajlm-933	60	10	58	58	NUM
ajlm-933	60	11	%	%	NOUN
ajlm-933	60	12	(	(	PUNCT
ajlm-933	60	13	182/313	182/313	PROPN
ajlm-933	60	14	)	)	PUNCT
ajlm-933	60	15	had	have	VERB
ajlm-933	60	16	cd4	cd4	PROPN
ajlm-933	60	17	counts	count	NOUN
ajlm-933	60	18	<	<	X
ajlm-933	60	19	200	200	NUM
ajlm-933	60	20	cells	cell	NOUN
ajlm-933	60	21	/	/	SYM
ajlm-933	60	22	mm3	mm3	NOUN
ajlm-933	60	23	by	by	ADP
ajlm-933	60	24	facscaliburtm	facscaliburtm	NOUN
ajlm-933	60	25	(	(	PUNCT
ajlm-933	60	26	figure	figure	NOUN
ajlm-933	60	27	1	1	NUM
ajlm-933	60	28	)	)	PUNCT
ajlm-933	60	29	.	.	PUNCT
ajlm-933	61	1	of	of	ADP
ajlm-933	61	2	the	the	DET
ajlm-933	61	3	182	182	NUM
ajlm-933	61	4	eligible	eligible	ADJ
ajlm-933	61	5	patients	patient	NOUN
ajlm-933	61	6	,	,	PUNCT
ajlm-933	61	7	79	79	NUM
ajlm-933	61	8	%	%	NOUN
ajlm-933	61	9	(	(	PUNCT
ajlm-933	61	10	144/182	144/182	NUM
ajlm-933	61	11	)	)	PUNCT
ajlm-933	61	12	were	be	AUX
ajlm-933	61	13	from	from	ADP
ajlm-933	61	14	the	the	DET
ajlm-933	61	15	outpatient	outpatient	NOUN
ajlm-933	61	16	voluntary	voluntary	ADJ
ajlm-933	61	17	counseling	counseling	NOUN
ajlm-933	61	18	and	and	CCONJ
ajlm-933	61	19	testing	testing	NOUN
ajlm-933	61	20	clinic	clinic	NOUN
ajlm-933	61	21	and	and	CCONJ
ajlm-933	61	22	21	21	NUM
ajlm-933	61	23	%	%	NOUN
ajlm-933	61	24	(	(	PUNCT
ajlm-933	61	25	38/182	38/182	NOUN
ajlm-933	61	26	)	)	PUNCT
ajlm-933	61	27	were	be	AUX
ajlm-933	61	28	from	from	ADP
ajlm-933	61	29	the	the	DET
ajlm-933	61	30	inpatient	inpatient	NOUN
ajlm-933	61	31	ward	ward	NOUN
ajlm-933	61	32	(	(	PUNCT
ajlm-933	61	33	table	table	NOUN
ajlm-933	61	34	1	1	NUM
ajlm-933	61	35	)	)	PUNCT
ajlm-933	61	36	.	.	PUNCT
ajlm-933	62	1	figure	figure	NOUN
ajlm-933	62	2	1	1	NUM
ajlm-933	62	3	:	:	PUNCT
ajlm-933	62	4	study	study	NOUN
ajlm-933	62	5	flow	flow	NOUN
ajlm-933	62	6	for	for	ADP
ajlm-933	62	7	cryptococcal	cryptococcal	ADJ
ajlm-933	62	8	screening	screening	NOUN
ajlm-933	62	9	at	at	ADP
ajlm-933	62	10	mbabane	mbabane	NOUN
ajlm-933	62	11	government	government	NOUN
ajlm-933	62	12	hospital	hospital	NOUN
ajlm-933	62	13	,	,	PUNCT
ajlm-933	62	14	eswatini	eswatini	NOUN
ajlm-933	62	15	,	,	PUNCT
ajlm-933	62	16	august	august	PROPN
ajlm-933	62	17	2014	2014	NUM
ajlm-933	62	18	to	to	ADP
ajlm-933	62	19	march	march	PROPN
ajlm-933	62	20	2015	2015	NUM
ajlm-933	62	21	.	.	PUNCT
ajlm-933	63	1	table	table	NOUN
ajlm-933	63	2	1	1	NUM
ajlm-933	63	3	:	:	PUNCT
ajlm-933	63	4	 	 	SPACE
ajlm-933	63	5	characteristics	characteristic	NOUN
ajlm-933	63	6	of	of	ADP
ajlm-933	63	7	patients	patient	NOUN
ajlm-933	63	8	enrolled	enrol	VERB
ajlm-933	63	9	in	in	ADP
ajlm-933	63	10	the	the	DET
ajlm-933	63	11	crag	crag	NOUN
ajlm-933	63	12	screening	screen	VERB
ajlm-933	63	13	study	study	NOUN
ajlm-933	63	14	of	of	ADP
ajlm-933	63	15	patients	patient	NOUN
ajlm-933	63	16	with	with	ADP
ajlm-933	63	17	a	a	DET
ajlm-933	63	18	cd4	cd4	PROPN
ajlm-933	63	19	count	count	NOUN
ajlm-933	63	20	<	<	X
ajlm-933	63	21	200	200	NUM
ajlm-933	63	22	cells	cell	NOUN
ajlm-933	63	23	/	/	SYM
ajlm-933	63	24	mm3	mm3	PROPN
ajlm-933	63	25	,	,	PUNCT
ajlm-933	63	26	eswatini	eswatini	NOUN
ajlm-933	63	27	,	,	PUNCT
ajlm-933	63	28	august	august	PROPN
ajlm-933	63	29	2014	2014	NUM
ajlm-933	63	30	to	to	ADP
ajlm-933	63	31	march	march	PROPN
ajlm-933	63	32	2015	2015	NUM
ajlm-933	63	33	.	.	PUNCT
ajlm-933	64	1	of	of	ADP
ajlm-933	64	2	the	the	DET
ajlm-933	64	3	182	182	NUM
ajlm-933	64	4	patients	patient	NOUN
ajlm-933	64	5	with	with	ADP
ajlm-933	64	6	cd4	cd4	PROPN
ajlm-933	64	7	counts	count	NOUN
ajlm-933	64	8	<	<	X
ajlm-933	64	9	200	200	NUM
ajlm-933	64	10	cells	cell	NOUN
ajlm-933	64	11	/	/	SYM
ajlm-933	64	12	mm3	mm3	NOUN
ajlm-933	64	13	by	by	ADP
ajlm-933	64	14	facscaliburtm	facscaliburtm	NOUN
ajlm-933	64	15	,	,	PUNCT
ajlm-933	64	16	42	42	NUM
ajlm-933	64	17	%	%	NOUN
ajlm-933	64	18	(	(	PUNCT
ajlm-933	64	19	76/182	76/182	NOUN
ajlm-933	64	20	)	)	PUNCT
ajlm-933	64	21	were	be	AUX
ajlm-933	64	22	women	woman	NOUN
ajlm-933	64	23	,	,	PUNCT
ajlm-933	64	24	the	the	DET
ajlm-933	64	25	median	median	ADJ
ajlm-933	64	26	age	age	NOUN
ajlm-933	64	27	of	of	ADP
ajlm-933	64	28	the	the	DET
ajlm-933	64	29	participants	participant	NOUN
ajlm-933	64	30	was	be	AUX
ajlm-933	64	31	35	35	NUM
ajlm-933	64	32	years	year	NOUN
ajlm-933	64	33	(	(	PUNCT
ajlm-933	64	34	interquartile	interquartile	NOUN
ajlm-933	64	35	range	range	NOUN
ajlm-933	64	36	:	:	PUNCT
ajlm-933	64	37	30–42	30–42	NUM
ajlm-933	64	38	)	)	PUNCT
ajlm-933	64	39	]	]	PUNCT
ajlm-933	64	40	,	,	PUNCT
ajlm-933	64	41	and	and	CCONJ
ajlm-933	64	42	61	61	NUM
ajlm-933	64	43	%	%	NOUN
ajlm-933	64	44	(	(	PUNCT
ajlm-933	64	45	111/182	111/182	NOUN
ajlm-933	64	46	)	)	PUNCT
ajlm-933	64	47	were	be	AUX
ajlm-933	64	48	from	from	ADP
ajlm-933	64	49	urban	urban	ADJ
ajlm-933	64	50	areas	area	NOUN
ajlm-933	64	51	(	(	PUNCT
ajlm-933	64	52	table	table	NOUN
ajlm-933	64	53	1	1	NUM
ajlm-933	64	54	)	)	PUNCT
ajlm-933	64	55	.	.	PUNCT
ajlm-933	65	1	most	most	ADJ
ajlm-933	65	2	(	(	PUNCT
ajlm-933	65	3	86	86	NUM
ajlm-933	65	4	%	%	NOUN
ajlm-933	65	5	,	,	PUNCT
ajlm-933	65	6	156/182	156/182	NUM
ajlm-933	65	7	)	)	PUNCT
ajlm-933	65	8	patients	patient	NOUN
ajlm-933	65	9	were	be	AUX
ajlm-933	65	10	from	from	ADP
ajlm-933	65	11	the	the	DET
ajlm-933	65	12	hhohho	hhohho	NOUN
ajlm-933	65	13	region	region	NOUN
ajlm-933	65	14	,	,	PUNCT
ajlm-933	65	15	10	10	NUM
ajlm-933	65	16	%	%	NOUN
ajlm-933	65	17	(	(	PUNCT
ajlm-933	65	18	18/182	18/182	NOUN
ajlm-933	65	19	)	)	PUNCT
ajlm-933	65	20	from	from	ADP
ajlm-933	65	21	manzini	manzini	NOUN
ajlm-933	65	22	,	,	PUNCT
ajlm-933	65	23	3	3	NUM
ajlm-933	65	24	%	%	NOUN
ajlm-933	65	25	(	(	PUNCT
ajlm-933	65	26	5/189	5/189	NUM
ajlm-933	65	27	)	)	PUNCT
ajlm-933	65	28	from	from	ADP
ajlm-933	65	29	shiselweni	shiselweni	ADJ
ajlm-933	65	30	,	,	PUNCT
ajlm-933	65	31	and	and	CCONJ
ajlm-933	65	32	2	2	NUM
ajlm-933	65	33	%	%	NOUN
ajlm-933	65	34	(	(	PUNCT
ajlm-933	65	35	3/182	3/182	NUM
ajlm-933	65	36	)	)	PUNCT
ajlm-933	65	37	from	from	ADP
ajlm-933	65	38	lubombo	lubombo	PROPN
ajlm-933	65	39	.	.	PUNCT
ajlm-933	66	1	almost	almost	ADV
ajlm-933	66	2	half	half	NOUN
ajlm-933	66	3	of	of	ADP
ajlm-933	66	4	the	the	DET
ajlm-933	66	5	patients	patient	NOUN
ajlm-933	66	6	(	(	PUNCT
ajlm-933	66	7	47	47	NUM
ajlm-933	66	8	%	%	NOUN
ajlm-933	66	9	,	,	PUNCT
ajlm-933	66	10	86/182	86/182	NUM
ajlm-933	66	11	)	)	PUNCT
ajlm-933	66	12	did	do	AUX
ajlm-933	66	13	not	not	PART
ajlm-933	66	14	complete	complete	VERB
ajlm-933	66	15	primary	primary	ADJ
ajlm-933	66	16	school	school	NOUN
ajlm-933	66	17	or	or	CCONJ
ajlm-933	66	18	did	do	AUX
ajlm-933	66	19	not	not	PART
ajlm-933	66	20	receive	receive	VERB
ajlm-933	66	21	any	any	DET
ajlm-933	66	22	schooling	schooling	NOUN
ajlm-933	66	23	,	,	PUNCT
ajlm-933	66	24	41	41	NUM
ajlm-933	66	25	%	%	NOUN
ajlm-933	66	26	(	(	PUNCT
ajlm-933	66	27	75/182	75/182	NOUN
ajlm-933	66	28	)	)	PUNCT
ajlm-933	66	29	completed	complete	VERB
ajlm-933	66	30	primary	primary	ADJ
ajlm-933	66	31	school	school	NOUN
ajlm-933	66	32	,	,	PUNCT
ajlm-933	66	33	and	and	CCONJ
ajlm-933	66	34	12	12	NUM
ajlm-933	66	35	%	%	NOUN
ajlm-933	66	36	(	(	PUNCT
ajlm-933	66	37	21/182	21/182	NOUN
ajlm-933	66	38	)	)	PUNCT
ajlm-933	66	39	completed	complete	VERB
ajlm-933	66	40	secondary	secondary	ADJ
ajlm-933	66	41	school	school	NOUN
ajlm-933	66	42	or	or	CCONJ
ajlm-933	66	43	higher	high	ADJ
ajlm-933	66	44	.	.	PUNCT
ajlm-933	67	1	most	most	ADJ
ajlm-933	67	2	(	(	PUNCT
ajlm-933	67	3	62	62	NUM
ajlm-933	67	4	%	%	NOUN
ajlm-933	67	5	,	,	PUNCT
ajlm-933	67	6	113/182	113/182	NUM
ajlm-933	67	7	)	)	PUNCT
ajlm-933	67	8	patients	patient	NOUN
ajlm-933	67	9	were	be	AUX
ajlm-933	67	10	single	single	ADJ
ajlm-933	67	11	and	and	CCONJ
ajlm-933	67	12	never	never	ADV
ajlm-933	67	13	married	married	ADJ
ajlm-933	67	14	,	,	PUNCT
ajlm-933	67	15	34	34	NUM
ajlm-933	67	16	%	%	NOUN
ajlm-933	67	17	(	(	PUNCT
ajlm-933	67	18	61/182	61/182	NOUN
ajlm-933	67	19	)	)	PUNCT
ajlm-933	67	20	were	be	AUX
ajlm-933	67	21	married	marry	VERB
ajlm-933	67	22	,	,	PUNCT
ajlm-933	67	23	and	and	CCONJ
ajlm-933	67	24	4	4	NUM
ajlm-933	67	25	%	%	NOUN
ajlm-933	67	26	(	(	PUNCT
ajlm-933	67	27	8/182	8/182	NOUN
ajlm-933	67	28	)	)	PUNCT
ajlm-933	67	29	were	be	AUX
ajlm-933	67	30	widowed	widow	VERB
ajlm-933	67	31	,	,	PUNCT
ajlm-933	67	32	divorced	divorce	VERB
ajlm-933	67	33	,	,	PUNCT
ajlm-933	67	34	or	or	CCONJ
ajlm-933	67	35	separated	separate	VERB
ajlm-933	67	36	.	.	PUNCT
ajlm-933	68	1	more	more	ADJ
ajlm-933	68	2	than	than	ADP
ajlm-933	68	3	half	half	NOUN
ajlm-933	68	4	of	of	ADP
ajlm-933	68	5	the	the	DET
ajlm-933	68	6	patients	patient	NOUN
ajlm-933	68	7	(	(	PUNCT
ajlm-933	68	8	54	54	NUM
ajlm-933	68	9	%	%	NOUN
ajlm-933	68	10	,	,	PUNCT
ajlm-933	68	11	99/182	99/182	NUM
ajlm-933	68	12	)	)	PUNCT
ajlm-933	68	13	were	be	AUX
ajlm-933	68	14	at	at	ADP
ajlm-933	68	15	who	who	PRON
ajlm-933	68	16	clinical	clinical	VERB
ajlm-933	68	17	stages	stage	NOUN
ajlm-933	68	18	i	i	PRON
ajlm-933	68	19	or	or	CCONJ
ajlm-933	68	20	ii	ii	NOUN
ajlm-933	68	21	,	,	PUNCT
ajlm-933	68	22	40	40	NUM
ajlm-933	68	23	%	%	NOUN
ajlm-933	68	24	(	(	PUNCT
ajlm-933	68	25	73/182	73/182	NOUN
ajlm-933	68	26	)	)	PUNCT
ajlm-933	68	27	at	at	ADP
ajlm-933	68	28	stage	stage	NOUN
ajlm-933	68	29	iii	iii	NOUN
ajlm-933	68	30	,	,	PUNCT
ajlm-933	68	31	and	and	CCONJ
ajlm-933	68	32	5	5	NUM
ajlm-933	68	33	%	%	NOUN
ajlm-933	68	34	(	(	PUNCT
ajlm-933	68	35	10/182	10/182	NUM
ajlm-933	68	36	)	)	PUNCT
ajlm-933	68	37	at	at	ADP
ajlm-933	68	38	stage	stage	NOUN
ajlm-933	68	39	iv	iv	NUM
ajlm-933	68	40	.	.	PUNCT
ajlm-933	68	41	of	of	ADP
ajlm-933	68	42	the	the	DET
ajlm-933	68	43	182	182	NUM
ajlm-933	68	44	patients	patient	NOUN
ajlm-933	68	45	with	with	ADP
ajlm-933	68	46	cd4	cd4	PROPN
ajlm-933	68	47	count	count	NOUN
ajlm-933	68	48	<	<	X
ajlm-933	68	49	200	200	NUM
ajlm-933	68	50	cells	cell	NOUN
ajlm-933	68	51	/	/	SYM
ajlm-933	68	52	mm3	mm3	PROPN
ajlm-933	68	53	,	,	PUNCT
ajlm-933	68	54	56	56	NUM
ajlm-933	68	55	%	%	NOUN
ajlm-933	68	56	(	(	PUNCT
ajlm-933	68	57	102/182	102/182	NOUN
ajlm-933	68	58	)	)	PUNCT
ajlm-933	68	59	had	have	VERB
ajlm-933	68	60	a	a	DET
ajlm-933	68	61	cd4	cd4	PROPN
ajlm-933	68	62	count	count	NOUN
ajlm-933	68	63	<	<	X
ajlm-933	68	64	100	100	NUM
ajlm-933	68	65	cells	cell	NOUN
ajlm-933	68	66	/	/	SYM
ajlm-933	68	67	mm3	mm3	NOUN
ajlm-933	68	68	.	.	PUNCT
ajlm-933	68	69	forty	forty	NUM
ajlm-933	68	70	-	-	PUNCT
ajlm-933	68	71	three	three	NUM
ajlm-933	68	72	percent	percent	NOUN
ajlm-933	68	73	(	(	PUNCT
ajlm-933	68	74	44/102	44/102	NUM
ajlm-933	68	75	)	)	PUNCT
ajlm-933	68	76	of	of	ADP
ajlm-933	68	77	these	these	PRON
ajlm-933	68	78	were	be	AUX
ajlm-933	68	79	at	at	ADP
ajlm-933	68	80	who	who	PRON
ajlm-933	68	81	clinical	clinical	VERB
ajlm-933	68	82	stages	stage	NOUN
ajlm-933	68	83	i	i	PRON
ajlm-933	68	84	or	or	CCONJ
ajlm-933	68	85	ii	ii	PROPN
ajlm-933	68	86	and	and	CCONJ
ajlm-933	68	87	57	57	NUM
ajlm-933	68	88	%	%	NOUN
ajlm-933	68	89	(	(	PUNCT
ajlm-933	68	90	58/102	58/102	NUM
ajlm-933	68	91	)	)	PUNCT
ajlm-933	68	92	at	at	ADP
ajlm-933	68	93	stages	stage	NOUN
ajlm-933	68	94	iii	iii	NUM
ajlm-933	68	95	or	or	CCONJ
ajlm-933	68	96	iv	iv	NUM
ajlm-933	68	97	.	.	PUNCT
ajlm-933	68	98	of	of	ADP
ajlm-933	68	99	patients	patient	NOUN
ajlm-933	68	100	with	with	ADP
ajlm-933	68	101	cd4	cd4	PROPN
ajlm-933	68	102	counts	count	VERB
ajlm-933	68	103	100	100	NUM
ajlm-933	68	104	cells	cell	NOUN
ajlm-933	68	105	/	/	SYM
ajlm-933	68	106	mm3	mm3	NOUN
ajlm-933	68	107	–	–	PUNCT
ajlm-933	68	108	199	199	NUM
ajlm-933	68	109	cells	cell	NOUN
ajlm-933	68	110	/	/	SYM
ajlm-933	68	111	mm3	mm3	PROPN
ajlm-933	68	112	,	,	PUNCT
ajlm-933	68	113	69	69	NUM
ajlm-933	68	114	%	%	NOUN
ajlm-933	68	115	(	(	PUNCT
ajlm-933	68	116	55/80	55/80	NUM
ajlm-933	68	117	)	)	PUNCT
ajlm-933	68	118	were	be	AUX
ajlm-933	68	119	at	at	ADP
ajlm-933	68	120	who	who	PRON
ajlm-933	68	121	clinical	clinical	VERB
ajlm-933	68	122	stages	stage	NOUN
ajlm-933	68	123	i	i	PRON
ajlm-933	68	124	or	or	CCONJ
ajlm-933	68	125	ii	ii	PROPN
ajlm-933	68	126	and	and	CCONJ
ajlm-933	68	127	31	31	NUM
ajlm-933	68	128	%	%	NOUN
ajlm-933	68	129	(	(	PUNCT
ajlm-933	68	130	25/80	25/80	NUM
ajlm-933	68	131	)	)	PUNCT
ajlm-933	68	132	at	at	ADP
ajlm-933	68	133	stages	stage	NOUN
ajlm-933	68	134	iii	iii	NUM
ajlm-933	68	135	or	or	CCONJ
ajlm-933	68	136	iv	iv	NUM
ajlm-933	68	137	.	.	PUNCT
ajlm-933	69	1	cryptococcal	cryptococcal	ADJ
ajlm-933	69	2	antigen	antigen	ADP
ajlm-933	69	3	lateral	lateral	ADJ
ajlm-933	69	4	prevalence	prevalence	NOUN
ajlm-933	69	5	the	the	DET
ajlm-933	69	6	plasma	plasma	NOUN
ajlm-933	69	7	crag	crag	NOUN
ajlm-933	69	8	prevalence	prevalence	NOUN
ajlm-933	69	9	was	be	AUX
ajlm-933	69	10	8	8	NUM
ajlm-933	69	11	%	%	NOUN
ajlm-933	69	12	(	(	PUNCT
ajlm-933	69	13	8/102	8/102	NUM
ajlm-933	69	14	,	,	PUNCT
ajlm-933	69	15	95	95	NUM
ajlm-933	69	16	%	%	NOUN
ajlm-933	69	17	ci	ci	NOUN
ajlm-933	69	18	:	:	PUNCT
ajlm-933	69	19	3–15	3–15	ADJ
ajlm-933	69	20	)	)	PUNCT
ajlm-933	69	21	amongst	amongst	ADP
ajlm-933	69	22	patients	patient	NOUN
ajlm-933	69	23	with	with	ADP
ajlm-933	69	24	cd4	cd4	PROPN
ajlm-933	69	25	counts	count	NOUN
ajlm-933	69	26	<	<	X
ajlm-933	69	27	100	100	NUM
ajlm-933	69	28	cells	cell	NOUN
ajlm-933	69	29	/	/	SYM
ajlm-933	69	30	mm3	mm3	PROPN
ajlm-933	69	31	.	.	PUNCT
ajlm-933	70	1	when	when	SCONJ
ajlm-933	70	2	considering	consider	VERB
ajlm-933	70	3	the	the	DET
ajlm-933	70	4	higher	high	ADJ
ajlm-933	70	5	cut	cut	NOUN
ajlm-933	70	6	-	-	PUNCT
ajlm-933	70	7	off	off	ADP
ajlm-933	70	8	point	point	NOUN
ajlm-933	70	9	of	of	ADP
ajlm-933	70	10	a	a	DET
ajlm-933	70	11	cd4	cd4	PROPN
ajlm-933	70	12	count	count	NOUN
ajlm-933	70	13	<	<	X
ajlm-933	70	14	200	200	NUM
ajlm-933	70	15	cells	cell	NOUN
ajlm-933	70	16	/	/	SYM
ajlm-933	70	17	mm3	mm3	PROPN
ajlm-933	70	18	,	,	PUNCT
ajlm-933	70	19	the	the	DET
ajlm-933	70	20	plasma	plasma	NOUN
ajlm-933	70	21	crag	crag	NOUN
ajlm-933	70	22	prevalence	prevalence	NOUN
ajlm-933	70	23	decreased	decrease	VERB
ajlm-933	70	24	to	to	ADP
ajlm-933	70	25	4	4	NUM
ajlm-933	70	26	%	%	NOUN
ajlm-933	70	27	(	(	PUNCT
ajlm-933	70	28	8/182	8/182	NUM
ajlm-933	70	29	,	,	PUNCT
ajlm-933	70	30	95	95	NUM
ajlm-933	70	31	%	%	NOUN
ajlm-933	70	32	ci	ci	NOUN
ajlm-933	70	33	:	:	PUNCT
ajlm-933	70	34	2–8	2–8	NUM
ajlm-933	70	35	)	)	PUNCT
ajlm-933	70	36	(	(	PUNCT
ajlm-933	70	37	figure	figure	NOUN
ajlm-933	70	38	1	1	NUM
ajlm-933	70	39	)	)	PUNCT
ajlm-933	70	40	.	.	PUNCT
ajlm-933	71	1	all	all	DET
ajlm-933	71	2	eight	eight	NUM
ajlm-933	71	3	plasma	plasma	NOUN
ajlm-933	71	4	crag	crag	NOUN
ajlm-933	71	5	-	-	PUNCT
ajlm-933	71	6	positive	positive	ADJ
ajlm-933	71	7	patients	patient	NOUN
ajlm-933	71	8	had	have	VERB
ajlm-933	71	9	cd4	cd4	PROPN
ajlm-933	71	10	cell	cell	NOUN
ajlm-933	71	11	counts	count	VERB
ajlm-933	71	12	<	<	X
ajlm-933	71	13	100	100	NUM
ajlm-933	71	14	cells	cell	NOUN
ajlm-933	71	15	/	/	SYM
ajlm-933	71	16	mm3	mm3	NOUN
ajlm-933	71	17	and	and	CCONJ
ajlm-933	71	18	none	none	NOUN
ajlm-933	71	19	had	have	VERB
ajlm-933	71	20	cd4	cd4	PROPN
ajlm-933	71	21	cell	cell	NOUN
ajlm-933	71	22	counts	count	NOUN
ajlm-933	71	23	in	in	ADP
ajlm-933	71	24	the	the	DET
ajlm-933	71	25	100	100	NUM
ajlm-933	71	26	cells	cell	NOUN
ajlm-933	71	27	/	/	SYM
ajlm-933	71	28	mm3	mm3	NOUN
ajlm-933	72	1	–	–	PUNCT
ajlm-933	72	2	199	199	NUM
ajlm-933	72	3	cells	cell	NOUN
ajlm-933	72	4	/	/	SYM
ajlm-933	72	5	mm3	mm3	NOUN
ajlm-933	72	6	range	range	NOUN
ajlm-933	72	7	(	(	PUNCT
ajlm-933	72	8	prevalence	prevalence	NOUN
ajlm-933	72	9	4	4	NUM
ajlm-933	72	10	%	%	NOUN
ajlm-933	72	11	[	[	X
ajlm-933	72	12	8/182	8/182	NUM
ajlm-933	72	13	]	]	X
ajlm-933	72	14	,	,	PUNCT
ajlm-933	72	15	95	95	NUM
ajlm-933	72	16	%	%	NOUN
ajlm-933	72	17	ci	ci	NOUN
ajlm-933	72	18	:	:	PUNCT
ajlm-933	72	19	2–8	2–8	NUM
ajlm-933	72	20	)	)	PUNCT
ajlm-933	72	21	.	.	PUNCT
ajlm-933	73	1	of	of	ADP
ajlm-933	73	2	the	the	DET
ajlm-933	73	3	patients	patient	NOUN
ajlm-933	73	4	at	at	ADP
ajlm-933	73	5	the	the	DET
ajlm-933	73	6	voluntary	voluntary	ADJ
ajlm-933	73	7	counseling	counseling	NOUN
ajlm-933	73	8	and	and	CCONJ
ajlm-933	73	9	testing	testing	NOUN
ajlm-933	73	10	clinic	clinic	NOUN
ajlm-933	73	11	,	,	PUNCT
ajlm-933	73	12	47	47	NUM
ajlm-933	73	13	%	%	NOUN
ajlm-933	73	14	(	(	PUNCT
ajlm-933	73	15	68/144	68/144	NUM
ajlm-933	73	16	)	)	PUNCT
ajlm-933	73	17	had	have	VERB
ajlm-933	73	18	cd4	cd4	PROPN
ajlm-933	73	19	counts	count	VERB
ajlm-933	73	20	100	100	NUM
ajlm-933	73	21	cells	cell	NOUN
ajlm-933	73	22	/	/	SYM
ajlm-933	73	23	mm3	mm3	NOUN
ajlm-933	73	24	–	–	PUNCT
ajlm-933	73	25	199	199	NUM
ajlm-933	73	26	cells	cell	NOUN
ajlm-933	73	27	/	/	SYM
ajlm-933	73	28	mm3	mm3	PROPN
ajlm-933	73	29	,	,	PUNCT
ajlm-933	73	30	and	and	CCONJ
ajlm-933	73	31	53	53	NUM
ajlm-933	73	32	%	%	NOUN
ajlm-933	73	33	(	(	PUNCT
ajlm-933	73	34	76/144	76/144	NUM
ajlm-933	73	35	)	)	PUNCT
ajlm-933	73	36	patients	patient	NOUN
ajlm-933	73	37	had	have	VERB
ajlm-933	73	38	cd4	cd4	PROPN
ajlm-933	73	39	counts	count	NOUN
ajlm-933	73	40	<	<	X
ajlm-933	73	41	100	100	NUM
ajlm-933	73	42	cells	cell	NOUN
ajlm-933	73	43	/	/	SYM
ajlm-933	73	44	mm3	mm3	NOUN
ajlm-933	73	45	.	.	PUNCT
ajlm-933	74	1	of	of	ADP
ajlm-933	74	2	the	the	DET
ajlm-933	74	3	76	76	NUM
ajlm-933	74	4	,	,	PUNCT
ajlm-933	74	5	5	5	NUM
ajlm-933	74	6	%	%	NOUN
ajlm-933	74	7	(	(	PUNCT
ajlm-933	74	8	4/76	4/76	NUM
ajlm-933	74	9	)	)	PUNCT
ajlm-933	74	10	,	,	PUNCT
ajlm-933	74	11	were	be	AUX
ajlm-933	74	12	plasma	plasma	NOUN
ajlm-933	74	13	crag	crag	NOUN
ajlm-933	74	14	-	-	PUNCT
ajlm-933	74	15	positive	positive	ADJ
ajlm-933	74	16	.	.	PUNCT
ajlm-933	75	1	three	three	NUM
ajlm-933	75	2	out	out	ADP
ajlm-933	75	3	of	of	ADP
ajlm-933	75	4	the	the	DET
ajlm-933	75	5	four	four	NUM
ajlm-933	75	6	patients	patient	NOUN
ajlm-933	75	7	who	who	PRON
ajlm-933	75	8	were	be	AUX
ajlm-933	75	9	plasma	plasma	NOUN
ajlm-933	75	10	crag	crag	NOUN
ajlm-933	75	11	-	-	PUNCT
ajlm-933	75	12	positive	positive	ADJ
ajlm-933	75	13	were	be	AUX
ajlm-933	75	14	csf	csf	ADJ
ajlm-933	75	15	crag	crag	NOUN
ajlm-933	75	16	negative	negative	ADJ
ajlm-933	75	17	;	;	PUNCT
ajlm-933	75	18	one	one	NUM
ajlm-933	75	19	patient	patient	NOUN
ajlm-933	75	20	did	do	AUX
ajlm-933	75	21	not	not	PART
ajlm-933	75	22	complete	complete	VERB
ajlm-933	75	23	a	a	DET
ajlm-933	75	24	lumbar	lumbar	NOUN
ajlm-933	75	25	puncture	puncture	NOUN
ajlm-933	75	26	.	.	PUNCT
ajlm-933	76	1	of	of	ADP
ajlm-933	76	2	the	the	DET
ajlm-933	76	3	patients	patient	NOUN
ajlm-933	76	4	at	at	ADP
ajlm-933	76	5	the	the	DET
ajlm-933	76	6	inpatient	inpatient	PROPN
ajlm-933	76	7	ward	ward	NOUN
ajlm-933	76	8	,	,	PUNCT
ajlm-933	76	9	32	32	NUM
ajlm-933	76	10	%	%	NOUN
ajlm-933	76	11	(	(	PUNCT
ajlm-933	76	12	12/38	12/38	NUM
ajlm-933	76	13	)	)	PUNCT
ajlm-933	76	14	had	have	VERB
ajlm-933	76	15	cd4	cd4	PROPN
ajlm-933	76	16	counts	count	VERB
ajlm-933	76	17	100	100	NUM
ajlm-933	76	18	cells	cell	NOUN
ajlm-933	76	19	/	/	SYM
ajlm-933	76	20	mm3	mm3	NOUN
ajlm-933	76	21	–	–	PUNCT
ajlm-933	76	22	199	199	NUM
ajlm-933	76	23	cells	cell	NOUN
ajlm-933	76	24	/	/	SYM
ajlm-933	76	25	mm3	mm3	NOUN
ajlm-933	76	26	and	and	CCONJ
ajlm-933	76	27	68	68	NUM
ajlm-933	76	28	%	%	NOUN
ajlm-933	76	29	(	(	PUNCT
ajlm-933	76	30	26/38	26/38	NUM
ajlm-933	76	31	)	)	PUNCT
ajlm-933	76	32	had	have	AUX
ajlm-933	76	33	cd4	cd4	PROPN
ajlm-933	76	34	counts	count	NOUN
ajlm-933	76	35	<	<	X
ajlm-933	76	36	100	100	NUM
ajlm-933	76	37	cells	cell	NOUN
ajlm-933	76	38	/	/	SYM
ajlm-933	76	39	mm3	mm3	NOUN
ajlm-933	76	40	.	.	PUNCT
ajlm-933	77	1	fifteen	fifteen	NUM
ajlm-933	77	2	percent	percent	NOUN
ajlm-933	77	3	(	(	PUNCT
ajlm-933	77	4	4/26	4/26	NUM
ajlm-933	77	5	)	)	PUNCT
ajlm-933	77	6	of	of	ADP
ajlm-933	77	7	patients	patient	NOUN
ajlm-933	77	8	,	,	PUNCT
ajlm-933	77	9	all	all	PRON
ajlm-933	77	10	with	with	ADP
ajlm-933	77	11	cd4	cd4	PROPN
ajlm-933	77	12	counts	count	NOUN
ajlm-933	77	13	<	<	X
ajlm-933	77	14	100	100	NUM
ajlm-933	77	15	cells	cell	NOUN
ajlm-933	77	16	/	/	SYM
ajlm-933	77	17	mm3	mm3	PROPN
ajlm-933	77	18	,	,	PUNCT
ajlm-933	77	19	were	be	AUX
ajlm-933	77	20	plasma	plasma	NOUN
ajlm-933	77	21	crag	crag	NOUN
ajlm-933	77	22	-	-	PUNCT
ajlm-933	77	23	positive	positive	ADJ
ajlm-933	77	24	.	.	PUNCT
ajlm-933	78	1	of	of	ADP
ajlm-933	78	2	the	the	DET
ajlm-933	78	3	four	four	NUM
ajlm-933	78	4	patients	patient	NOUN
ajlm-933	78	5	who	who	PRON
ajlm-933	78	6	were	be	AUX
ajlm-933	78	7	plasma	plasma	NOUN
ajlm-933	78	8	crag	crag	NOUN
ajlm-933	78	9	-	-	PUNCT
ajlm-933	78	10	positive	positive	ADJ
ajlm-933	78	11	at	at	ADP
ajlm-933	78	12	the	the	DET
ajlm-933	78	13	inpatient	inpatient	NOUN
ajlm-933	78	14	ward	ward	NOUN
ajlm-933	78	15	,	,	PUNCT
ajlm-933	78	16	one	one	NUM
ajlm-933	78	17	patient	patient	NOUN
ajlm-933	78	18	was	be	AUX
ajlm-933	78	19	csf	csf	ADJ
ajlm-933	78	20	crag	crag	NOUN
ajlm-933	78	21	-	-	PUNCT
ajlm-933	78	22	positive	positive	ADJ
ajlm-933	78	23	and	and	CCONJ
ajlm-933	78	24	the	the	DET
ajlm-933	78	25	other	other	ADJ
ajlm-933	78	26	three	three	NUM
ajlm-933	78	27	patients	patient	NOUN
ajlm-933	78	28	were	be	AUX
ajlm-933	78	29	csf	csf	ADJ
ajlm-933	78	30	crag	crag	NOUN
ajlm-933	78	31	negative	negative	ADJ
ajlm-933	78	32	(	(	PUNCT
ajlm-933	78	33	figure	figure	NOUN
ajlm-933	78	34	1	1	NUM
ajlm-933	78	35	)	)	PUNCT
ajlm-933	78	36	.	.	PUNCT
ajlm-933	79	1	sensitivity	sensitivity	NOUN
ajlm-933	79	2	and	and	CCONJ
ajlm-933	79	3	specificity	specificity	NOUN
ajlm-933	79	4	of	of	ADP
ajlm-933	79	5	urine	urine	NOUN
ajlm-933	79	6	cryptococcal	cryptococcal	ADJ
ajlm-933	79	7	antigen	antigen	ADP
ajlm-933	79	8	lateral	lateral	ADJ
ajlm-933	79	9	flow	flow	NOUN
ajlm-933	79	10	assay	assay	VERB
ajlm-933	79	11	urine	urine	NOUN
ajlm-933	79	12	samples	sample	NOUN
ajlm-933	79	13	were	be	AUX
ajlm-933	79	14	collected	collect	VERB
ajlm-933	79	15	from	from	ADP
ajlm-933	79	16	168	168	NUM
ajlm-933	79	17	patients	patient	NOUN
ajlm-933	79	18	;	;	PUNCT
ajlm-933	79	19	82	82	NUM
ajlm-933	79	20	%	%	NOUN
ajlm-933	79	21	(	(	PUNCT
ajlm-933	79	22	137/168	137/168	PROPN
ajlm-933	79	23	)	)	PUNCT
ajlm-933	79	24	from	from	ADP
ajlm-933	79	25	the	the	DET
ajlm-933	79	26	voluntary	voluntary	ADJ
ajlm-933	79	27	counseling	counseling	NOUN
ajlm-933	79	28	and	and	CCONJ
ajlm-933	79	29	testing	testing	NOUN
ajlm-933	79	30	clinic	clinic	NOUN
ajlm-933	79	31	and	and	CCONJ
ajlm-933	79	32	18	18	NUM
ajlm-933	79	33	%	%	NOUN
ajlm-933	79	34	(	(	PUNCT
ajlm-933	79	35	31/168	31/168	NUM
ajlm-933	79	36	)	)	PUNCT
ajlm-933	79	37	from	from	ADP
ajlm-933	79	38	the	the	DET
ajlm-933	79	39	inpatient	inpatient	NOUN
ajlm-933	79	40	ward	ward	NOUN
ajlm-933	79	41	.	.	PUNCT
ajlm-933	80	1	forty	forty	NUM
ajlm-933	80	2	-	-	PUNCT
ajlm-933	80	3	six	six	NUM
ajlm-933	80	4	percent	percent	NOUN
ajlm-933	80	5	(	(	PUNCT
ajlm-933	80	6	77/168	77/168	NUM
ajlm-933	80	7	)	)	PUNCT
ajlm-933	80	8	of	of	ADP
ajlm-933	80	9	patients	patient	NOUN
ajlm-933	80	10	had	have	VERB
ajlm-933	80	11	cd4	cd4	PROPN
ajlm-933	80	12	counts	count	NOUN
ajlm-933	80	13	of	of	ADP
ajlm-933	80	14	100	100	NUM
ajlm-933	80	15	cells	cell	NOUN
ajlm-933	80	16	/	/	SYM
ajlm-933	80	17	mm3	mm3	NOUN
ajlm-933	80	18	–	–	PUNCT
ajlm-933	80	19	199	199	NUM
ajlm-933	80	20	cells	cell	NOUN
ajlm-933	80	21	/	/	SYM
ajlm-933	80	22	mm3	mm3	NOUN
ajlm-933	80	23	and	and	CCONJ
ajlm-933	80	24	54	54	NUM
ajlm-933	80	25	%	%	NOUN
ajlm-933	80	26	(	(	PUNCT
ajlm-933	80	27	91/168	91/168	NUM
ajlm-933	80	28	)	)	PUNCT
ajlm-933	80	29	had	have	VERB
ajlm-933	80	30	cd4	cd4	PROPN
ajlm-933	80	31	counts	count	NOUN
ajlm-933	80	32	<	<	X
ajlm-933	80	33	100	100	NUM
ajlm-933	80	34	cells	cell	NOUN
ajlm-933	80	35	/	/	SYM
ajlm-933	80	36	mm3	mm3	NOUN
ajlm-933	80	37	by	by	ADP
ajlm-933	80	38	facscaliburtm	facscaliburtm	NOUN
ajlm-933	80	39	.	.	PUNCT
ajlm-933	81	1	urine	urine	NOUN
ajlm-933	81	2	crag	crag	NOUN
ajlm-933	81	3	-	-	PUNCT
ajlm-933	81	4	positive	positive	ADJ
ajlm-933	81	5	prevalence	prevalence	NOUN
ajlm-933	81	6	was	be	AUX
ajlm-933	81	7	25	25	NUM
ajlm-933	81	8	%	%	NOUN
ajlm-933	81	9	(	(	PUNCT
ajlm-933	81	10	23/91	23/91	NUM
ajlm-933	81	11	)	)	PUNCT
ajlm-933	81	12	amongst	amongst	ADP
ajlm-933	81	13	patients	patient	NOUN
ajlm-933	81	14	with	with	ADP
ajlm-933	81	15	cd4	cd4	PROPN
ajlm-933	81	16	counts	count	NOUN
ajlm-933	81	17	<	<	X
ajlm-933	81	18	100	100	NUM
ajlm-933	81	19	cells	cell	NOUN
ajlm-933	81	20	/	/	SYM
ajlm-933	81	21	mm3	mm3	NOUN
ajlm-933	81	22	and	and	CCONJ
ajlm-933	81	23	22	22	NUM
ajlm-933	81	24	%	%	NOUN
ajlm-933	81	25	(	(	PUNCT
ajlm-933	81	26	17/77	17/77	NUM
ajlm-933	81	27	)	)	PUNCT
ajlm-933	81	28	amongst	amongst	ADP
ajlm-933	81	29	patients	patient	NOUN
ajlm-933	81	30	with	with	ADP
ajlm-933	81	31	cd4	cd4	PROPN
ajlm-933	81	32	counts	count	VERB
ajlm-933	81	33	100	100	NUM
ajlm-933	81	34	cells	cell	NOUN
ajlm-933	81	35	/	/	SYM
ajlm-933	81	36	mm3	mm3	NOUN
ajlm-933	81	37	–	–	PUNCT
ajlm-933	81	38	199	199	NUM
ajlm-933	81	39	cells	cell	NOUN
ajlm-933	81	40	/	/	SYM
ajlm-933	81	41	mm3	mm3	NOUN
ajlm-933	81	42	.	.	PUNCT
ajlm-933	81	43	urine	urine	PROPN
ajlm-933	81	44	crag	crag	NOUN
ajlm-933	81	45	lfa	lfa	PROPN
ajlm-933	81	46	had	have	VERB
ajlm-933	81	47	a	a	DET
ajlm-933	81	48	sensitivity	sensitivity	NOUN
ajlm-933	81	49	of	of	ADP
ajlm-933	81	50	100	100	NUM
ajlm-933	81	51	%	%	NOUN
ajlm-933	81	52	(	(	PUNCT
ajlm-933	81	53	95	95	NUM
ajlm-933	81	54	%	%	NOUN
ajlm-933	81	55	ci	ci	NOUN
ajlm-933	81	56	:	:	PUNCT
ajlm-933	81	57	59–100	59–100	NUM
ajlm-933	81	58	)	)	PUNCT
ajlm-933	81	59	and	and	CCONJ
ajlm-933	81	60	a	a	DET
ajlm-933	81	61	specificity	specificity	NOUN
ajlm-933	81	62	of	of	ADP
ajlm-933	81	63	80	80	NUM
ajlm-933	81	64	%	%	NOUN
ajlm-933	81	65	(	(	PUNCT
ajlm-933	81	66	95	95	NUM
ajlm-933	81	67	%	%	NOUN
ajlm-933	81	68	ci	ci	NOUN
ajlm-933	81	69	:	:	PUNCT
ajlm-933	81	70	72–86	72–86	NUM
ajlm-933	81	71	)	)	PUNCT
ajlm-933	81	72	compared	compare	VERB
ajlm-933	81	73	with	with	ADP
ajlm-933	81	74	plasma	plasma	NOUN
ajlm-933	81	75	crag	crag	NOUN
ajlm-933	81	76	lfa	lfa	PROPN
ajlm-933	81	77	for	for	ADP
ajlm-933	81	78	patients	patient	NOUN
ajlm-933	81	79	with	with	ADP
ajlm-933	81	80	cd4	cd4	PROPN
ajlm-933	81	81	<	<	X
ajlm-933	81	82	200	200	NUM
ajlm-933	81	83	cells	cell	NOUN
ajlm-933	81	84	/	/	SYM
ajlm-933	81	85	mm3	mm3	NOUN
ajlm-933	81	86	.	.	PUNCT
ajlm-933	82	1	there	there	PRON
ajlm-933	82	2	were	be	VERB
ajlm-933	82	3	seven	seven	NUM
ajlm-933	82	4	true	true	ADJ
ajlm-933	82	5	positives	positive	NOUN
ajlm-933	82	6	,	,	PUNCT
ajlm-933	82	7	33	33	NUM
ajlm-933	82	8	false	false	ADJ
ajlm-933	82	9	positives	positive	NOUN
ajlm-933	82	10	(	(	PUNCT
ajlm-933	82	11	i.e.	i.e.	X
ajlm-933	82	12	,	,	PUNCT
ajlm-933	82	13	positive	positive	ADJ
ajlm-933	82	14	on	on	ADP
ajlm-933	82	15	urine	urine	NOUN
ajlm-933	82	16	crag	crag	NOUN
ajlm-933	82	17	lfa	lfa	PROPN
ajlm-933	82	18	but	but	CCONJ
ajlm-933	82	19	negative	negative	ADJ
ajlm-933	82	20	on	on	ADP
ajlm-933	82	21	plasma	plasma	NOUN
ajlm-933	82	22	crag	crag	PROPN
ajlm-933	82	23	lfa	lfa	PROPN
ajlm-933	82	24	)	)	PUNCT
ajlm-933	82	25	,	,	PUNCT
ajlm-933	82	26	128	128	NUM
ajlm-933	82	27	true	true	ADJ
ajlm-933	82	28	negatives	negative	NOUN
ajlm-933	82	29	,	,	PUNCT
ajlm-933	82	30	and	and	CCONJ
ajlm-933	82	31	zero	zero	NUM
ajlm-933	82	32	false	false	ADJ
ajlm-933	82	33	negatives	negative	NOUN
ajlm-933	82	34	(	(	PUNCT
ajlm-933	82	35	i.e.	i.e.	X
ajlm-933	82	36	,	,	PUNCT
ajlm-933	82	37	negatives	negative	NOUN
ajlm-933	82	38	on	on	ADP
ajlm-933	82	39	urine	urine	NOUN
ajlm-933	82	40	crag	crag	NOUN
ajlm-933	82	41	lfa	lfa	PROPN
ajlm-933	82	42	but	but	CCONJ
ajlm-933	82	43	positive	positive	ADJ
ajlm-933	82	44	on	on	ADP
ajlm-933	82	45	plasma	plasma	NOUN
ajlm-933	82	46	crag	crag	PROPN
ajlm-933	82	47	lfa	lfa	PROPN
ajlm-933	82	48	)	)	PUNCT
ajlm-933	82	49	(	(	PUNCT
ajlm-933	82	50	table	table	NOUN
ajlm-933	82	51	2	2	NUM
ajlm-933	82	52	)	)	PUNCT
ajlm-933	82	53	.	.	PUNCT
ajlm-933	83	1	table	table	NOUN
ajlm-933	83	2	2	2	NUM
ajlm-933	83	3	:	:	PUNCT
ajlm-933	83	4	 	 	SPACE
ajlm-933	83	5	sensitivity	sensitivity	NOUN
ajlm-933	83	6	and	and	CCONJ
ajlm-933	83	7	specificity	specificity	NOUN
ajlm-933	83	8	of	of	ADP
ajlm-933	83	9	urine	urine	NOUN
ajlm-933	83	10	cryptococcal	cryptococcal	ADJ
ajlm-933	83	11	antigen	antigen	ADP
ajlm-933	83	12	lateral	lateral	ADJ
ajlm-933	83	13	flow	flow	NOUN
ajlm-933	83	14	assay	assay	NOUN
ajlm-933	83	15	compared	compare	VERB
ajlm-933	83	16	with	with	ADP
ajlm-933	83	17	plasma	plasma	NOUN
ajlm-933	83	18	cryptococcal	cryptococcal	ADJ
ajlm-933	83	19	antigen	antigen	ADP
ajlm-933	83	20	lateral	lateral	ADJ
ajlm-933	83	21	flow	flow	NOUN
ajlm-933	83	22	assay	assay	NOUN
ajlm-933	83	23	for	for	ADP
ajlm-933	83	24	patients	patient	NOUN
ajlm-933	83	25	with	with	ADP
ajlm-933	83	26	a	a	DET
ajlm-933	83	27	cd4	cd4	PROPN
ajlm-933	83	28	count	count	NOUN
ajlm-933	83	29	<	<	X
ajlm-933	83	30	200	200	NUM
ajlm-933	83	31	cells	cell	NOUN
ajlm-933	83	32	/	/	SYM
ajlm-933	83	33	mm3	mm3	PROPN
ajlm-933	83	34	,	,	PUNCT
ajlm-933	83	35	eswatini	eswatini	NOUN
ajlm-933	83	36	,	,	PUNCT
ajlm-933	83	37	august	august	PROPN
ajlm-933	83	38	2014	2014	NUM
ajlm-933	83	39	to	to	ADP
ajlm-933	83	40	march	march	PROPN
ajlm-933	83	41	2015	2015	NUM
ajlm-933	83	42	.	.	PUNCT
ajlm-933	84	1	for	for	ADP
ajlm-933	84	2	patients	patient	NOUN
ajlm-933	84	3	with	with	ADP
ajlm-933	84	4	<	<	X
ajlm-933	84	5	100	100	NUM
ajlm-933	84	6	cells	cell	NOUN
ajlm-933	84	7	/	/	SYM
ajlm-933	84	8	mm3	mm3	ADJ
ajlm-933	84	9	,	,	PUNCT
ajlm-933	84	10	sensitivity	sensitivity	NOUN
ajlm-933	84	11	of	of	ADP
ajlm-933	84	12	the	the	DET
ajlm-933	84	13	urine	urine	NOUN
ajlm-933	84	14	crag	crag	NOUN
ajlm-933	84	15	lfa	lfa	PROPN
ajlm-933	84	16	compared	compare	VERB
ajlm-933	84	17	with	with	ADP
ajlm-933	84	18	plasma	plasma	NOUN
ajlm-933	84	19	crag	crag	NOUN
ajlm-933	84	20	lfa	lfa	PROPN
ajlm-933	84	21	was	be	AUX
ajlm-933	84	22	100	100	NUM
ajlm-933	84	23	%	%	NOUN
ajlm-933	84	24	(	(	PUNCT
ajlm-933	84	25	95	95	NUM
ajlm-933	84	26	%	%	NOUN
ajlm-933	84	27	ci	ci	NOUN
ajlm-933	84	28	:	:	PUNCT
ajlm-933	84	29	59–100	59–100	NUM
ajlm-933	84	30	)	)	PUNCT
ajlm-933	84	31	,	,	PUNCT
ajlm-933	84	32	and	and	CCONJ
ajlm-933	84	33	specificity	specificity	NOUN
ajlm-933	84	34	was	be	AUX
ajlm-933	84	35	81	81	NUM
ajlm-933	84	36	%	%	NOUN
ajlm-933	84	37	(	(	PUNCT
ajlm-933	84	38	95	95	NUM
ajlm-933	84	39	%	%	NOUN
ajlm-933	84	40	ci	ci	NOUN
ajlm-933	84	41	:	:	PUNCT
ajlm-933	84	42	71–89	71–89	NUM
ajlm-933	84	43	)	)	PUNCT
ajlm-933	84	44	.	.	PUNCT
ajlm-933	85	1	there	there	PRON
ajlm-933	85	2	were	be	VERB
ajlm-933	85	3	seven	seven	NUM
ajlm-933	85	4	true	true	ADJ
ajlm-933	85	5	positives	positive	NOUN
ajlm-933	85	6	,	,	PUNCT
ajlm-933	85	7	16	16	NUM
ajlm-933	85	8	false	false	ADJ
ajlm-933	85	9	positives	positive	NOUN
ajlm-933	85	10	(	(	PUNCT
ajlm-933	85	11	i.e.	i.e.	X
ajlm-933	85	12	,	,	PUNCT
ajlm-933	85	13	positive	positive	ADJ
ajlm-933	85	14	on	on	ADP
ajlm-933	85	15	urine	urine	NOUN
ajlm-933	85	16	crag	crag	NOUN
ajlm-933	85	17	lfa	lfa	PROPN
ajlm-933	85	18	but	but	CCONJ
ajlm-933	85	19	negative	negative	ADJ
ajlm-933	85	20	on	on	ADP
ajlm-933	85	21	plasma	plasma	NOUN
ajlm-933	85	22	crag	crag	PROPN
ajlm-933	85	23	lfa	lfa	PROPN
ajlm-933	85	24	)	)	PUNCT
ajlm-933	85	25	,	,	PUNCT
ajlm-933	85	26	68	68	NUM
ajlm-933	85	27	true	true	ADJ
ajlm-933	85	28	negatives	negative	NOUN
ajlm-933	85	29	,	,	PUNCT
ajlm-933	85	30	and	and	CCONJ
ajlm-933	85	31	zero	zero	NUM
ajlm-933	85	32	false	false	ADJ
ajlm-933	85	33	negatives	negative	NOUN
ajlm-933	85	34	(	(	PUNCT
ajlm-933	85	35	i.e.	i.e.	X
ajlm-933	85	36	,	,	PUNCT
ajlm-933	85	37	negatives	negative	NOUN
ajlm-933	85	38	on	on	ADP
ajlm-933	85	39	urine	urine	NOUN
ajlm-933	85	40	crag	crag	NOUN
ajlm-933	85	41	lfa	lfa	PROPN
ajlm-933	85	42	but	but	CCONJ
ajlm-933	85	43	positive	positive	ADJ
ajlm-933	85	44	on	on	ADP
ajlm-933	85	45	plasma	plasma	NOUN
ajlm-933	85	46	crag	crag	PROPN
ajlm-933	85	47	lfa	lfa	PROPN
ajlm-933	85	48	)	)	PUNCT
ajlm-933	85	49	(	(	PUNCT
ajlm-933	85	50	table	table	NOUN
ajlm-933	85	51	3	3	NUM
ajlm-933	85	52	)	)	PUNCT
ajlm-933	85	53	.	.	PUNCT
ajlm-933	86	1	table	table	NOUN
ajlm-933	86	2	3	3	NUM
ajlm-933	86	3	:	:	PUNCT
ajlm-933	86	4	 	 	SPACE
ajlm-933	86	5	sensitivity	sensitivity	NOUN
ajlm-933	86	6	and	and	CCONJ
ajlm-933	86	7	specificity	specificity	NOUN
ajlm-933	86	8	of	of	ADP
ajlm-933	86	9	urine	urine	NOUN
ajlm-933	86	10	cryptococcal	cryptococcal	ADJ
ajlm-933	86	11	antigen	antigen	ADP
ajlm-933	86	12	lateral	lateral	ADJ
ajlm-933	86	13	flow	flow	NOUN
ajlm-933	86	14	assay	assay	NOUN
ajlm-933	86	15	compared	compare	VERB
ajlm-933	86	16	with	with	ADP
ajlm-933	86	17	the	the	DET
ajlm-933	86	18	plasma	plasma	NOUN
ajlm-933	86	19	cryptococcal	cryptococcal	ADJ
ajlm-933	86	20	antigen	antigen	ADP
ajlm-933	86	21	lateral	lateral	ADJ
ajlm-933	86	22	flow	flow	NOUN
ajlm-933	86	23	assay	assay	NOUN
ajlm-933	86	24	for	for	ADP
ajlm-933	86	25	patients	patient	NOUN
ajlm-933	86	26	with	with	ADP
ajlm-933	86	27	a	a	DET
ajlm-933	86	28	cd4	cd4	PROPN
ajlm-933	86	29	count	count	NOUN
ajlm-933	86	30	<	<	X
ajlm-933	86	31	100	100	NUM
ajlm-933	86	32	cells	cell	NOUN
ajlm-933	86	33	/	/	SYM
ajlm-933	86	34	mm3	mm3	PROPN
ajlm-933	86	35	,	,	PUNCT
ajlm-933	86	36	eswatini	eswatini	NOUN
ajlm-933	86	37	,	,	PUNCT
ajlm-933	86	38	august	august	PROPN
ajlm-933	86	39	2014	2014	NUM
ajlm-933	86	40	to	to	ADP
ajlm-933	86	41	march	march	PROPN
ajlm-933	86	42	2015	2015	NUM
ajlm-933	86	43	.	.	PUNCT
ajlm-933	87	1	discussion	discussion	NOUN
ajlm-933	87	2	we	we	PRON
ajlm-933	87	3	conducted	conduct	VERB
ajlm-933	87	4	a	a	DET
ajlm-933	87	5	cross	cross	ADJ
ajlm-933	87	6	-	-	ADJ
ajlm-933	87	7	sectional	sectional	ADJ
ajlm-933	87	8	study	study	NOUN
ajlm-933	87	9	on	on	ADP
ajlm-933	87	10	crag	crag	NOUN
ajlm-933	87	11	prevalence	prevalence	NOUN
ajlm-933	87	12	at	at	ADP
ajlm-933	87	13	a	a	DET
ajlm-933	87	14	national	national	ADJ
ajlm-933	87	15	reference	reference	NOUN
ajlm-933	87	16	hospital	hospital	NOUN
ajlm-933	87	17	in	in	ADP
ajlm-933	87	18	eswatini	eswatini	NOUN
ajlm-933	87	19	.	.	PUNCT
ajlm-933	88	1	the	the	DET
ajlm-933	88	2	study	study	NOUN
ajlm-933	88	3	showed	show	VERB
ajlm-933	88	4	that	that	SCONJ
ajlm-933	88	5	patients	patient	NOUN
ajlm-933	88	6	with	with	ADP
ajlm-933	88	7	cd4	cd4	PROPN
ajlm-933	88	8	<	<	X
ajlm-933	88	9	100	100	NUM
ajlm-933	88	10	cells	cell	NOUN
ajlm-933	88	11	/	/	SYM
ajlm-933	88	12	mm3	mm3	NOUN
ajlm-933	88	13	at	at	ADP
ajlm-933	88	14	the	the	DET
ajlm-933	88	15	national	national	PROPN
ajlm-933	88	16	reference	reference	PROPN
ajlm-933	88	17	hospital	hospital	NOUN
ajlm-933	88	18	had	have	VERB
ajlm-933	88	19	a	a	DET
ajlm-933	88	20	crag	crag	NOUN
ajlm-933	88	21	prevalence	prevalence	NOUN
ajlm-933	88	22	of	of	ADP
ajlm-933	88	23	8	8	NUM
ajlm-933	88	24	%	%	NOUN
ajlm-933	88	25	,	,	PUNCT
ajlm-933	88	26	which	which	PRON
ajlm-933	88	27	is	be	AUX
ajlm-933	88	28	higher	high	ADJ
ajlm-933	88	29	than	than	ADP
ajlm-933	88	30	the	the	DET
ajlm-933	88	31	2014	2014	NUM
ajlm-933	88	32	global	global	ADJ
ajlm-933	88	33	estimate	estimate	NOUN
ajlm-933	88	34	of	of	ADP
ajlm-933	88	35	6%2	6%2	NUM
ajlm-933	88	36	and	and	CCONJ
ajlm-933	88	37	similar	similar	ADJ
ajlm-933	88	38	to	to	ADP
ajlm-933	88	39	the	the	DET
ajlm-933	88	40	prevalence	prevalence	NOUN
ajlm-933	88	41	found	find	VERB
ajlm-933	88	42	in	in	ADP
ajlm-933	88	43	uganda5	uganda5	PROPN
ajlm-933	88	44	and	and	CCONJ
ajlm-933	88	45	south	south	PROPN
ajlm-933	88	46	africa.11	africa.11	PROPN
ajlm-933	88	47	this	this	DET
ajlm-933	88	48	study	study	NOUN
ajlm-933	88	49	is	be	AUX
ajlm-933	88	50	relevant	relevant	ADJ
ajlm-933	88	51	in	in	ADP
ajlm-933	88	52	the	the	DET
ajlm-933	88	53	context	context	NOUN
ajlm-933	88	54	of	of	ADP
ajlm-933	88	55	recent	recent	ADJ
ajlm-933	88	56	who	who	PRON
ajlm-933	88	57	guidelines	guideline	VERB
ajlm-933	88	58	on	on	ADP
ajlm-933	88	59	managing	manage	VERB
ajlm-933	88	60	advanced	advanced	ADJ
ajlm-933	88	61	hiv	hiv	PROPN
ajlm-933	88	62	disease	disease	NOUN
ajlm-933	88	63	,	,	PUNCT
ajlm-933	88	64	rapid	rapid	ADJ
ajlm-933	88	65	initiation	initiation	NOUN
ajlm-933	88	66	of	of	ADP
ajlm-933	88	67	art,1,9	art,1,9	PROPN
ajlm-933	88	68	and	and	CCONJ
ajlm-933	88	69	the	the	DET
ajlm-933	88	70	current	current	ADJ
ajlm-933	88	71	recommendation	recommendation	NOUN
ajlm-933	88	72	to	to	PART
ajlm-933	88	73	include	include	VERB
ajlm-933	88	74	crag	crag	NOUN
ajlm-933	88	75	screening	screening	NOUN
ajlm-933	88	76	in	in	ADP
ajlm-933	88	77	national	national	ADJ
ajlm-933	88	78	guidelines	guideline	NOUN
ajlm-933	88	79	in	in	ADP
ajlm-933	88	80	eswatini12	eswatini12	NOUN
ajlm-933	88	81	and	and	CCONJ
ajlm-933	88	82	in	in	ADP
ajlm-933	88	83	other	other	ADJ
ajlm-933	88	84	countries.13	countries.13	NOUN
ajlm-933	88	85	combining	combine	VERB
ajlm-933	88	86	crag	crag	NOUN
ajlm-933	88	87	screening	screening	NOUN
ajlm-933	88	88	and	and	CCONJ
ajlm-933	88	89	early	early	ADJ
ajlm-933	88	90	treatment	treatment	NOUN
ajlm-933	88	91	for	for	ADP
ajlm-933	88	92	cryptococcal	cryptococcal	ADJ
ajlm-933	88	93	infection	infection	NOUN
ajlm-933	88	94	are	be	AUX
ajlm-933	88	95	cost	cost	NOUN
ajlm-933	88	96	-	-	PUNCT
ajlm-933	88	97	effective	effective	ADJ
ajlm-933	88	98	interventions	intervention	NOUN
ajlm-933	88	99	compared	compare	VERB
ajlm-933	88	100	with	with	ADP
ajlm-933	88	101	standard	standard	ADJ
ajlm-933	88	102	care	care	NOUN
ajlm-933	88	103	to	to	PART
ajlm-933	88	104	prevent	prevent	VERB
ajlm-933	88	105	morbidity	morbidity	NOUN
ajlm-933	88	106	and	and	CCONJ
ajlm-933	88	107	mortality	mortality	NOUN
ajlm-933	88	108	from	from	ADP
ajlm-933	88	109	cryptococcal	cryptococcal	ADJ
ajlm-933	88	110	meningitis	meningiti	NOUN
ajlm-933	88	111	amongst	amongst	ADP
ajlm-933	88	112	immunocompromised	immunocompromise	VERB
ajlm-933	88	113	people	people	NOUN
ajlm-933	88	114	living	live	VERB
ajlm-933	88	115	with	with	ADP
ajlm-933	88	116	hiv.5,11,14,15,16,17	hiv.5,11,14,15,16,17	NOUN
ajlm-933	88	117	most	most	ADV
ajlm-933	88	118	importantly	importantly	ADV
ajlm-933	88	119	,	,	PUNCT
ajlm-933	88	120	crag	crag	NOUN
ajlm-933	88	121	screening	screening	NOUN
ajlm-933	88	122	has	have	VERB
ajlm-933	88	123	the	the	DET
ajlm-933	88	124	potential	potential	NOUN
ajlm-933	88	125	to	to	PART
ajlm-933	88	126	improve	improve	VERB
ajlm-933	88	127	hiv	hiv	PROPN
ajlm-933	88	128	outcomes	outcome	NOUN
ajlm-933	88	129	by	by	ADP
ajlm-933	88	130	reducing	reduce	VERB
ajlm-933	88	131	morbidity	morbidity	NOUN
ajlm-933	88	132	and	and	CCONJ
ajlm-933	88	133	mortality	mortality	NOUN
ajlm-933	88	134	.	.	PUNCT
ajlm-933	89	1	the	the	DET
ajlm-933	89	2	‘	'	PUNCT
ajlm-933	89	3	reduction	reduction	NOUN
ajlm-933	89	4	of	of	ADP
ajlm-933	89	5	early	early	ADJ
ajlm-933	89	6	mortality	mortality	NOUN
ajlm-933	89	7	among	among	ADP
ajlm-933	89	8	hiv	hiv	PROPN
ajlm-933	89	9	-	-	PUNCT
ajlm-933	89	10	infected	infect	VERB
ajlm-933	89	11	subjects	subject	NOUN
ajlm-933	89	12	starting	start	VERB
ajlm-933	89	13	antiretroviral	antiretroviral	ADJ
ajlm-933	89	14	therapy	therapy	NOUN
ajlm-933	89	15	’	'	PUNCT
ajlm-933	89	16	(	(	PUNCT
ajlm-933	89	17	remstart	remstart	NOUN
ajlm-933	89	18	)	)	PUNCT
ajlm-933	89	19	trial	trial	NOUN
ajlm-933	89	20	in	in	ADP
ajlm-933	89	21	tanzania	tanzania	PROPN
ajlm-933	89	22	and	and	CCONJ
ajlm-933	89	23	zambia	zambia	PROPN
ajlm-933	89	24	showed	show	VERB
ajlm-933	89	25	crag	crag	NOUN
ajlm-933	89	26	screening	screening	NOUN
ajlm-933	89	27	,	,	PUNCT
ajlm-933	89	28	pre	pre	ADJ
ajlm-933	89	29	-	-	ADJ
ajlm-933	89	30	emptive	emptive	ADJ
ajlm-933	89	31	treatment	treatment	NOUN
ajlm-933	89	32	,	,	PUNCT
ajlm-933	89	33	and	and	CCONJ
ajlm-933	89	34	community	community	NOUN
ajlm-933	89	35	support	support	NOUN
ajlm-933	89	36	that	that	PRON
ajlm-933	89	37	led	lead	VERB
ajlm-933	89	38	to	to	ADP
ajlm-933	89	39	a	a	DET
ajlm-933	89	40	28	28	NUM
ajlm-933	89	41	%	%	NOUN
ajlm-933	89	42	reduction	reduction	NOUN
ajlm-933	89	43	in	in	ADP
ajlm-933	89	44	mortality	mortality	NOUN
ajlm-933	89	45	amongst	amongst	ADP
ajlm-933	89	46	patients	patient	NOUN
ajlm-933	89	47	with	with	ADP
ajlm-933	89	48	advanced	advanced	ADJ
ajlm-933	89	49	hiv	hiv	PROPN
ajlm-933	89	50	disease,18	disease,18	PROPN
ajlm-933	89	51	and	and	CCONJ
ajlm-933	89	52	the	the	DET
ajlm-933	89	53	‘	'	PUNCT
ajlm-933	89	54	reduction	reduction	NOUN
ajlm-933	89	55	of	of	ADP
ajlm-933	89	56	early	early	ADJ
ajlm-933	89	57	mortality	mortality	NOUN
ajlm-933	89	58	in	in	ADP
ajlm-933	89	59	hiv	hiv	PROPN
ajlm-933	89	60	-	-	PUNCT
ajlm-933	89	61	infected	infect	VERB
ajlm-933	89	62	african	african	ADJ
ajlm-933	89	63	adults	adult	NOUN
ajlm-933	89	64	and	and	CCONJ
ajlm-933	89	65	children	child	NOUN
ajlm-933	89	66	starting	start	VERB
ajlm-933	89	67	antiretroviral	antiretroviral	ADJ
ajlm-933	89	68	therapy	therapy	NOUN
ajlm-933	89	69	’	'	PUNCT
ajlm-933	89	70	(	(	PUNCT
ajlm-933	89	71	reality	reality	NOUN
ajlm-933	89	72	)	)	PUNCT
ajlm-933	89	73	trial	trial	NOUN
ajlm-933	89	74	in	in	ADP
ajlm-933	89	75	kenya	kenya	PROPN
ajlm-933	89	76	,	,	PUNCT
ajlm-933	89	77	malawi	malawi	PROPN
ajlm-933	89	78	,	,	PUNCT
ajlm-933	89	79	uganda	uganda	PROPN
ajlm-933	89	80	,	,	PUNCT
ajlm-933	89	81	and	and	CCONJ
ajlm-933	89	82	zimbabwe	zimbabwe	PROPN
ajlm-933	89	83	showed	show	VERB
ajlm-933	89	84	that	that	SCONJ
ajlm-933	89	85	an	an	DET
ajlm-933	89	86	enhanced	enhanced	ADJ
ajlm-933	89	87	prophylaxis	prophylaxis	ADJ
ajlm-933	89	88	package	package	NOUN
ajlm-933	89	89	reduced	reduce	VERB
ajlm-933	89	90	mortality	mortality	NOUN
ajlm-933	89	91	by	by	ADP
ajlm-933	89	92	27%.19	27%.19	NUM
ajlm-933	89	93	cd4	cd4	PROPN
ajlm-933	89	94	cell	cell	NOUN
ajlm-933	89	95	counts	count	NOUN
ajlm-933	89	96	are	be	AUX
ajlm-933	89	97	essential	essential	ADJ
ajlm-933	89	98	in	in	ADP
ajlm-933	89	99	determining	determine	VERB
ajlm-933	89	100	the	the	DET
ajlm-933	89	101	timing	timing	NOUN
ajlm-933	89	102	of	of	ADP
ajlm-933	89	103	art	art	NOUN
ajlm-933	89	104	initiation	initiation	NOUN
ajlm-933	89	105	for	for	ADP
ajlm-933	89	106	patients	patient	NOUN
ajlm-933	89	107	with	with	ADP
ajlm-933	89	108	advanced	advanced	ADJ
ajlm-933	89	109	hiv	hiv	PROPN
ajlm-933	89	110	disease	disease	NOUN
ajlm-933	89	111	,	,	PUNCT
ajlm-933	89	112	because	because	SCONJ
ajlm-933	89	113	early	early	ADJ
ajlm-933	89	114	art	art	NOUN
ajlm-933	89	115	initiation	initiation	NOUN
ajlm-933	89	116	could	could	AUX
ajlm-933	89	117	lead	lead	VERB
ajlm-933	89	118	to	to	ADP
ajlm-933	89	119	worse	bad	ADJ
ajlm-933	89	120	outcomes	outcome	NOUN
ajlm-933	89	121	for	for	ADP
ajlm-933	89	122	crag	crag	NOUN
ajlm-933	89	123	-	-	PUNCT
ajlm-933	89	124	positive	positive	ADJ
ajlm-933	89	125	patients.20	patients.20	NOUN
ajlm-933	89	126	current	current	NOUN
ajlm-933	89	127	who	who	PRON
ajlm-933	89	128	recommendations	recommendation	NOUN
ajlm-933	89	129	include	include	VERB
ajlm-933	89	130	crag	crag	NOUN
ajlm-933	89	131	screening	screen	VERB
ajlm-933	89	132	for	for	ADP
ajlm-933	89	133	people	people	NOUN
ajlm-933	89	134	living	live	VERB
ajlm-933	89	135	with	with	ADP
ajlm-933	89	136	hiv	hiv	PROPN
ajlm-933	89	137	at	at	ADP
ajlm-933	89	138	cd4	cd4	PROPN
ajlm-933	89	139	cell	cell	NOUN
ajlm-933	89	140	counts	count	VERB
ajlm-933	89	141	<	<	X
ajlm-933	89	142	100	100	NUM
ajlm-933	89	143	cells	cell	NOUN
ajlm-933	89	144	/	/	SYM
ajlm-933	89	145	mm3	mm3	PROPN
ajlm-933	89	146	,	,	PUNCT
ajlm-933	89	147	and	and	CCONJ
ajlm-933	89	148	offering	offer	VERB
ajlm-933	89	149	pre	pre	ADJ
ajlm-933	89	150	-	-	ADJ
ajlm-933	89	151	emptive	emptive	ADJ
ajlm-933	89	152	antifungal	antifungal	ADJ
ajlm-933	89	153	therapy	therapy	NOUN
ajlm-933	89	154	before	before	ADP
ajlm-933	89	155	initiating	initiate	VERB
ajlm-933	89	156	art.1	art.1	PROPN
ajlm-933	89	157	in	in	ADP
ajlm-933	89	158	the	the	DET
ajlm-933	89	159	era	era	NOUN
ajlm-933	89	160	of	of	ADP
ajlm-933	89	161	‘	'	PUNCT
ajlm-933	89	162	90	90	NUM
ajlm-933	89	163	-	-	SYM
ajlm-933	89	164	90	90	NUM
ajlm-933	89	165	-	-	PUNCT
ajlm-933	89	166	90’21	90’21	NOUN
ajlm-933	89	167	and	and	CCONJ
ajlm-933	89	168	‘	'	PUNCT
ajlm-933	89	169	test	test	NOUN
ajlm-933	89	170	and	and	CCONJ
ajlm-933	89	171	start	start	VERB
ajlm-933	89	172	’	'	PUNCT
ajlm-933	89	173	strategies	strategy	NOUN
ajlm-933	89	174	where	where	SCONJ
ajlm-933	89	175	rapid	rapid	ADJ
ajlm-933	89	176	art	art	NOUN
ajlm-933	89	177	initiation	initiation	NOUN
ajlm-933	89	178	is	be	AUX
ajlm-933	89	179	promoted	promote	VERB
ajlm-933	89	180	,	,	PUNCT
ajlm-933	89	181	there	there	PRON
ajlm-933	89	182	is	be	VERB
ajlm-933	89	183	potential	potential	ADJ
ajlm-933	89	184	risk	risk	NOUN
ajlm-933	89	185	in	in	ADP
ajlm-933	89	186	offering	offer	VERB
ajlm-933	89	187	art	art	NOUN
ajlm-933	89	188	to	to	ADP
ajlm-933	89	189	patients	patient	NOUN
ajlm-933	89	190	presenting	present	VERB
ajlm-933	89	191	with	with	ADP
ajlm-933	89	192	advanced	advanced	ADJ
ajlm-933	89	193	hiv	hiv	PROPN
ajlm-933	89	194	disease	disease	NOUN
ajlm-933	89	195	with	with	ADP
ajlm-933	89	196	low	low	ADJ
ajlm-933	89	197	cd4	cd4	PROPN
ajlm-933	89	198	cell	cell	NOUN
ajlm-933	89	199	counts	count	NOUN
ajlm-933	89	200	or	or	CCONJ
ajlm-933	89	201	who	who	PRON
ajlm-933	89	202	clinical	clinical	VERB
ajlm-933	89	203	stages	stage	NOUN
ajlm-933	89	204	iii	iii	NOUN
ajlm-933	89	205	or	or	CCONJ
ajlm-933	89	206	iv22	iv22	PROPN
ajlm-933	89	207	who	who	PRON
ajlm-933	89	208	are	be	AUX
ajlm-933	89	209	at	at	ADP
ajlm-933	89	210	high	high	ADJ
ajlm-933	89	211	risk	risk	NOUN
ajlm-933	89	212	of	of	ADP
ajlm-933	89	213	opportunistic	opportunistic	ADJ
ajlm-933	89	214	infection.23	infection.23	NOUN
ajlm-933	89	215	screening	screen	VERB
ajlm-933	89	216	these	these	DET
ajlm-933	89	217	patients	patient	NOUN
ajlm-933	89	218	for	for	ADP
ajlm-933	89	219	undiagnosed	undiagnosed	ADJ
ajlm-933	89	220	cryptococcus	cryptococcus	NOUN
ajlm-933	89	221	infection	infection	NOUN
ajlm-933	89	222	can	can	AUX
ajlm-933	89	223	prevent	prevent	VERB
ajlm-933	89	224	life	life	NOUN
ajlm-933	89	225	-	-	PUNCT
ajlm-933	89	226	threatening	threaten	VERB
ajlm-933	89	227	immune	immune	ADJ
ajlm-933	89	228	reconstitution	reconstitution	NOUN
ajlm-933	89	229	inflammatory	inflammatory	ADJ
ajlm-933	89	230	syndrome.26	syndrome.26	NOUN
ajlm-933	89	231	yet	yet	ADV
ajlm-933	89	232	,	,	PUNCT
ajlm-933	89	233	assessment	assessment	NOUN
ajlm-933	89	234	of	of	ADP
ajlm-933	89	235	a	a	DET
ajlm-933	89	236	clinical	clinical	ADJ
ajlm-933	89	237	stage	stage	NOUN
ajlm-933	89	238	without	without	ADP
ajlm-933	89	239	a	a	DET
ajlm-933	89	240	cd4	cd4	PROPN
ajlm-933	89	241	count	count	NOUN
ajlm-933	89	242	is	be	AUX
ajlm-933	89	243	not	not	PART
ajlm-933	89	244	sufficient	sufficient	ADJ
ajlm-933	89	245	.	.	PUNCT
ajlm-933	90	1	in	in	ADP
ajlm-933	90	2	our	our	PRON
ajlm-933	90	3	study	study	NOUN
ajlm-933	90	4	,	,	PUNCT
ajlm-933	90	5	43	43	NUM
ajlm-933	90	6	%	%	NOUN
ajlm-933	90	7	of	of	ADP
ajlm-933	90	8	patients	patient	NOUN
ajlm-933	90	9	with	with	ADP
ajlm-933	90	10	cd4	cd4	PROPN
ajlm-933	90	11	<	<	X
ajlm-933	90	12	100	100	NUM
ajlm-933	90	13	cells	cell	NOUN
ajlm-933	90	14	/	/	SYM
ajlm-933	90	15	mm3	mm3	NOUN
ajlm-933	90	16	were	be	AUX
ajlm-933	90	17	classified	classify	VERB
ajlm-933	90	18	as	as	ADP
ajlm-933	90	19	who	who	PRON
ajlm-933	90	20	clinical	clinical	VERB
ajlm-933	90	21	stages	stage	NOUN
ajlm-933	90	22	i	i	PRON
ajlm-933	90	23	or	or	CCONJ
ajlm-933	90	24	ii	ii	NOUN
ajlm-933	90	25	.	.	PUNCT
ajlm-933	91	1	these	these	DET
ajlm-933	91	2	patients	patient	NOUN
ajlm-933	91	3	would	would	AUX
ajlm-933	91	4	not	not	PART
ajlm-933	91	5	have	have	AUX
ajlm-933	91	6	been	be	AUX
ajlm-933	91	7	screened	screen	VERB
ajlm-933	91	8	for	for	ADP
ajlm-933	91	9	crag	crag	NOUN
ajlm-933	91	10	in	in	ADP
ajlm-933	91	11	the	the	DET
ajlm-933	91	12	absence	absence	NOUN
ajlm-933	91	13	of	of	ADP
ajlm-933	91	14	cd4	cd4	PROPN
ajlm-933	91	15	cell	cell	NOUN
ajlm-933	91	16	count	count	NOUN
ajlm-933	91	17	testing	testing	NOUN
ajlm-933	91	18	.	.	PUNCT
ajlm-933	92	1	although	although	SCONJ
ajlm-933	92	2	studies	study	NOUN
ajlm-933	92	3	suggest	suggest	VERB
ajlm-933	92	4	that	that	SCONJ
ajlm-933	92	5	screening	screening	NOUN
ajlm-933	92	6	may	may	AUX
ajlm-933	92	7	be	be	AUX
ajlm-933	92	8	considered	consider	VERB
ajlm-933	92	9	at	at	ADP
ajlm-933	92	10	cd4	cd4	PROPN
ajlm-933	92	11	<	<	X
ajlm-933	92	12	200	200	NUM
ajlm-933	92	13	cells	cell	NOUN
ajlm-933	92	14	/	/	SYM
ajlm-933	92	15	mm3,24	mm3,24	NOUN
ajlm-933	92	16	our	our	PRON
ajlm-933	92	17	study	study	NOUN
ajlm-933	92	18	suggests	suggest	VERB
ajlm-933	92	19	that	that	SCONJ
ajlm-933	92	20	selecting	select	VERB
ajlm-933	92	21	for	for	ADP
ajlm-933	92	22	patients	patient	NOUN
ajlm-933	92	23	with	with	ADP
ajlm-933	92	24	cd4	cd4	PROPN
ajlm-933	92	25	<	<	X
ajlm-933	92	26	100	100	NUM
ajlm-933	92	27	cells	cell	NOUN
ajlm-933	92	28	/	/	SYM
ajlm-933	92	29	mm3	mm3	NOUN
ajlm-933	92	30	might	might	AUX
ajlm-933	92	31	be	be	AUX
ajlm-933	92	32	a	a	DET
ajlm-933	92	33	priority	priority	NOUN
ajlm-933	92	34	,	,	PUNCT
ajlm-933	92	35	since	since	SCONJ
ajlm-933	92	36	all	all	DET
ajlm-933	92	37	plasma	plasma	NOUN
ajlm-933	92	38	crag	crag	NOUN
ajlm-933	92	39	-	-	PUNCT
ajlm-933	92	40	positive	positive	ADJ
ajlm-933	92	41	patients	patient	NOUN
ajlm-933	92	42	had	have	VERB
ajlm-933	92	43	cd4	cd4	PROPN
ajlm-933	92	44	<	<	X
ajlm-933	92	45	100	100	NUM
ajlm-933	92	46	cells	cell	NOUN
ajlm-933	92	47	/	/	SYM
ajlm-933	92	48	mm3	mm3	PROPN
ajlm-933	92	49	.	.	PUNCT
ajlm-933	93	1	since	since	SCONJ
ajlm-933	93	2	crag	crag	NOUN
ajlm-933	93	3	-	-	PUNCT
ajlm-933	93	4	positive	positive	ADJ
ajlm-933	93	5	patients	patient	NOUN
ajlm-933	93	6	were	be	AUX
ajlm-933	93	7	found	find	VERB
ajlm-933	93	8	at	at	ADP
ajlm-933	93	9	both	both	DET
ajlm-933	93	10	outpatient	outpatient	NOUN
ajlm-933	93	11	(	(	PUNCT
ajlm-933	93	12	prevalence	prevalence	NOUN
ajlm-933	93	13	:	:	PUNCT
ajlm-933	93	14	5	5	NUM
ajlm-933	93	15	%	%	NOUN
ajlm-933	93	16	)	)	PUNCT
ajlm-933	93	17	and	and	CCONJ
ajlm-933	93	18	inpatient	inpatient	NOUN
ajlm-933	93	19	(	(	PUNCT
ajlm-933	93	20	prevalence	prevalence	NOUN
ajlm-933	93	21	:	:	PUNCT
ajlm-933	93	22	15	15	NUM
ajlm-933	93	23	%	%	NOUN
ajlm-933	93	24	)	)	PUNCT
ajlm-933	93	25	facilities	facility	NOUN
ajlm-933	93	26	,	,	PUNCT
ajlm-933	93	27	cd4	cd4	PROPN
ajlm-933	93	28	-	-	PUNCT
ajlm-933	93	29	directed	direct	VERB
ajlm-933	93	30	crag	crag	NOUN
ajlm-933	93	31	screening	screening	NOUN
ajlm-933	93	32	should	should	AUX
ajlm-933	93	33	be	be	AUX
ajlm-933	93	34	recommended	recommend	VERB
ajlm-933	93	35	for	for	ADP
ajlm-933	93	36	patients	patient	NOUN
ajlm-933	93	37	presenting	present	VERB
ajlm-933	93	38	in	in	ADP
ajlm-933	93	39	either	either	DET
ajlm-933	93	40	setting	setting	NOUN
ajlm-933	93	41	.	.	PUNCT
ajlm-933	94	1	the	the	DET
ajlm-933	94	2	sensitivity	sensitivity	NOUN
ajlm-933	94	3	and	and	CCONJ
ajlm-933	94	4	specificity	specificity	NOUN
ajlm-933	94	5	of	of	ADP
ajlm-933	94	6	urine	urine	NOUN
ajlm-933	94	7	crag	crag	NOUN
ajlm-933	94	8	compared	compare	VERB
ajlm-933	94	9	with	with	ADP
ajlm-933	94	10	plasma	plasma	NOUN
ajlm-933	94	11	crag	crag	NOUN
ajlm-933	94	12	testing	testing	NOUN
ajlm-933	94	13	were	be	AUX
ajlm-933	94	14	similar	similar	ADJ
ajlm-933	94	15	to	to	ADP
ajlm-933	94	16	the	the	DET
ajlm-933	94	17	finding	finding	NOUN
ajlm-933	94	18	of	of	ADP
ajlm-933	94	19	a	a	DET
ajlm-933	94	20	tanzanian	tanzanian	ADJ
ajlm-933	94	21	study.25	study.25	NOUN
ajlm-933	94	22	those	those	DET
ajlm-933	94	23	findings	finding	NOUN
ajlm-933	94	24	showed	show	VERB
ajlm-933	94	25	that	that	SCONJ
ajlm-933	94	26	urine	urine	NOUN
ajlm-933	94	27	crag	crag	NOUN
ajlm-933	94	28	testing	testing	NOUN
ajlm-933	94	29	could	could	AUX
ajlm-933	94	30	be	be	AUX
ajlm-933	94	31	useful	useful	ADJ
ajlm-933	94	32	in	in	ADP
ajlm-933	94	33	ruling	rule	VERB
ajlm-933	94	34	out	out	ADP
ajlm-933	94	35	disease	disease	NOUN
ajlm-933	94	36	,	,	PUNCT
ajlm-933	94	37	if	if	SCONJ
ajlm-933	94	38	the	the	DET
ajlm-933	94	39	result	result	NOUN
ajlm-933	94	40	is	be	AUX
ajlm-933	94	41	negative	negative	ADJ
ajlm-933	94	42	,	,	PUNCT
ajlm-933	94	43	but	but	CCONJ
ajlm-933	94	44	may	may	AUX
ajlm-933	94	45	not	not	PART
ajlm-933	94	46	be	be	AUX
ajlm-933	94	47	a	a	DET
ajlm-933	94	48	reliable	reliable	ADJ
ajlm-933	94	49	stand	stand	NOUN
ajlm-933	94	50	-	-	PUNCT
ajlm-933	94	51	alone	alone	ADV
ajlm-933	94	52	screening	screen	VERB
ajlm-933	94	53	tool	tool	NOUN
ajlm-933	94	54	because	because	SCONJ
ajlm-933	94	55	of	of	ADP
ajlm-933	94	56	the	the	DET
ajlm-933	94	57	prevalence	prevalence	NOUN
ajlm-933	94	58	of	of	ADP
ajlm-933	94	59	false	false	ADJ
ajlm-933	94	60	-	-	PUNCT
ajlm-933	94	61	positive	positive	ADJ
ajlm-933	94	62	results	result	NOUN
ajlm-933	94	63	.	.	PUNCT
ajlm-933	95	1	the	the	DET
ajlm-933	95	2	eswatini	eswatini	PROPN
ajlm-933	95	3	ministry	ministry	PROPN
ajlm-933	95	4	of	of	ADP
ajlm-933	95	5	health	health	PROPN
ajlm-933	95	6	revised	revise	VERB
ajlm-933	95	7	its	its	PRON
ajlm-933	95	8	hiv	hiv	PROPN
ajlm-933	95	9	guidelines	guideline	NOUN
ajlm-933	95	10	in	in	ADP
ajlm-933	95	11	2018	2018	NUM
ajlm-933	95	12	and	and	CCONJ
ajlm-933	95	13	included	include	VERB
ajlm-933	95	14	crag	crag	NOUN
ajlm-933	95	15	screening	screen	VERB
ajlm-933	95	16	for	for	ADP
ajlm-933	95	17	adults	adult	NOUN
ajlm-933	95	18	with	with	ADP
ajlm-933	95	19	cd4	cd4	PROPN
ajlm-933	95	20	cell	cell	NOUN
ajlm-933	95	21	<	<	X
ajlm-933	95	22	100	100	NUM
ajlm-933	95	23	cells	cell	NOUN
ajlm-933	95	24	/	/	SYM
ajlm-933	95	25	mm3	mm3	NOUN
ajlm-933	95	26	or	or	CCONJ
ajlm-933	95	27	children	child	NOUN
ajlm-933	95	28	with	with	ADP
ajlm-933	95	29	cd4	cd4	PROPN
ajlm-933	95	30	counts	count	NOUN
ajlm-933	95	31	at	at	ADP
ajlm-933	95	32	less	less	ADJ
ajlm-933	95	33	than	than	ADP
ajlm-933	95	34	25	25	NUM
ajlm-933	95	35	%	%	NOUN
ajlm-933	95	36	of	of	ADP
ajlm-933	95	37	total	total	ADJ
ajlm-933	95	38	lymphocytes,12	lymphocytes,12	PROPN
ajlm-933	95	39	as	as	ADV
ajlm-933	95	40	well	well	ADV
ajlm-933	95	41	as	as	ADP
ajlm-933	95	42	pre	pre	ADJ
ajlm-933	95	43	-	-	ADJ
ajlm-933	95	44	emptive	emptive	ADJ
ajlm-933	95	45	treatment	treatment	NOUN
ajlm-933	95	46	as	as	ADP
ajlm-933	95	47	a	a	DET
ajlm-933	95	48	package	package	NOUN
ajlm-933	95	49	for	for	ADP
ajlm-933	95	50	advanced	advanced	ADJ
ajlm-933	95	51	disease	disease	NOUN
ajlm-933	95	52	management	management	NOUN
ajlm-933	95	53	to	to	PART
ajlm-933	95	54	reduce	reduce	VERB
ajlm-933	95	55	morbity	morbity	NOUN
ajlm-933	95	56	and	and	CCONJ
ajlm-933	95	57	mortality.26,27,28	mortality.26,27,28	ADP
ajlm-933	95	58	education	education	NOUN
ajlm-933	95	59	of	of	ADP
ajlm-933	95	60	patients	patient	NOUN
ajlm-933	95	61	is	be	AUX
ajlm-933	95	62	important	important	ADJ
ajlm-933	95	63	in	in	ADP
ajlm-933	95	64	order	order	NOUN
ajlm-933	95	65	to	to	PART
ajlm-933	95	66	inform	inform	VERB
ajlm-933	95	67	them	they	PRON
ajlm-933	95	68	that	that	SCONJ
ajlm-933	95	69	cryptococcal	cryptococcal	ADJ
ajlm-933	95	70	meningitis	meningitis	NOUN
ajlm-933	95	71	is	be	AUX
ajlm-933	95	72	not	not	PART
ajlm-933	95	73	,	,	PUNCT
ajlm-933	95	74	as	as	SCONJ
ajlm-933	95	75	some	some	DET
ajlm-933	95	76	swazi	swazi	ADJ
ajlm-933	95	77	patients	patient	NOUN
ajlm-933	95	78	refer	refer	VERB
ajlm-933	95	79	to	to	ADP
ajlm-933	95	80	it	it	PRON
ajlm-933	95	81	,	,	PUNCT
ajlm-933	95	82	the	the	DET
ajlm-933	95	83	‘	'	PUNCT
ajlm-933	95	84	headache	headache	NOUN
ajlm-933	95	85	that	that	PRON
ajlm-933	95	86	kills	kill	VERB
ajlm-933	95	87	’	'	PUNCT
ajlm-933	95	88	,	,	PUNCT
ajlm-933	95	89	but	but	CCONJ
ajlm-933	95	90	rather	rather	ADV
ajlm-933	95	91	a	a	DET
ajlm-933	95	92	preventable	preventable	ADJ
ajlm-933	95	93	and	and	CCONJ
ajlm-933	95	94	treatable	treatable	ADJ
ajlm-933	95	95	disease	disease	NOUN
ajlm-933	95	96	(	(	PUNCT
ajlm-933	95	97	personal	personal	ADJ
ajlm-933	95	98	communication	communication	NOUN
ajlm-933	95	99	with	with	ADP
ajlm-933	95	100	patients	patient	NOUN
ajlm-933	95	101	)	)	PUNCT
ajlm-933	95	102	.	.	PUNCT
ajlm-933	96	1	before	before	ADP
ajlm-933	96	2	rollout	rollout	NOUN
ajlm-933	96	3	,	,	PUNCT
ajlm-933	96	4	training	training	NOUN
ajlm-933	96	5	of	of	ADP
ajlm-933	96	6	the	the	DET
ajlm-933	96	7	clinical	clinical	ADJ
ajlm-933	96	8	and	and	CCONJ
ajlm-933	96	9	laboratory	laboratory	NOUN
ajlm-933	96	10	workforce	workforce	NOUN
ajlm-933	96	11	on	on	ADP
ajlm-933	96	12	crag	crag	NOUN
ajlm-933	96	13	testing	testing	NOUN
ajlm-933	96	14	and	and	CCONJ
ajlm-933	96	15	reporting	reporting	NOUN
ajlm-933	96	16	,	,	PUNCT
ajlm-933	96	17	and	and	CCONJ
ajlm-933	96	18	ensuring	ensure	VERB
ajlm-933	96	19	adequate	adequate	ADJ
ajlm-933	96	20	supplies	supply	NOUN
ajlm-933	96	21	of	of	ADP
ajlm-933	96	22	antifungal	antifungal	ADJ
ajlm-933	96	23	prophylaxis	prophylaxis	PROPN
ajlm-933	96	24	,	,	PUNCT
ajlm-933	96	25	treatment	treatment	NOUN
ajlm-933	96	26	(	(	PUNCT
ajlm-933	96	27	fluconazole	fluconazole	NOUN
ajlm-933	96	28	,	,	PUNCT
ajlm-933	96	29	flucytocine	flucytocine	VERB
ajlm-933	96	30	,	,	PUNCT
ajlm-933	96	31	and	and	CCONJ
ajlm-933	96	32	amphotericin	amphotericin	ADP
ajlm-933	96	33	b	b	X
ajlm-933	96	34	)	)	PUNCT
ajlm-933	96	35	,	,	PUNCT
ajlm-933	96	36	lumbar	lumbar	NOUN
ajlm-933	96	37	puncture	puncture	NOUN
ajlm-933	96	38	kits	kit	NOUN
ajlm-933	96	39	and	and	CCONJ
ajlm-933	96	40	crag	crag	PROPN
ajlm-933	96	41	lfa	lfa	PROPN
ajlm-933	96	42	kits	kits	PROPN
ajlm-933	96	43	are	be	AUX
ajlm-933	96	44	essential	essential	ADJ
ajlm-933	96	45	.	.	PUNCT
ajlm-933	97	1	moreover	moreover	ADV
ajlm-933	97	2	,	,	PUNCT
ajlm-933	97	3	joint	joint	ADJ
ajlm-933	97	4	ownership	ownership	NOUN
ajlm-933	97	5	of	of	ADP
ajlm-933	97	6	the	the	DET
ajlm-933	97	7	crag	crag	NOUN
ajlm-933	97	8	screening	screen	VERB
ajlm-933	97	9	program	program	NOUN
ajlm-933	97	10	by	by	ADP
ajlm-933	97	11	the	the	DET
ajlm-933	97	12	swaziland	swaziland	PROPN
ajlm-933	97	13	national	national	PROPN
ajlm-933	97	14	hiv	hiv	PROPN
ajlm-933	97	15	/	/	SYM
ajlm-933	97	16	aids	aids	PROPN
ajlm-933	97	17	programme	programme	NOUN
ajlm-933	97	18	and	and	CCONJ
ajlm-933	97	19	swaziland	swaziland	PROPN
ajlm-933	97	20	health	health	PROPN
ajlm-933	97	21	laboratory	laboratory	NOUN
ajlm-933	97	22	services	service	NOUN
ajlm-933	97	23	have	have	AUX
ajlm-933	97	24	been	be	AUX
ajlm-933	97	25	established	establish	VERB
ajlm-933	97	26	in	in	ADP
ajlm-933	97	27	-	-	PUNCT
ajlm-933	97	28	country	country	NOUN
ajlm-933	97	29	,	,	PUNCT
ajlm-933	97	30	which	which	PRON
ajlm-933	97	31	could	could	AUX
ajlm-933	97	32	help	help	VERB
ajlm-933	97	33	accelerate	accelerate	VERB
ajlm-933	97	34	buy	buy	VERB
ajlm-933	97	35	-	-	PUNCT
ajlm-933	97	36	in	in	NOUN
ajlm-933	97	37	from	from	ADP
ajlm-933	97	38	the	the	DET
ajlm-933	97	39	clinical	clinical	ADJ
ajlm-933	97	40	and	and	CCONJ
ajlm-933	97	41	laboratory	laboratory	NOUN
ajlm-933	97	42	workforces	workforce	NOUN
ajlm-933	97	43	and	and	CCONJ
ajlm-933	97	44	successfully	successfully	ADV
ajlm-933	97	45	roll	roll	VERB
ajlm-933	97	46	out	out	ADP
ajlm-933	97	47	the	the	DET
ajlm-933	97	48	national	national	ADJ
ajlm-933	97	49	crag	crag	NOUN
ajlm-933	97	50	screening	screen	VERB
ajlm-933	97	51	programme	programme	NOUN
ajlm-933	97	52	.	.	PUNCT
ajlm-933	98	1	limitations	limitation	NOUN
ajlm-933	98	2	there	there	PRON
ajlm-933	98	3	are	be	VERB
ajlm-933	98	4	several	several	ADJ
ajlm-933	98	5	limitations	limitation	NOUN
ajlm-933	98	6	to	to	ADP
ajlm-933	98	7	this	this	DET
ajlm-933	98	8	study	study	NOUN
ajlm-933	98	9	.	.	PUNCT
ajlm-933	99	1	firstly	firstly	ADV
ajlm-933	99	2	,	,	PUNCT
ajlm-933	99	3	the	the	DET
ajlm-933	99	4	study	study	NOUN
ajlm-933	99	5	was	be	AUX
ajlm-933	99	6	conducted	conduct	VERB
ajlm-933	99	7	in	in	ADP
ajlm-933	99	8	one	one	NUM
ajlm-933	99	9	hospital	hospital	NOUN
ajlm-933	99	10	,	,	PUNCT
ajlm-933	99	11	thus	thus	ADV
ajlm-933	99	12	it	it	PRON
ajlm-933	99	13	is	be	AUX
ajlm-933	99	14	not	not	PART
ajlm-933	99	15	a	a	DET
ajlm-933	99	16	nationally	nationally	ADV
ajlm-933	99	17	-	-	PUNCT
ajlm-933	99	18	representative	representative	NOUN
ajlm-933	99	19	sample	sample	NOUN
ajlm-933	99	20	.	.	PUNCT
ajlm-933	100	1	however	however	ADV
ajlm-933	100	2	,	,	PUNCT
ajlm-933	100	3	this	this	DET
ajlm-933	100	4	hospital	hospital	NOUN
ajlm-933	100	5	is	be	AUX
ajlm-933	100	6	a	a	DET
ajlm-933	100	7	national	national	ADJ
ajlm-933	100	8	reference	reference	NOUN
ajlm-933	100	9	hospital	hospital	NOUN
ajlm-933	100	10	that	that	PRON
ajlm-933	100	11	captures	capture	VERB
ajlm-933	100	12	a	a	DET
ajlm-933	100	13	large	large	ADJ
ajlm-933	100	14	number	number	NOUN
ajlm-933	100	15	of	of	ADP
ajlm-933	100	16	patients	patient	NOUN
ajlm-933	100	17	who	who	PRON
ajlm-933	100	18	are	be	AUX
ajlm-933	100	19	crag	crag	NOUN
ajlm-933	100	20	-	-	PUNCT
ajlm-933	100	21	positive	positive	ADJ
ajlm-933	100	22	.	.	PUNCT
ajlm-933	101	1	secondly	secondly	ADV
ajlm-933	101	2	,	,	PUNCT
ajlm-933	101	3	the	the	DET
ajlm-933	101	4	study	study	NOUN
ajlm-933	101	5	only	only	ADV
ajlm-933	101	6	assessed	assess	VERB
ajlm-933	101	7	art	art	NOUN
ajlm-933	101	8	-	-	PUNCT
ajlm-933	101	9	naïve	naïve	ADJ
ajlm-933	101	10	patients	patient	NOUN
ajlm-933	101	11	,	,	PUNCT
ajlm-933	101	12	whereas	whereas	SCONJ
ajlm-933	101	13	patients	patient	NOUN
ajlm-933	101	14	failing	fail	VERB
ajlm-933	101	15	art	art	NOUN
ajlm-933	101	16	may	may	AUX
ajlm-933	101	17	also	also	ADV
ajlm-933	101	18	have	have	VERB
ajlm-933	101	19	cd4	cd4	PROPN
ajlm-933	101	20	cell	cell	NOUN
ajlm-933	101	21	counts	count	VERB
ajlm-933	101	22	<	<	X
ajlm-933	101	23	100	100	NUM
ajlm-933	101	24	cell	cell	NOUN
ajlm-933	101	25	/	/	SYM
ajlm-933	101	26	mm3	mm3	NOUN
ajlm-933	101	27	and	and	CCONJ
ajlm-933	101	28	become	become	VERB
ajlm-933	101	29	at	at	ADP
ajlm-933	101	30	risk	risk	NOUN
ajlm-933	101	31	of	of	ADP
ajlm-933	101	32	cryptococcal	cryptococcal	ADJ
ajlm-933	101	33	infection	infection	NOUN
ajlm-933	101	34	.	.	PUNCT
ajlm-933	102	1	in	in	ADP
ajlm-933	102	2	addition	addition	NOUN
ajlm-933	102	3	,	,	PUNCT
ajlm-933	102	4	the	the	DET
ajlm-933	102	5	cross	cross	ADJ
ajlm-933	102	6	-	-	ADJ
ajlm-933	102	7	sectional	sectional	ADJ
ajlm-933	102	8	study	study	NOUN
ajlm-933	102	9	design	design	NOUN
ajlm-933	102	10	and	and	CCONJ
ajlm-933	102	11	small	small	ADJ
ajlm-933	102	12	sample	sample	NOUN
ajlm-933	102	13	size	size	NOUN
ajlm-933	102	14	limited	limit	VERB
ajlm-933	102	15	our	our	PRON
ajlm-933	102	16	ability	ability	NOUN
ajlm-933	102	17	to	to	PART
ajlm-933	102	18	measure	measure	VERB
ajlm-933	102	19	or	or	CCONJ
ajlm-933	102	20	compare	compare	VERB
ajlm-933	102	21	patient	patient	ADJ
ajlm-933	102	22	outcomes	outcome	NOUN
ajlm-933	102	23	.	.	PUNCT
ajlm-933	103	1	further	further	ADJ
ajlm-933	103	2	studies	study	NOUN
ajlm-933	103	3	to	to	PART
ajlm-933	103	4	examine	examine	VERB
ajlm-933	103	5	patient	patient	ADJ
ajlm-933	103	6	treatment	treatment	NOUN
ajlm-933	103	7	and	and	CCONJ
ajlm-933	103	8	outcome	outcome	NOUN
ajlm-933	103	9	measures	measure	NOUN
ajlm-933	103	10	,	,	PUNCT
ajlm-933	103	11	and	and	CCONJ
ajlm-933	103	12	address	address	VERB
ajlm-933	103	13	crag	crag	NOUN
ajlm-933	103	14	prevalence	prevalence	NOUN
ajlm-933	103	15	among	among	ADP
ajlm-933	103	16	art	art	NOUN
ajlm-933	103	17	-	-	PUNCT
ajlm-933	103	18	experienced	experience	VERB
ajlm-933	103	19	patients	patient	NOUN
ajlm-933	103	20	,	,	PUNCT
ajlm-933	103	21	are	be	AUX
ajlm-933	103	22	warranted	warrant	VERB
ajlm-933	103	23	.	.	PUNCT
ajlm-933	104	1	finally	finally	ADV
ajlm-933	104	2	,	,	PUNCT
ajlm-933	104	3	sensitivity	sensitivity	NOUN
ajlm-933	104	4	and	and	CCONJ
ajlm-933	104	5	specificity	specificity	NOUN
ajlm-933	104	6	analyses	analysis	NOUN
ajlm-933	104	7	of	of	ADP
ajlm-933	104	8	urine	urine	NOUN
ajlm-933	104	9	crag	crag	NOUN
ajlm-933	104	10	lfa	lfa	PROPN
ajlm-933	104	11	were	be	AUX
ajlm-933	104	12	evaluated	evaluate	VERB
ajlm-933	104	13	compared	compare	VERB
ajlm-933	104	14	with	with	ADP
ajlm-933	104	15	plasma	plasma	NOUN
ajlm-933	104	16	lfa	lfa	PROPN
ajlm-933	104	17	and	and	CCONJ
ajlm-933	104	18	did	do	AUX
ajlm-933	104	19	not	not	PART
ajlm-933	104	20	take	take	VERB
ajlm-933	104	21	into	into	ADP
ajlm-933	104	22	account	account	NOUN
ajlm-933	104	23	radiological	radiological	ADJ
ajlm-933	104	24	or	or	CCONJ
ajlm-933	104	25	clinical	clinical	ADJ
ajlm-933	104	26	findings	finding	NOUN
ajlm-933	104	27	.	.	PUNCT
ajlm-933	105	1	conclusion	conclusion	NOUN
ajlm-933	105	2	this	this	DET
ajlm-933	105	3	study	study	NOUN
ajlm-933	105	4	indicated	indicate	VERB
ajlm-933	105	5	that	that	SCONJ
ajlm-933	105	6	the	the	DET
ajlm-933	105	7	crag	crag	NOUN
ajlm-933	105	8	prevalence	prevalence	NOUN
ajlm-933	105	9	at	at	ADP
ajlm-933	105	10	a	a	DET
ajlm-933	105	11	national	national	ADJ
ajlm-933	105	12	hospital	hospital	NOUN
ajlm-933	105	13	in	in	ADP
ajlm-933	105	14	eswatini	eswatini	PROPN
ajlm-933	105	15	was	be	AUX
ajlm-933	105	16	higher	high	ADJ
ajlm-933	105	17	than	than	ADP
ajlm-933	105	18	the	the	DET
ajlm-933	105	19	global	global	ADJ
ajlm-933	105	20	crag	crag	NOUN
ajlm-933	105	21	estimates	estimate	NOUN
ajlm-933	105	22	of	of	ADP
ajlm-933	105	23	6	6	NUM
ajlm-933	105	24	%	%	NOUN
ajlm-933	105	25	amongst	amongst	ADP
ajlm-933	105	26	hiv	hiv	PROPN
ajlm-933	105	27	-	-	PUNCT
ajlm-933	105	28	positive	positive	ADJ
ajlm-933	105	29	people	people	NOUN
ajlm-933	105	30	with	with	ADP
ajlm-933	105	31	cd4	cd4	PROPN
ajlm-933	105	32	<	<	X
ajlm-933	105	33	100	100	NUM
ajlm-933	105	34	cell	cell	NOUN
ajlm-933	105	35	/	/	SYM
ajlm-933	105	36	mm3	mm3	NOUN
ajlm-933	105	37	.	.	PUNCT
ajlm-933	106	1	our	our	PRON
ajlm-933	106	2	findings	finding	NOUN
ajlm-933	106	3	support	support	VERB
ajlm-933	106	4	the	the	DET
ajlm-933	106	5	current	current	ADJ
ajlm-933	106	6	eswatini	eswatini	NOUN
ajlm-933	106	7	national	national	PROPN
ajlm-933	106	8	cryptococcal	cryptococcal	ADJ
ajlm-933	106	9	screening	screening	NOUN
ajlm-933	106	10	and	and	CCONJ
ajlm-933	106	11	treatment	treatment	NOUN
ajlm-933	106	12	guidelines	guideline	NOUN
ajlm-933	106	13	.	.	PUNCT
ajlm-933	107	1	issues	issue	NOUN
ajlm-933	107	2	of	of	ADP
ajlm-933	107	3	drug	drug	NOUN
ajlm-933	107	4	and	and	CCONJ
ajlm-933	107	5	commodity	commodity	NOUN
ajlm-933	107	6	supply	supply	NOUN
ajlm-933	107	7	and	and	CCONJ
ajlm-933	107	8	training	training	NOUN
ajlm-933	107	9	mechanisms	mechanism	NOUN
ajlm-933	107	10	for	for	ADP
ajlm-933	107	11	crag	crag	NOUN
ajlm-933	107	12	testing	testing	NOUN
ajlm-933	107	13	,	,	PUNCT
ajlm-933	107	14	monitoring	monitoring	NOUN
ajlm-933	107	15	,	,	PUNCT
ajlm-933	107	16	evaluation	evaluation	NOUN
ajlm-933	107	17	and	and	CCONJ
ajlm-933	107	18	reporting	reporting	NOUN
ajlm-933	107	19	are	be	AUX
ajlm-933	107	20	important	important	ADJ
ajlm-933	107	21	considerations	consideration	NOUN
ajlm-933	107	22	,	,	PUNCT
ajlm-933	107	23	before	before	ADP
ajlm-933	107	24	national	national	ADJ
ajlm-933	107	25	implementation	implementation	NOUN
ajlm-933	107	26	of	of	ADP
ajlm-933	107	27	plasma	plasma	NOUN
ajlm-933	107	28	crag	crag	NOUN
ajlm-933	107	29	lfa	lfa	PROPN
ajlm-933	107	30	screening	screening	PROPN
ajlm-933	107	31	.	.	PUNCT
ajlm-933	108	1	trustworthiness	trustworthiness	NOUN
ajlm-933	108	2	the	the	DET
ajlm-933	108	3	following	follow	VERB
ajlm-933	108	4	measures	measure	NOUN
ajlm-933	108	5	were	be	AUX
ajlm-933	108	6	undertaken	undertake	VERB
ajlm-933	108	7	to	to	PART
ajlm-933	108	8	ensure	ensure	VERB
ajlm-933	108	9	trustworthiness	trustworthiness	NOUN
ajlm-933	108	10	:	:	PUNCT
ajlm-933	108	11	cryptococcal	cryptococcal	ADJ
ajlm-933	108	12	antigen	antigen	ADP
ajlm-933	108	13	lateral	lateral	ADJ
ajlm-933	108	14	flow	flow	NOUN
ajlm-933	108	15	assay	assay	PROPN
ajlm-933	108	16	quality	quality	NOUN
ajlm-933	108	17	control	control	NOUN
ajlm-933	108	18	:	:	PUNCT
ajlm-933	108	19	laboratory	laboratory	NOUN
ajlm-933	108	20	technologists	technologist	NOUN
ajlm-933	108	21	at	at	ADP
ajlm-933	108	22	the	the	DET
ajlm-933	108	23	national	national	PROPN
ajlm-933	108	24	reference	reference	PROPN
ajlm-933	108	25	laboratory	laboratory	NOUN
ajlm-933	108	26	conducted	conduct	VERB
ajlm-933	108	27	quality	quality	NOUN
ajlm-933	108	28	control	control	NOUN
ajlm-933	108	29	testing	testing	NOUN
ajlm-933	108	30	for	for	ADP
ajlm-933	108	31	the	the	DET
ajlm-933	108	32	crag	crag	NOUN
ajlm-933	108	33	lfa	lfa	PROPN
ajlm-933	108	34	reagents	reagent	VERB
ajlm-933	108	35	on	on	ADP
ajlm-933	108	36	a	a	DET
ajlm-933	108	37	weekly	weekly	ADJ
ajlm-933	108	38	basis	basis	NOUN
ajlm-933	108	39	.	.	PUNCT
ajlm-933	109	1	a	a	DET
ajlm-933	109	2	positive	positive	ADJ
ajlm-933	109	3	and	and	CCONJ
ajlm-933	109	4	negative	negative	ADJ
ajlm-933	109	5	control	control	NOUN
ajlm-933	109	6	lfa	lfa	PROPN
ajlm-933	109	7	test	test	PROPN
ajlm-933	109	8	as	as	ADV
ajlm-933	109	9	well	well	ADV
ajlm-933	109	10	as	as	ADP
ajlm-933	109	11	lot	lot	NOUN
ajlm-933	109	12	-	-	PUNCT
ajlm-933	109	13	to	to	ADP
ajlm-933	109	14	-	-	PUNCT
ajlm-933	109	15	lot	lot	NOUN
ajlm-933	109	16	testing	testing	NOUN
ajlm-933	109	17	were	be	AUX
ajlm-933	109	18	performed	perform	VERB
ajlm-933	109	19	to	to	PART
ajlm-933	109	20	ensure	ensure	VERB
ajlm-933	109	21	the	the	DET
ajlm-933	109	22	quality	quality	NOUN
ajlm-933	109	23	of	of	ADP
ajlm-933	109	24	the	the	DET
ajlm-933	109	25	reagents	reagent	NOUN
ajlm-933	109	26	.	.	PUNCT
ajlm-933	110	1	the	the	DET
ajlm-933	110	2	reagents	reagent	NOUN
ajlm-933	110	3	were	be	AUX
ajlm-933	110	4	discarded	discard	VERB
ajlm-933	110	5	when	when	SCONJ
ajlm-933	110	6	the	the	DET
ajlm-933	110	7	positive	positive	ADJ
ajlm-933	110	8	or	or	CCONJ
ajlm-933	110	9	negative	negative	ADJ
ajlm-933	110	10	controls	control	NOUN
ajlm-933	110	11	did	do	AUX
ajlm-933	110	12	not	not	PART
ajlm-933	110	13	yield	yield	VERB
ajlm-933	110	14	the	the	DET
ajlm-933	110	15	expected	expect	VERB
ajlm-933	110	16	results	result	NOUN
ajlm-933	110	17	,	,	PUNCT
ajlm-933	110	18	and	and	CCONJ
ajlm-933	110	19	a	a	DET
ajlm-933	110	20	new	new	ADJ
ajlm-933	110	21	set	set	NOUN
ajlm-933	110	22	of	of	ADP
ajlm-933	110	23	lfa	lfa	PROPN
ajlm-933	110	24	reagents	reagent	NOUN
ajlm-933	110	25	were	be	AUX
ajlm-933	110	26	requested	request	VERB
ajlm-933	110	27	from	from	ADP
ajlm-933	110	28	the	the	DET
ajlm-933	110	29	laboratory	laboratory	NOUN
ajlm-933	110	30	supervisor	supervisor	NOUN
ajlm-933	110	31	and	and	CCONJ
ajlm-933	110	32	tested	test	VERB
ajlm-933	110	33	prior	prior	ADV
ajlm-933	110	34	to	to	ADP
ajlm-933	110	35	further	further	ADJ
ajlm-933	110	36	patient	patient	ADJ
ajlm-933	110	37	testing	testing	NOUN
ajlm-933	110	38	for	for	ADP
ajlm-933	110	39	crag	crag	NOUN
ajlm-933	110	40	.	.	PUNCT
ajlm-933	111	1	training	training	NOUN
ajlm-933	111	2	of	of	ADP
ajlm-933	111	3	clinicians	clinician	NOUN
ajlm-933	111	4	and	and	CCONJ
ajlm-933	111	5	study	study	NOUN
ajlm-933	111	6	personnel	personnel	NOUN
ajlm-933	111	7	:	:	PUNCT
ajlm-933	111	8	the	the	DET
ajlm-933	111	9	cdc	cdc	PROPN
ajlm-933	111	10	-	-	PUNCT
ajlm-933	111	11	eswatini	eswatini	PROPN
ajlm-933	111	12	and	and	CCONJ
ajlm-933	111	13	cdc	cdc	PROPN
ajlm-933	111	14	-	-	PUNCT
ajlm-933	111	15	atlanta	atlanta	PROPN
ajlm-933	111	16	study	study	NOUN
ajlm-933	111	17	teams	team	NOUN
ajlm-933	111	18	,	,	PUNCT
ajlm-933	111	19	who	who	PRON
ajlm-933	111	20	were	be	AUX
ajlm-933	111	21	experienced	experience	VERB
ajlm-933	111	22	in	in	ADP
ajlm-933	111	23	crag	crag	NOUN
ajlm-933	111	24	screening	screening	NOUN
ajlm-933	111	25	,	,	PUNCT
ajlm-933	111	26	trained	train	VERB
ajlm-933	111	27	the	the	DET
ajlm-933	111	28	research	research	NOUN
ajlm-933	111	29	assistants	assistant	NOUN
ajlm-933	111	30	,	,	PUNCT
ajlm-933	111	31	clinicians	clinician	NOUN
ajlm-933	111	32	and	and	CCONJ
ajlm-933	111	33	laboratory	laboratory	NOUN
ajlm-933	111	34	personnel	personnel	NOUN
ajlm-933	111	35	involved	involve	VERB
ajlm-933	111	36	in	in	ADP
ajlm-933	111	37	the	the	DET
ajlm-933	111	38	care	care	NOUN
ajlm-933	111	39	of	of	ADP
ajlm-933	111	40	patients	patient	NOUN
ajlm-933	111	41	.	.	PUNCT
ajlm-933	112	1	the	the	DET
ajlm-933	112	2	training	training	NOUN
ajlm-933	112	3	of	of	ADP
ajlm-933	112	4	clinicians	clinician	NOUN
ajlm-933	112	5	and	and	CCONJ
ajlm-933	112	6	study	study	NOUN
ajlm-933	112	7	personnel	personnel	NOUN
ajlm-933	112	8	covered	cover	VERB
ajlm-933	112	9	the	the	DET
ajlm-933	112	10	following	follow	VERB
ajlm-933	112	11	topics	topic	NOUN
ajlm-933	112	12	:	:	PUNCT
ajlm-933	112	13	basic	basic	ADJ
ajlm-933	112	14	information	information	NOUN
ajlm-933	112	15	about	about	ADP
ajlm-933	112	16	cryptococcal	cryptococcal	ADJ
ajlm-933	112	17	disease	disease	NOUN
ajlm-933	112	18	,	,	PUNCT
ajlm-933	112	19	including	include	VERB
ajlm-933	112	20	early	early	ADV
ajlm-933	112	21	and	and	CCONJ
ajlm-933	112	22	disseminated	disseminate	VERB
ajlm-933	112	23	infection	infection	NOUN
ajlm-933	112	24	explanation	explanation	NOUN
ajlm-933	112	25	of	of	ADP
ajlm-933	112	26	the	the	DET
ajlm-933	112	27	rationale	rationale	NOUN
ajlm-933	112	28	behind	behind	ADP
ajlm-933	112	29	the	the	DET
ajlm-933	112	30	implementation	implementation	NOUN
ajlm-933	112	31	of	of	ADP
ajlm-933	112	32	this	this	DET
ajlm-933	112	33	screening	screen	VERB
ajlm-933	112	34	programme	programme	NOUN
ajlm-933	112	35	review	review	NOUN
ajlm-933	112	36	of	of	ADP
ajlm-933	112	37	the	the	DET
ajlm-933	112	38	algorithm	algorithm	NOUN
ajlm-933	112	39	for	for	ADP
ajlm-933	112	40	implementation	implementation	NOUN
ajlm-933	112	41	and	and	CCONJ
ajlm-933	112	42	associated	associated	ADJ
ajlm-933	112	43	study	study	NOUN
ajlm-933	112	44	forms	form	NOUN
ajlm-933	112	45	and	and	CCONJ
ajlm-933	112	46	documents	document	NOUN
ajlm-933	112	47	review	review	NOUN
ajlm-933	112	48	of	of	ADP
ajlm-933	112	49	procedure	procedure	NOUN
ajlm-933	112	50	for	for	ADP
ajlm-933	112	51	sending	send	VERB
ajlm-933	112	52	samples	sample	NOUN
ajlm-933	112	53	to	to	ADP
ajlm-933	112	54	the	the	DET
ajlm-933	112	55	national	national	ADJ
ajlm-933	112	56	reference	reference	PROPN
ajlm-933	112	57	laboratory	laboratory	NOUN
ajlm-933	112	58	and	and	CCONJ
ajlm-933	112	59	obtaining	obtain	VERB
ajlm-933	112	60	results	result	NOUN
ajlm-933	112	61	role	role	NOUN
ajlm-933	112	62	-	-	PUNCT
ajlm-933	112	63	playing	playing	NOUN
ajlm-933	112	64	using	use	VERB
ajlm-933	112	65	different	different	ADJ
ajlm-933	112	66	clinical	clinical	ADJ
ajlm-933	112	67	scenarios	scenario	NOUN
ajlm-933	112	68	in	in	ADP
ajlm-933	112	69	order	order	NOUN
ajlm-933	112	70	to	to	PART
ajlm-933	112	71	ensure	ensure	VERB
ajlm-933	112	72	proper	proper	ADJ
ajlm-933	112	73	adherence	adherence	NOUN
ajlm-933	112	74	to	to	ADP
ajlm-933	112	75	the	the	DET
ajlm-933	112	76	algorithm	algorithm	NOUN
ajlm-933	112	77	and	and	CCONJ
ajlm-933	112	78	flow	flow	NOUN
ajlm-933	112	79	of	of	ADP
ajlm-933	112	80	patients	patient	NOUN
ajlm-933	112	81	instructions	instruction	NOUN
ajlm-933	112	82	and	and	CCONJ
ajlm-933	112	83	practice	practice	NOUN
ajlm-933	112	84	in	in	ADP
ajlm-933	112	85	performing	perform	VERB
ajlm-933	112	86	and	and	CCONJ
ajlm-933	112	87	interpreting	interpret	VERB
ajlm-933	112	88	the	the	DET
ajlm-933	112	89	lfa	lfa	PROPN
ajlm-933	112	90	crag	crag	PROPN
ajlm-933	112	91	test	test	NOUN
ajlm-933	112	92	review	review	NOUN
ajlm-933	112	93	of	of	ADP
ajlm-933	112	94	the	the	DET
ajlm-933	112	95	procedure	procedure	NOUN
ajlm-933	112	96	for	for	ADP
ajlm-933	112	97	sending	send	VERB
ajlm-933	112	98	csf	csf	ADJ
ajlm-933	112	99	crag	crag	NOUN
ajlm-933	112	100	results	result	NOUN
ajlm-933	112	101	to	to	ADP
ajlm-933	112	102	hiv	hiv	PROPN
ajlm-933	112	103	care	care	PROPN
ajlm-933	112	104	centre	centre	PROPN
ajlm-933	112	105	staff	staff	NOUN
ajlm-933	112	106	reviewing	review	VERB
ajlm-933	112	107	standard	standard	ADJ
ajlm-933	112	108	operating	operating	NOUN
ajlm-933	112	109	procedures	procedure	NOUN
ajlm-933	112	110	relevant	relevant	ADJ
ajlm-933	112	111	to	to	ADP
ajlm-933	112	112	the	the	DET
ajlm-933	112	113	laboratory	laboratory	NOUN
ajlm-933	112	114	staff	staff	NOUN
ajlm-933	112	115	study	study	NOUN
ajlm-933	112	116	protocol	protocol	NOUN
ajlm-933	112	117	data	datum	NOUN
ajlm-933	112	118	collection	collection	NOUN
ajlm-933	112	119	tools	tool	NOUN
ajlm-933	112	120	research	research	NOUN
ajlm-933	112	121	ethics	ethic	NOUN
ajlm-933	112	122	quality	quality	NOUN
ajlm-933	112	123	assurance	assurance	NOUN
ajlm-933	112	124	.	.	PUNCT
ajlm-933	113	1	acknowledgements	acknowledgement	NOUN
ajlm-933	113	2	we	we	PRON
ajlm-933	113	3	would	would	AUX
ajlm-933	113	4	like	like	VERB
ajlm-933	113	5	to	to	PART
ajlm-933	113	6	thank	thank	VERB
ajlm-933	113	7	the	the	DET
ajlm-933	113	8	eswatini	eswatini	PROPN
ajlm-933	113	9	ministry	ministry	PROPN
ajlm-933	113	10	of	of	ADP
ajlm-933	113	11	health	health	PROPN
ajlm-933	113	12	,	,	PUNCT
ajlm-933	113	13	the	the	DET
ajlm-933	113	14	mbabane	mbabane	NOUN
ajlm-933	113	15	government	government	NOUN
ajlm-933	113	16	hospital	hospital	NOUN
ajlm-933	113	17	voluntary	voluntary	ADJ
ajlm-933	113	18	counseling	counseling	NOUN
ajlm-933	113	19	and	and	CCONJ
ajlm-933	113	20	testing	testing	NOUN
ajlm-933	113	21	clinic	clinic	NOUN
ajlm-933	113	22	,	,	PUNCT
ajlm-933	113	23	laboratory	laboratory	NOUN
ajlm-933	113	24	,	,	PUNCT
ajlm-933	113	25	and	and	CCONJ
ajlm-933	113	26	inpatient	inpatient	NOUN
ajlm-933	113	27	wards	ward	NOUN
ajlm-933	113	28	for	for	ADP
ajlm-933	113	29	facilitating	facilitate	VERB
ajlm-933	113	30	the	the	DET
ajlm-933	113	31	study	study	NOUN
ajlm-933	113	32	and	and	CCONJ
ajlm-933	113	33	all	all	PRON
ajlm-933	113	34	of	of	ADP
ajlm-933	113	35	the	the	DET
ajlm-933	113	36	patients	patient	NOUN
ajlm-933	113	37	and	and	CCONJ
ajlm-933	113	38	healthcare	healthcare	NOUN
ajlm-933	113	39	workers	worker	NOUN
ajlm-933	113	40	who	who	PRON
ajlm-933	113	41	participated	participate	VERB
ajlm-933	113	42	in	in	ADP
ajlm-933	113	43	this	this	DET
ajlm-933	113	44	study	study	NOUN
ajlm-933	113	45	.	.	PUNCT
ajlm-933	114	1	we	we	PRON
ajlm-933	114	2	thank	thank	VERB
ajlm-933	114	3	charmaine	charmaine	PROPN
ajlm-933	114	4	khudzie	khudzie	PROPN
ajlm-933	114	5	mlambo	mlambo	PROPN
ajlm-933	114	6	,	,	PUNCT
ajlm-933	114	7	lydia	lydia	PROPN
ajlm-933	114	8	mpango	mpango	PROPN
ajlm-933	114	9	and	and	CCONJ
ajlm-933	114	10	marianne	marianne	PROPN
ajlm-933	114	11	calnan	calnan	PROPN
ajlm-933	114	12	for	for	ADP
ajlm-933	114	13	being	be	AUX
ajlm-933	114	14	part	part	NOUN
ajlm-933	114	15	of	of	ADP
ajlm-933	114	16	the	the	DET
ajlm-933	114	17	team	team	NOUN
ajlm-933	114	18	that	that	PRON
ajlm-933	114	19	conceptualised	conceptualise	VERB
ajlm-933	114	20	this	this	DET
ajlm-933	114	21	study	study	NOUN
ajlm-933	114	22	,	,	PUNCT
ajlm-933	114	23	kelly	kelly	PROPN
ajlm-933	114	24	rose	rise	VERB
ajlm-933	114	25	-	-	PUNCT
ajlm-933	114	26	clarke	clarke	PROPN
ajlm-933	114	27	and	and	CCONJ
ajlm-933	114	28	greg	greg	PROPN
ajlm-933	114	29	greene	greene	PROPN
ajlm-933	114	30	for	for	ADP
ajlm-933	114	31	training	train	VERB
ajlm-933	114	32	data	datum	NOUN
ajlm-933	114	33	collectors	collector	NOUN
ajlm-933	114	34	,	,	PUNCT
ajlm-933	114	35	thokozani	thokozani	NOUN
ajlm-933	114	36	maseko	maseko	NOUN
ajlm-933	114	37	and	and	CCONJ
ajlm-933	114	38	mulungie	mulungie	NOUN
ajlm-933	114	39	mwembo	mwembo	ADJ
ajlm-933	114	40	for	for	ADP
ajlm-933	114	41	enrolling	enrol	VERB
ajlm-933	114	42	participants	participant	NOUN
ajlm-933	114	43	and	and	CCONJ
ajlm-933	114	44	collecting	collect	VERB
ajlm-933	114	45	specimens	specimen	NOUN
ajlm-933	114	46	,	,	PUNCT
ajlm-933	114	47	dan	dan	PROPN
ajlm-933	114	48	gama	gama	NOUN
ajlm-933	114	49	for	for	ADP
ajlm-933	114	50	facilitating	facilitate	VERB
ajlm-933	114	51	reagent	reagent	ADJ
ajlm-933	114	52	support	support	NOUN
ajlm-933	114	53	from	from	ADP
ajlm-933	114	54	the	the	DET
ajlm-933	114	55	african	african	ADJ
ajlm-933	114	56	society	society	NOUN
ajlm-933	114	57	for	for	ADP
ajlm-933	114	58	laboratory	laboratory	NOUN
ajlm-933	114	59	medicine	medicine	NOUN
ajlm-933	114	60	,	,	PUNCT
ajlm-933	114	61	and	and	CCONJ
ajlm-933	114	62	nombuso	nombuso	PROPN
ajlm-933	114	63	ntshalintshali	ntshalintshali	VERB
ajlm-933	114	64	for	for	ADP
ajlm-933	114	65	testing	test	VERB
ajlm-933	114	66	specimens	specimen	NOUN
ajlm-933	114	67	in	in	ADP
ajlm-933	114	68	the	the	DET
ajlm-933	114	69	laboratory	laboratory	NOUN
ajlm-933	114	70	.	.	PUNCT
ajlm-933	115	1	we	we	PRON
ajlm-933	115	2	are	be	AUX
ajlm-933	115	3	grateful	grateful	ADJ
ajlm-933	115	4	to	to	ADP
ajlm-933	115	5	brendan	brendan	PROPN
ajlm-933	115	6	r.	r.	PROPN
ajlm-933	115	7	jackson	jackson	PROPN
ajlm-933	115	8	,	,	PUNCT
ajlm-933	115	9	alexander	alexander	PROPN
ajlm-933	115	10	jordan	jordan	PROPN
ajlm-933	115	11	,	,	PUNCT
ajlm-933	115	12	and	and	CCONJ
ajlm-933	115	13	juliana	juliana	PROPN
ajlm-933	115	14	da	da	PROPN
ajlm-933	115	15	silva	silva	PROPN
ajlm-933	115	16	for	for	ADP
ajlm-933	115	17	providing	provide	VERB
ajlm-933	115	18	valuable	valuable	ADJ
ajlm-933	115	19	feedback	feedback	NOUN
ajlm-933	115	20	to	to	ADP
ajlm-933	115	21	the	the	DET
ajlm-933	115	22	draft	draft	NOUN
ajlm-933	115	23	manuscript	manuscript	NOUN
ajlm-933	115	24	.	.	PUNCT
ajlm-933	116	1	competing	compete	VERB
ajlm-933	116	2	interests	interest	NOUN
ajlm-933	116	3	authors	author	NOUN
ajlm-933	116	4	declare	declare	VERB
ajlm-933	116	5	that	that	SCONJ
ajlm-933	116	6	they	they	PRON
ajlm-933	116	7	have	have	VERB
ajlm-933	116	8	no	no	DET
ajlm-933	116	9	competing	compete	VERB
ajlm-933	116	10	interests	interest	NOUN
ajlm-933	116	11	.	.	PUNCT
ajlm-933	117	1	authors	author	NOUN
ajlm-933	117	2	’	’	PART
ajlm-933	117	3	contributions	contribution	NOUN
ajlm-933	117	4	s.m.h	s.m.h	ADJ
ajlm-933	117	5	.	.	PUNCT
ajlm-933	118	1	(	(	PUNCT
ajlm-933	118	2	project	project	NOUN
ajlm-933	118	3	team	team	NOUN
ajlm-933	118	4	leader	leader	NOUN
ajlm-933	118	5	)	)	PUNCT
ajlm-933	118	6	,	,	PUNCT
ajlm-933	118	7	p.e	p.e	PROPN
ajlm-933	118	8	.	.	PROPN
ajlm-933	118	9	,	,	PUNCT
ajlm-933	118	10	t.a	t.a	PROPN
ajlm-933	118	11	.	.	PROPN
ajlm-933	118	12	and	and	CCONJ
ajlm-933	118	13	t.c	t.c	PROPN
ajlm-933	118	14	.	.	PROPN
ajlm-933	118	15	conceived	conceive	VERB
ajlm-933	118	16	the	the	DET
ajlm-933	118	17	study	study	NOUN
ajlm-933	118	18	.	.	PUNCT
ajlm-933	119	1	r.j	r.j	PROPN
ajlm-933	119	2	.	.	PUNCT
ajlm-933	120	1	(	(	PUNCT
ajlm-933	120	2	overall	overall	ADJ
ajlm-933	120	3	study	study	NOUN
ajlm-933	120	4	implementation	implementation	NOUN
ajlm-933	120	5	coordinator	coordinator	NOUN
ajlm-933	120	6	)	)	PUNCT
ajlm-933	120	7	,	,	PUNCT
ajlm-933	120	8	s.m.h	s.m.h	ADP
ajlm-933	120	9	.	.	PUNCT
ajlm-933	120	10	,	,	PUNCT
ajlm-933	120	11	m.p	m.p	PROPN
ajlm-933	120	12	.	.	PROPN
ajlm-933	120	13	,	,	PUNCT
ajlm-933	120	14	t.a	t.a	PROPN
ajlm-933	120	15	.	.	PROPN
ajlm-933	120	16	,	,	PUNCT
ajlm-933	120	17	n.l	n.l	PROPN
ajlm-933	120	18	.	.	PROPN
ajlm-933	120	19	,	,	PUNCT
ajlm-933	120	20	s.m	s.m	PROPN
ajlm-933	120	21	.	.	PROPN
ajlm-933	120	22	and	and	CCONJ
ajlm-933	120	23	r.m.s	r.m.	NOUN
ajlm-933	120	24	.	.	PUNCT
ajlm-933	121	1	oversaw	oversaw	ADJ
ajlm-933	121	2	implementation	implementation	NOUN
ajlm-933	121	3	of	of	ADP
ajlm-933	121	4	the	the	DET
ajlm-933	121	5	study	study	NOUN
ajlm-933	121	6	.	.	PUNCT
ajlm-933	122	1	m.t	m.t	PROPN
ajlm-933	122	2	.	.	PROPN
ajlm-933	122	3	and	and	CCONJ
ajlm-933	122	4	r.j	r.j	PROPN
ajlm-933	122	5	.	.	PROPN
ajlm-933	122	6	performed	perform	VERB
ajlm-933	122	7	the	the	DET
ajlm-933	122	8	analysis	analysis	NOUN
ajlm-933	122	9	,	,	PUNCT
ajlm-933	122	10	and	and	CCONJ
ajlm-933	122	11	m.t	m.t	PROPN
ajlm-933	122	12	.	.	PROPN
ajlm-933	122	13	,	,	PUNCT
ajlm-933	122	14	s.m.h	s.m.h	ADJ
ajlm-933	122	15	.	.	PROPN
ajlm-933	122	16	,	,	PUNCT
ajlm-933	122	17	m.m	m.m	PROPN
ajlm-933	122	18	.	.	PROPN
ajlm-933	122	19	and	and	CCONJ
ajlm-933	122	20	r.j	r.j	PROPN
ajlm-933	122	21	.	.	PROPN
ajlm-933	122	22	wrote	write	VERB
ajlm-933	122	23	the	the	DET
ajlm-933	122	24	original	original	ADJ
ajlm-933	122	25	draft	draft	NOUN
ajlm-933	122	26	.	.	PUNCT
ajlm-933	123	1	all	all	DET
ajlm-933	123	2	authors	author	NOUN
ajlm-933	123	3	read	read	VERB
ajlm-933	123	4	and	and	CCONJ
ajlm-933	123	5	approved	approve	VERB
ajlm-933	123	6	the	the	DET
ajlm-933	123	7	final	final	ADJ
ajlm-933	123	8	manuscript	manuscript	NOUN
ajlm-933	123	9	.	.	PUNCT
ajlm-933	124	1	source	source	NOUN
ajlm-933	124	2	of	of	ADP
ajlm-933	124	3	support	support	NOUN
ajlm-933	124	4	the	the	DET
ajlm-933	124	5	study	study	NOUN
ajlm-933	124	6	was	be	AUX
ajlm-933	124	7	made	make	VERB
ajlm-933	124	8	possible	possible	ADJ
ajlm-933	124	9	by	by	ADP
ajlm-933	124	10	the	the	DET
ajlm-933	124	11	generous	generous	ADJ
ajlm-933	124	12	support	support	NOUN
ajlm-933	124	13	of	of	ADP
ajlm-933	124	14	the	the	DET
ajlm-933	124	15	american	american	ADJ
ajlm-933	124	16	people	people	NOUN
ajlm-933	124	17	through	through	ADP
ajlm-933	124	18	the	the	DET
ajlm-933	124	19	united	united	PROPN
ajlm-933	124	20	states	states	PROPN
ajlm-933	124	21	president	president	PROPN
ajlm-933	124	22	’s	’s	PART
ajlm-933	124	23	emergency	emergency	NOUN
ajlm-933	124	24	plan	plan	NOUN
ajlm-933	124	25	for	for	ADP
ajlm-933	124	26	aids	aid	NOUN
ajlm-933	124	27	relief	relief	NOUN
ajlm-933	124	28	through	through	ADP
ajlm-933	124	29	the	the	DET
ajlm-933	124	30	united	united	PROPN
ajlm-933	124	31	states	states	PROPN
ajlm-933	124	32	centers	center	NOUN
ajlm-933	124	33	for	for	ADP
ajlm-933	124	34	disease	disease	NOUN
ajlm-933	124	35	control	control	NOUN
ajlm-933	124	36	and	and	CCONJ
ajlm-933	124	37	prevention	prevention	NOUN
ajlm-933	124	38	under	under	ADP
ajlm-933	124	39	the	the	DET
ajlm-933	124	40	provision	provision	NOUN
ajlm-933	124	41	of	of	ADP
ajlm-933	124	42	hiv	hiv	PROPN
ajlm-933	124	43	/	/	SYM
ajlm-933	124	44	aids	aid	NOUN
ajlm-933	124	45	and	and	CCONJ
ajlm-933	124	46	tb	tb	ADP
ajlm-933	124	47	related	relate	VERB
ajlm-933	124	48	laboratory	laboratory	NOUN
ajlm-933	124	49	support	support	NOUN
ajlm-933	124	50	and	and	CCONJ
ajlm-933	124	51	technical	technical	ADJ
ajlm-933	124	52	assistance	assistance	NOUN
ajlm-933	124	53	project	project	NOUN
ajlm-933	124	54	in	in	ADP
ajlm-933	124	55	eswatini	eswatini	NOUN
ajlm-933	124	56	managed	manage	VERB
ajlm-933	124	57	by	by	ADP
ajlm-933	124	58	university	university	PROPN
ajlm-933	124	59	research	research	PROPN
ajlm-933	124	60	co.	co.	PROPN
ajlm-933	124	61	,	,	PUNCT
ajlm-933	124	62	llc	llc	PROPN
ajlm-933	124	63	(	(	PUNCT
ajlm-933	124	64	cooperative	cooperative	ADJ
ajlm-933	124	65	agreement	agreement	NOUN
ajlm-933	124	66	number	number	NOUN
ajlm-933	124	67	1u2g	1u2g	NUM
ajlm-933	124	68	/	/	SYM
ajlm-933	124	69	ps001896	ps001896	NOUN
ajlm-933	124	70	and	and	CCONJ
ajlm-933	124	71	principal	principal	ADJ
ajlm-933	124	72	investigator	investigator	NOUN
ajlm-933	124	73	–	–	PUNCT
ajlm-933	124	74	dr	dr	PROPN
ajlm-933	124	75	.	.	PROPN
ajlm-933	124	76	neeraj	neeraj	PROPN
ajlm-933	124	77	kak	kak	PROPN
ajlm-933	124	78	)	)	PUNCT
ajlm-933	124	79	.	.	PUNCT
ajlm-933	125	1	study	study	NOUN
ajlm-933	125	2	reagents	reagent	NOUN
ajlm-933	125	3	were	be	AUX
ajlm-933	125	4	procured	procure	VERB
ajlm-933	125	5	through	through	ADP
ajlm-933	125	6	the	the	DET
ajlm-933	125	7	african	african	ADJ
ajlm-933	125	8	society	society	NOUN
ajlm-933	125	9	for	for	ADP
ajlm-933	125	10	laboratory	laboratory	NOUN
ajlm-933	125	11	medicine	medicine	NOUN
ajlm-933	125	12	.	.	PUNCT
ajlm-933	126	1	data	datum	NOUN
ajlm-933	126	2	availability	availability	NOUN
ajlm-933	126	3	statement	statement	NOUN
ajlm-933	126	4	the	the	DET
ajlm-933	126	5	data	datum	NOUN
ajlm-933	126	6	that	that	PRON
ajlm-933	126	7	support	support	VERB
ajlm-933	126	8	the	the	DET
ajlm-933	126	9	findings	finding	NOUN
ajlm-933	126	10	of	of	ADP
ajlm-933	126	11	this	this	DET
ajlm-933	126	12	study	study	NOUN
ajlm-933	126	13	are	be	AUX
ajlm-933	126	14	available	available	ADJ
ajlm-933	126	15	from	from	ADP
ajlm-933	126	16	the	the	DET
ajlm-933	126	17	corresponding	corresponding	ADJ
ajlm-933	126	18	author	author	NOUN
ajlm-933	126	19	,	,	PUNCT
ajlm-933	127	1	[	[	X
ajlm-933	127	2	s.m.h	s.m.h	ADJ
ajlm-933	127	3	.	.	PUNCT
ajlm-933	127	4	]	]	X
ajlm-933	127	5	,	,	PUNCT
ajlm-933	127	6	upon	upon	SCONJ
ajlm-933	127	7	reasonable	reasonable	ADJ
ajlm-933	127	8	request	request	NOUN
ajlm-933	127	9	.	.	PUNCT
ajlm-933	128	1	disclaimer	disclaimer	VERB
ajlm-933	128	2	the	the	DET
ajlm-933	128	3	findings	finding	NOUN
ajlm-933	128	4	and	and	CCONJ
ajlm-933	128	5	conclusion	conclusion	NOUN
ajlm-933	128	6	in	in	ADP
ajlm-933	128	7	this	this	DET
ajlm-933	128	8	report	report	NOUN
ajlm-933	128	9	are	be	AUX
ajlm-933	128	10	those	those	PRON
ajlm-933	128	11	of	of	ADP
ajlm-933	128	12	the	the	DET
ajlm-933	128	13	authors	author	NOUN
ajlm-933	128	14	and	and	CCONJ
ajlm-933	128	15	do	do	AUX
ajlm-933	128	16	not	not	PART
ajlm-933	128	17	necessarily	necessarily	ADV
ajlm-933	128	18	represent	represent	VERB
ajlm-933	128	19	the	the	DET
ajlm-933	128	20	official	official	ADJ
ajlm-933	128	21	position	position	NOUN
ajlm-933	128	22	of	of	ADP
ajlm-933	128	23	the	the	DET
ajlm-933	128	24	centers	center	NOUN
ajlm-933	128	25	for	for	ADP
ajlm-933	128	26	disease	disease	NOUN
ajlm-933	128	27	control	control	NOUN
ajlm-933	128	28	and	and	CCONJ
ajlm-933	128	29	prevention	prevention	NOUN
ajlm-933	128	30	.	.	PUNCT
ajlm-933	129	1	references	reference	NOUN
ajlm-933	129	2	world	world	PROPN
ajlm-933	129	3	health	health	PROPN
ajlm-933	129	4	organization	organization	PROPN
ajlm-933	129	5	.	.	PUNCT
ajlm-933	130	1	guidelines	guideline	NOUN
ajlm-933	130	2	for	for	ADP
ajlm-933	130	3	the	the	DET
ajlm-933	130	4	diagnosis	diagnosis	NOUN
ajlm-933	130	5	,	,	PUNCT
ajlm-933	130	6	prevention	prevention	NOUN
ajlm-933	130	7	,	,	PUNCT
ajlm-933	130	8	and	and	CCONJ
ajlm-933	130	9	management	management	NOUN
ajlm-933	130	10	of	of	ADP
ajlm-933	130	11	cryptococcal	cryptococcal	ADJ
ajlm-933	130	12	disease	disease	NOUN
ajlm-933	130	13	in	in	ADP
ajlm-933	130	14	hiv	hiv	PROPN
ajlm-933	130	15	-	-	PUNCT
ajlm-933	130	16	infected	infect	VERB
ajlm-933	130	17	adults	adult	NOUN
ajlm-933	130	18	,	,	PUNCT
ajlm-933	130	19	adolescents	adolescent	NOUN
ajlm-933	130	20	and	and	CCONJ
ajlm-933	130	21	children	child	NOUN
ajlm-933	130	22	,	,	PUNCT
ajlm-933	130	23	march	march	PROPN
ajlm-933	130	24	2018	2018	NUM
ajlm-933	130	25	:	:	PUNCT
ajlm-933	130	26	supplement	supplement	NOUN
ajlm-933	130	27	to	to	ADP
ajlm-933	130	28	the	the	DET
ajlm-933	130	29	2016	2016	NUM
ajlm-933	130	30	consolidated	consolidated	ADJ
ajlm-933	130	31	guidelines	guideline	NOUN
ajlm-933	130	32	of	of	ADP
ajlm-933	130	33	the	the	DET
ajlm-933	130	34	use	use	NOUN
ajlm-933	130	35	of	of	ADP
ajlm-933	130	36	antiretroviral	antiretroviral	ADJ
ajlm-933	130	37	drugs	drug	NOUN
ajlm-933	130	38	for	for	ADP
ajlm-933	130	39	treating	treat	VERB
ajlm-933	130	40	and	and	CCONJ
ajlm-933	130	41	preventing	prevent	VERB
ajlm-933	130	42	hiv	hiv	PROPN
ajlm-933	130	43	infection	infection	NOUN
ajlm-933	131	1	[	[	X
ajlm-933	131	2	homepage	homepage	NOUN
ajlm-933	131	3	on	on	ADP
ajlm-933	131	4	the	the	DET
ajlm-933	131	5	internet	internet	NOUN
ajlm-933	131	6	]	]	PUNCT
ajlm-933	131	7	.	.	PUNCT
ajlm-933	131	8	2018	2018	NUM
ajlm-933	132	1	[	[	X
ajlm-933	132	2	cited	cite	VERB
ajlm-933	132	3	2018	2018	NUM
ajlm-933	132	4	may	may	AUX
ajlm-933	132	5	18	18	NUM
ajlm-933	132	6	]	]	PUNCT
ajlm-933	132	7	.	.	PUNCT
ajlm-933	133	1	available	available	ADJ
ajlm-933	133	2	from	from	ADP
ajlm-933	133	3	:	:	PUNCT
ajlm-933	133	4	http://www.who.int/hiv/pub/guidelines/cryptococcal-disease/en/	http://www.who.int/hiv/pub/guidelines/cryptococcal-disease/en/	PROPN
ajlm-933	133	5	rajasingham	rajasingham	PROPN
ajlm-933	133	6	r	r	PROPN
ajlm-933	133	7	,	,	PUNCT
ajlm-933	133	8	smith	smith	PROPN
ajlm-933	133	9	rm	rm	PROPN
ajlm-933	133	10	,	,	PUNCT
ajlm-933	133	11	park	park	NOUN
ajlm-933	133	12	bj	bj	NOUN
ajlm-933	133	13	,	,	PUNCT
ajlm-933	133	14	et	et	PROPN
ajlm-933	133	15	al	al	PROPN
ajlm-933	133	16	.	.	PUNCT
ajlm-933	134	1	global	global	ADJ
ajlm-933	134	2	burden	burden	NOUN
ajlm-933	134	3	of	of	ADP
ajlm-933	134	4	disease	disease	NOUN
ajlm-933	134	5	of	of	ADP
ajlm-933	134	6	hiv	hiv	PROPN
ajlm-933	134	7	-	-	PUNCT
ajlm-933	134	8	associated	associate	VERB
ajlm-933	134	9	cryptococcal	cryptococcal	ADJ
ajlm-933	134	10	meningitis	meningitis	NOUN
ajlm-933	134	11	:	:	PUNCT
ajlm-933	134	12	an	an	DET
ajlm-933	134	13	updated	update	VERB
ajlm-933	134	14	analysis	analysis	NOUN
ajlm-933	134	15	.	.	PUNCT
ajlm-933	135	1	lancet	lancet	PROPN
ajlm-933	135	2	infect	infect	PROPN
ajlm-933	135	3	dis	dis	PROPN
ajlm-933	135	4	.	.	PUNCT
ajlm-933	136	1	2017;17(8):873–881	2017;17(8):873–881	X
ajlm-933	136	2	.	.	NOUN
ajlm-933	136	3	https://doi.org/10.1016/s1473-3099(17)30243-8	https://doi.org/10.1016/s1473-3099(17)30243-8	PROPN
ajlm-933	136	4	world	world	PROPN
ajlm-933	136	5	health	health	PROPN
ajlm-933	136	6	organization	organization	NOUN
ajlm-933	136	7	.	.	PUNCT
ajlm-933	137	1	rapid	rapid	ADJ
ajlm-933	137	2	advice	advice	NOUN
ajlm-933	137	3	:	:	PUNCT
ajlm-933	137	4	diagnosis	diagnosis	NOUN
ajlm-933	137	5	,	,	PUNCT
ajlm-933	137	6	prevention	prevention	NOUN
ajlm-933	137	7	and	and	CCONJ
ajlm-933	137	8	management	management	NOUN
ajlm-933	137	9	of	of	ADP
ajlm-933	137	10	cryptococcal	cryptococcal	ADJ
ajlm-933	137	11	disease	disease	NOUN
ajlm-933	137	12	in	in	ADP
ajlm-933	137	13	hiv	hiv	PROPN
ajlm-933	137	14	-	-	PUNCT
ajlm-933	137	15	infected	infect	VERB
ajlm-933	137	16	adults	adult	NOUN
ajlm-933	137	17	,	,	PUNCT
ajlm-933	137	18	adolescents	adolescent	NOUN
ajlm-933	137	19	and	and	CCONJ
ajlm-933	137	20	children	child	NOUN
ajlm-933	138	1	[	[	X
ajlm-933	138	2	homepage	homepage	NOUN
ajlm-933	138	3	on	on	ADP
ajlm-933	138	4	the	the	DET
ajlm-933	138	5	internet	internet	NOUN
ajlm-933	138	6	]	]	PUNCT
ajlm-933	138	7	.	.	PUNCT
ajlm-933	138	8	2011	2011	NUM
ajlm-933	139	1	[	[	X
ajlm-933	139	2	cited	cite	VERB
ajlm-933	139	3	2018	2018	NUM
ajlm-933	139	4	jan	jan	PROPN
ajlm-933	139	5	10	10	NUM
ajlm-933	139	6	]	]	PUNCT
ajlm-933	139	7	.	.	PUNCT
ajlm-933	140	1	available	available	ADJ
ajlm-933	140	2	from	from	ADP
ajlm-933	140	3	:	:	PUNCT
ajlm-933	140	4	http://www.who.int/hiv/pub/cryptococcal_disease2011/en/	http://www.who.int/hiv/pub/cryptococcal_disease2011/en/	NOUN
ajlm-933	140	5	boulware	boulware	PROPN
ajlm-933	140	6	dr	dr	PROPN
ajlm-933	140	7	,	,	PUNCT
ajlm-933	140	8	rolfes	rolfes	PROPN
ajlm-933	140	9	ma	ma	PROPN
ajlm-933	140	10	,	,	PUNCT
ajlm-933	140	11	rajasingham	rajasingham	PROPN
ajlm-933	140	12	r	r	PROPN
ajlm-933	140	13	,	,	PUNCT
ajlm-933	140	14	et	et	PROPN
ajlm-933	140	15	al	al	PROPN
ajlm-933	140	16	.	.	PROPN
ajlm-933	140	17	multisite	multisite	ADJ
ajlm-933	140	18	validation	validation	NOUN
ajlm-933	140	19	of	of	ADP
ajlm-933	140	20	cryptococcal	cryptococcal	ADJ
ajlm-933	140	21	antigen	antigen	ADJ
ajlm-933	140	22	lateral	lateral	ADJ
ajlm-933	140	23	flow	flow	NOUN
ajlm-933	140	24	assay	assay	NOUN
ajlm-933	140	25	and	and	CCONJ
ajlm-933	140	26	quantification	quantification	NOUN
ajlm-933	140	27	by	by	ADP
ajlm-933	140	28	laser	laser	NOUN
ajlm-933	140	29	thermal	thermal	ADJ
ajlm-933	140	30	contrast	contrast	NOUN
ajlm-933	140	31	.	.	PUNCT
ajlm-933	141	1	emerg	emerg	PROPN
ajlm-933	141	2	infect	infect	PROPN
ajlm-933	141	3	dis	dis	PROPN
ajlm-933	141	4	.	.	PUNCT
ajlm-933	142	1	2014;20(1):45	2014;20(1):45	X
ajlm-933	142	2	.	.	PUNCT
ajlm-933	143	1	https://doi.org/10.3201/eid2001.130906	https://doi.org/10.3201/eid2001.130906	DET
ajlm-933	143	2	meya	meya	PROPN
ajlm-933	143	3	db	db	PROPN
ajlm-933	143	4	,	,	PUNCT
ajlm-933	143	5	manabe	manabe	ADJ
ajlm-933	143	6	yc	yc	PROPN
ajlm-933	143	7	,	,	PUNCT
ajlm-933	143	8	castelnuovo	castelnuovo	PROPN
ajlm-933	143	9	b	b	PROPN
ajlm-933	143	10	,	,	PUNCT
ajlm-933	143	11	et	et	PROPN
ajlm-933	143	12	al	al	PROPN
ajlm-933	143	13	.	.	PROPN
ajlm-933	143	14	serum	serum	PROPN
ajlm-933	143	15	cryptococcal	cryptococcal	ADJ
ajlm-933	143	16	antigen	antigen	NOUN
ajlm-933	143	17	(	(	PUNCT
ajlm-933	143	18	crag	crag	NOUN
ajlm-933	143	19	)	)	PUNCT
ajlm-933	143	20	screening	screening	NOUN
ajlm-933	143	21	is	be	AUX
ajlm-933	143	22	a	a	DET
ajlm-933	143	23	cost	cost	NOUN
ajlm-933	143	24	-	-	PUNCT
ajlm-933	143	25	effective	effective	ADJ
ajlm-933	143	26	method	method	NOUN
ajlm-933	143	27	to	to	PART
ajlm-933	143	28	prevent	prevent	VERB
ajlm-933	143	29	death	death	NOUN
ajlm-933	143	30	in	in	ADP
ajlm-933	143	31	hiv	hiv	PROPN
ajlm-933	143	32	-	-	PUNCT
ajlm-933	143	33	infected	infect	VERB
ajlm-933	143	34	persons	person	NOUN
ajlm-933	143	35	with	with	ADP
ajlm-933	143	36	cd4≤	cd4≤	PROPN
ajlm-933	143	37	100	100	NUM
ajlm-933	143	38	/	/	SYM
ajlm-933	143	39	μl	μl	ADP
ajlm-933	143	40	starting	start	VERB
ajlm-933	143	41	hiv	hiv	PROPN
ajlm-933	143	42	therapy	therapy	NOUN
ajlm-933	143	43	in	in	ADP
ajlm-933	143	44	resource	resource	NOUN
ajlm-933	143	45	-	-	PUNCT
ajlm-933	143	46	limited	limit	VERB
ajlm-933	143	47	settings	setting	NOUN
ajlm-933	143	48	.	.	PUNCT
ajlm-933	144	1	clin	clin	PROPN
ajlm-933	144	2	infect	infect	PROPN
ajlm-933	144	3	dis	dis	PROPN
ajlm-933	144	4	.	.	PUNCT
ajlm-933	145	1	2010;51(4):448	2010;51(4):448	NUM
ajlm-933	145	2	.	.	PUNCT
ajlm-933	145	3	https://doi.org/10.1086/655143	https://doi.org/10.1086/655143	PROPN
ajlm-933	145	4	kozel	kozel	PROPN
ajlm-933	145	5	tr	tr	VERB
ajlm-933	145	6	,	,	PUNCT
ajlm-933	145	7	bauman	bauman	NOUN
ajlm-933	145	8	sk	sk	PROPN
ajlm-933	145	9	.	.	PROPN
ajlm-933	146	1	crag	crag	PROPN
ajlm-933	147	1	lateral	lateral	ADJ
ajlm-933	147	2	flow	flow	NOUN
ajlm-933	147	3	assay	assay	VERB
ajlm-933	147	4	for	for	ADP
ajlm-933	147	5	cryptococcosis	cryptococcosis	NOUN
ajlm-933	147	6	.	.	PUNCT
ajlm-933	148	1	expert	expert	NOUN
ajlm-933	148	2	opin	opin	NOUN
ajlm-933	148	3	med	med	ADJ
ajlm-933	148	4	diagn	diagn	NOUN
ajlm-933	148	5	.	.	PUNCT
ajlm-933	149	1	2012;6(3):245–251	2012;6(3):245–251	NUM
ajlm-933	149	2	.	.	PUNCT
ajlm-933	150	1	https://doi.org/10.1517/17530059.2012.681300	https://doi.org/10.1517/17530059.2012.681300	PUNCT
ajlm-933	151	1	nkambule	nkambule	NOUN
ajlm-933	151	2	r	r	NOUN
ajlm-933	151	3	,	,	PUNCT
ajlm-933	151	4	nuwagaba	nuwagaba	NOUN
ajlm-933	151	5	-	-	PUNCT
ajlm-933	151	6	biribonwoha	biribonwoha	PROPN
ajlm-933	151	7	h	h	NOUN
ajlm-933	151	8	,	,	PUNCT
ajlm-933	151	9	mnisi	mnisi	PROPN
ajlm-933	151	10	z	z	PROPN
ajlm-933	151	11	,	,	PUNCT
ajlm-933	151	12	et	et	PROPN
ajlm-933	151	13	al	al	PROPN
ajlm-933	151	14	.	.	PUNCT
ajlm-933	152	1	substantial	substantial	ADJ
ajlm-933	152	2	progress	progress	NOUN
ajlm-933	152	3	in	in	ADP
ajlm-933	152	4	confronting	confront	VERB
ajlm-933	152	5	the	the	DET
ajlm-933	152	6	hiv	hiv	PROPN
ajlm-933	152	7	epidemic	epidemic	NOUN
ajlm-933	152	8	in	in	ADP
ajlm-933	152	9	swaziland	swaziland	PROPN
ajlm-933	152	10	:	:	PUNCT
ajlm-933	152	11	first	first	ADJ
ajlm-933	152	12	evidence	evidence	NOUN
ajlm-933	152	13	of	of	ADP
ajlm-933	152	14	national	national	ADJ
ajlm-933	152	15	impact	impact	NOUN
ajlm-933	152	16	.	.	PUNCT
ajlm-933	153	1	in	in	ADP
ajlm-933	153	2	:	:	PUNCT
ajlm-933	153	3	proceedings	proceeding	NOUN
ajlm-933	153	4	from	from	ADP
ajlm-933	153	5	the	the	DET
ajlm-933	153	6	international	international	ADJ
ajlm-933	153	7	aids	aids	PROPN
ajlm-933	153	8	society	society	PROPN
ajlm-933	153	9	9th	9th	ADJ
ajlm-933	153	10	ias	ias	PROPN
ajlm-933	153	11	conference	conference	NOUN
ajlm-933	153	12	on	on	ADP
ajlm-933	153	13	hiv	hiv	PROPN
ajlm-933	153	14	science	science	NOUN
ajlm-933	153	15	,	,	PUNCT
ajlm-933	153	16	23	23	NUM
ajlm-933	153	17	-	-	SYM
ajlm-933	153	18	26	26	NUM
ajlm-933	153	19	july	july	PROPN
ajlm-933	153	20	2017	2017	NUM
ajlm-933	153	21	,	,	PUNCT
ajlm-933	153	22	paris	paris	PROPN
ajlm-933	153	23	,	,	PUNCT
ajlm-933	153	24	france	france	PROPN
ajlm-933	153	25	.	.	PUNCT
ajlm-933	154	1	abstract	abstract	ADJ
ajlm-933	154	2	5837	5837	NUM
ajlm-933	155	1	[	[	X
ajlm-933	155	2	homepage	homepage	NOUN
ajlm-933	155	3	on	on	ADP
ajlm-933	155	4	the	the	DET
ajlm-933	155	5	internet	internet	NOUN
ajlm-933	155	6	]	]	PUNCT
ajlm-933	155	7	.	.	PUNCT
ajlm-933	156	1	2017	2017	NUM
ajlm-933	157	1	[	[	X
ajlm-933	157	2	cited	cite	VERB
ajlm-933	157	3	2018	2018	NUM
ajlm-933	157	4	may	may	AUX
ajlm-933	157	5	18	18	NUM
ajlm-933	157	6	]	]	PUNCT
ajlm-933	157	7	.	.	PUNCT
ajlm-933	158	1	available	available	ADJ
ajlm-933	158	2	from	from	ADP
ajlm-933	158	3	:	:	PUNCT
ajlm-933	158	4	http://programme.ias2017.org/abstract/abstract/5837	http://programme.ias2017.org/abstract/abstract/5837	PROPN
ajlm-933	158	5	.	.	PUNCT
ajlm-933	159	1	swaziland	swaziland	PROPN
ajlm-933	159	2	central	central	ADJ
ajlm-933	159	3	statistical	statistical	ADJ
ajlm-933	159	4	office	office	NOUN
ajlm-933	159	5	.	.	PUNCT
ajlm-933	160	1	the	the	DET
ajlm-933	160	2	2017	2017	NUM
ajlm-933	160	3	population	population	NOUN
ajlm-933	160	4	and	and	CCONJ
ajlm-933	160	5	housing	housing	NOUN
ajlm-933	160	6	census	census	NOUN
ajlm-933	160	7	:	:	PUNCT
ajlm-933	160	8	preliminary	preliminary	ADJ
ajlm-933	160	9	results	result	NOUN
ajlm-933	161	1	[	[	X
ajlm-933	161	2	homepage	homepage	NOUN
ajlm-933	161	3	on	on	ADP
ajlm-933	161	4	the	the	DET
ajlm-933	161	5	internet	internet	NOUN
ajlm-933	161	6	]	]	PUNCT
ajlm-933	161	7	.	.	PUNCT
ajlm-933	162	1	mbabane	mbabane	NOUN
ajlm-933	162	2	;	;	PUNCT
ajlm-933	162	3	2017	2017	NUM
ajlm-933	162	4	[	[	PUNCT
ajlm-933	162	5	cited	cite	VERB
ajlm-933	162	6	2019	2019	NUM
ajlm-933	162	7	may	may	AUX
ajlm-933	162	8	17	17	NUM
ajlm-933	162	9	]	]	PUNCT
ajlm-933	162	10	.	.	PUNCT
ajlm-933	163	1	available	available	ADJ
ajlm-933	163	2	from	from	ADP
ajlm-933	163	3	:	:	PUNCT
ajlm-933	163	4	http://sz.one.un.org/content/unct/swaziland/en/home/news-centre/news/swaziland-releases-population-count-from-2017-housing-and-popula.html	http://sz.one.un.org/content/unct/swaziland/en/home/news-centre/news/swaziland-releases-population-count-from-2017-housing-and-popula.html	NOUN
ajlm-933	163	5	world	world	PROPN
ajlm-933	163	6	health	health	PROPN
ajlm-933	163	7	organization	organization	NOUN
ajlm-933	163	8	.	.	PUNCT
ajlm-933	164	1	guidelines	guideline	NOUN
ajlm-933	164	2	for	for	ADP
ajlm-933	164	3	managing	manage	VERB
ajlm-933	164	4	advanced	advanced	ADJ
ajlm-933	164	5	hiv	hiv	PROPN
ajlm-933	164	6	disease	disease	NOUN
ajlm-933	164	7	and	and	CCONJ
ajlm-933	164	8	rapid	rapid	ADJ
ajlm-933	164	9	initiation	initiation	NOUN
ajlm-933	164	10	of	of	ADP
ajlm-933	164	11	antiretroviral	antiretroviral	ADJ
ajlm-933	164	12	therapy	therapy	NOUN
ajlm-933	164	13	[	[	X
ajlm-933	164	14	homepage	homepage	NOUN
ajlm-933	164	15	on	on	ADP
ajlm-933	164	16	the	the	DET
ajlm-933	164	17	internet	internet	NOUN
ajlm-933	164	18	]	]	PUNCT
ajlm-933	164	19	.	.	PUNCT
ajlm-933	165	1	2017	2017	NUM
ajlm-933	166	1	[	[	X
ajlm-933	166	2	cited	cite	VERB
ajlm-933	166	3	2018	2018	NUM
ajlm-933	166	4	jan	jan	PROPN
ajlm-933	166	5	12	12	NUM
ajlm-933	166	6	]	]	PUNCT
ajlm-933	166	7	.	.	PUNCT
ajlm-933	167	1	available	available	ADJ
ajlm-933	167	2	from	from	ADP
ajlm-933	167	3	:	:	PUNCT
ajlm-933	167	4	http://www.who.int/hiv/pub/guidelines/advanced-hiv-disease/en/	http://www.who.int/hiv/pub/guidelines/advanced-hiv-disease/en/	PROPN
ajlm-933	167	5	govender	govender	NOUN
ajlm-933	167	6	n	n	CCONJ
ajlm-933	167	7	,	,	PUNCT
ajlm-933	167	8	meintjes	meintjes	ADJ
ajlm-933	167	9	g	g	NOUN
ajlm-933	167	10	,	,	PUNCT
ajlm-933	167	11	bicanic	bicanic	PROPN
ajlm-933	167	12	t	t	PROPN
ajlm-933	167	13	,	,	PUNCT
ajlm-933	167	14	et	et	PROPN
ajlm-933	167	15	al	al	PROPN
ajlm-933	167	16	.	.	PROPN
ajlm-933	167	17	guideline	guideline	NOUN
ajlm-933	167	18	for	for	ADP
ajlm-933	167	19	the	the	DET
ajlm-933	167	20	prevention	prevention	NOUN
ajlm-933	167	21	,	,	PUNCT
ajlm-933	167	22	diagnosis	diagnosis	NOUN
ajlm-933	167	23	and	and	CCONJ
ajlm-933	167	24	management	management	NOUN
ajlm-933	167	25	of	of	ADP
ajlm-933	167	26	cryptococcal	cryptococcal	ADJ
ajlm-933	167	27	meningitis	meningitis	NOUN
ajlm-933	167	28	among	among	ADP
ajlm-933	167	29	hiv	hiv	PROPN
ajlm-933	167	30	-	-	PUNCT
ajlm-933	167	31	infected	infect	VERB
ajlm-933	167	32	persons	person	NOUN
ajlm-933	167	33	:	:	PUNCT
ajlm-933	167	34	2013	2013	NUM
ajlm-933	167	35	update	update	NOUN
ajlm-933	167	36	.	.	PUNCT
ajlm-933	168	1	s	s	PROPN
ajlm-933	168	2	afr	afr	PROPN
ajlm-933	168	3	j	j	PROPN
ajlm-933	168	4	hiv	hiv	PROPN
ajlm-933	168	5	med	me	VERB
ajlm-933	168	6	.	.	PUNCT
ajlm-933	169	1	2013;14(2):76–86	2013;14(2):76–86	NUM
ajlm-933	169	2	.	.	PUNCT
ajlm-933	170	1	https://doi.org/10.4102/sajhivmed.v14i2.82	https://doi.org/10.4102/sajhivmed.v14i2.82	PROPN
ajlm-933	170	2	jarvis	jarvis	PROPN
ajlm-933	170	3	jn	jn	PROPN
ajlm-933	170	4	,	,	PUNCT
ajlm-933	170	5	lawn	lawn	NOUN
ajlm-933	170	6	sd	sd	NOUN
ajlm-933	170	7	,	,	PUNCT
ajlm-933	170	8	vogt	vogt	PROPN
ajlm-933	170	9	m	m	PROPN
ajlm-933	170	10	,	,	PUNCT
ajlm-933	170	11	et	et	PROPN
ajlm-933	170	12	al	al	PROPN
ajlm-933	170	13	.	.	PUNCT
ajlm-933	170	14	screening	screen	VERB
ajlm-933	170	15	for	for	ADP
ajlm-933	170	16	cryptococcal	cryptococcal	ADJ
ajlm-933	170	17	antigenemia	antigenemia	NOUN
ajlm-933	170	18	in	in	ADP
ajlm-933	170	19	patients	patient	NOUN
ajlm-933	170	20	accessing	access	VERB
ajlm-933	170	21	an	an	DET
ajlm-933	170	22	antiretroviral	antiretroviral	ADJ
ajlm-933	170	23	treatment	treatment	NOUN
ajlm-933	170	24	program	program	NOUN
ajlm-933	170	25	in	in	ADP
ajlm-933	170	26	south	south	PROPN
ajlm-933	170	27	africa	africa	PROPN
ajlm-933	170	28	.	.	PUNCT
ajlm-933	171	1	clin	clin	PROPN
ajlm-933	171	2	infect	infect	PROPN
ajlm-933	171	3	dis	dis	PROPN
ajlm-933	171	4	.	.	PUNCT
ajlm-933	172	1	2009;48(7):856–862	2009;48(7):856–862	NUM
ajlm-933	172	2	.	.	PUNCT
ajlm-933	173	1	https://doi.org/10.1086/597262	https://doi.org/10.1086/597262	DET
ajlm-933	173	2	ministry	ministry	PROPN
ajlm-933	173	3	of	of	ADP
ajlm-933	173	4	health	health	PROPN
ajlm-933	173	5	:	:	PUNCT
ajlm-933	173	6	swaziland	swaziland	PROPN
ajlm-933	173	7	.	.	PUNCT
ajlm-933	174	1	swaziland	swaziland	PROPN
ajlm-933	174	2	integrated	integrate	VERB
ajlm-933	174	3	hiv	hiv	PROPN
ajlm-933	174	4	management	management	NOUN
ajlm-933	174	5	guidelines	guideline	NOUN
ajlm-933	175	1	[	[	X
ajlm-933	175	2	homepage	homepage	NOUN
ajlm-933	175	3	on	on	ADP
ajlm-933	175	4	the	the	DET
ajlm-933	175	5	internet	internet	NOUN
ajlm-933	175	6	]	]	PUNCT
ajlm-933	175	7	.	.	PUNCT
ajlm-933	175	8	2018	2018	NUM
ajlm-933	176	1	[	[	X
ajlm-933	176	2	cited	cite	VERB
ajlm-933	176	3	18	18	NUM
ajlm-933	176	4	may	may	PROPN
ajlm-933	176	5	2019	2019	NUM
ajlm-933	176	6	]	]	PUNCT
ajlm-933	176	7	.	.	PUNCT
ajlm-933	177	1	available	available	ADJ
ajlm-933	177	2	from	from	ADP
ajlm-933	177	3	:	:	PUNCT
ajlm-933	177	4	http://www.infocenter.nercha.org.sz/sites/default/files/swaziland%20integrated%20hiv%20management%20guidelines_0.pdf	http://www.infocenter.nercha.org.sz/sites/default/files/swaziland%20integrated%20hiv%20management%20guidelines_0.pdf	PROPN
ajlm-933	177	5	greene	greene	PROPN
ajlm-933	177	6	g	g	PROPN
ajlm-933	177	7	,	,	PUNCT
ajlm-933	177	8	sriruttan	sriruttan	PROPN
ajlm-933	177	9	c	c	X
ajlm-933	177	10	,	,	PUNCT
ajlm-933	177	11	le	le	PROPN
ajlm-933	177	12	t	t	PROPN
ajlm-933	177	13	,	,	PUNCT
ajlm-933	177	14	et	et	PROPN
ajlm-933	177	15	al	al	PROPN
ajlm-933	177	16	.	.	PUNCT
ajlm-933	178	1	looking	look	VERB
ajlm-933	178	2	for	for	ADP
ajlm-933	178	3	fungi	fungus	NOUN
ajlm-933	178	4	in	in	ADP
ajlm-933	178	5	all	all	DET
ajlm-933	178	6	the	the	DET
ajlm-933	178	7	right	right	ADJ
ajlm-933	178	8	places	place	NOUN
ajlm-933	178	9	:	:	PUNCT
ajlm-933	178	10	screening	screen	VERB
ajlm-933	178	11	for	for	ADP
ajlm-933	178	12	cryptococcal	cryptococcal	ADJ
ajlm-933	178	13	disease	disease	NOUN
ajlm-933	178	14	and	and	CCONJ
ajlm-933	178	15	other	other	ADJ
ajlm-933	178	16	aids	aids	PROPN
ajlm-933	178	17	-	-	PUNCT
ajlm-933	178	18	related	relate	VERB
ajlm-933	178	19	mycoses	mycose	NOUN
ajlm-933	178	20	among	among	ADP
ajlm-933	178	21	patients	patient	NOUN
ajlm-933	178	22	with	with	ADP
ajlm-933	178	23	advanced	advanced	ADJ
ajlm-933	178	24	hiv	hiv	PROPN
ajlm-933	178	25	disease	disease	NOUN
ajlm-933	178	26	.	.	PUNCT
ajlm-933	179	1	curr	curr	PROPN
ajlm-933	179	2	opin	opin	PROPN
ajlm-933	179	3	hiv	hiv	PROPN
ajlm-933	179	4	aids	aids	PROPN
ajlm-933	179	5	.	.	PUNCT
ajlm-933	180	1	2017;12(2):139–147	2017;12(2):139–147	X
ajlm-933	180	2	.	.	PUNCT
ajlm-933	181	1	https://doi.org/10.1097/coh.0000000000000347	https://doi.org/10.1097/coh.0000000000000347	PROPN
ajlm-933	181	2	beyene	beyene	PROPN
ajlm-933	181	3	t	t	PROPN
ajlm-933	181	4	,	,	PUNCT
ajlm-933	181	5	woldeamanuel	woldeamanuel	PROPN
ajlm-933	181	6	y	y	PROPN
ajlm-933	181	7	,	,	PUNCT
ajlm-933	181	8	asrat	asrat	PROPN
ajlm-933	181	9	d	d	PROPN
ajlm-933	181	10	,	,	PUNCT
ajlm-933	181	11	et	et	PROPN
ajlm-933	181	12	al	al	PROPN
ajlm-933	181	13	.	.	PROPN
ajlm-933	181	14	comparison	comparison	NOUN
ajlm-933	181	15	of	of	ADP
ajlm-933	181	16	cryptococcal	cryptococcal	ADJ
ajlm-933	181	17	antigenemia	antigenemia	NOUN
ajlm-933	181	18	between	between	ADP
ajlm-933	181	19	antiretroviral	antiretroviral	ADJ
ajlm-933	181	20	naïve	naïve	ADJ
ajlm-933	181	21	and	and	CCONJ
ajlm-933	181	22	antiretroviral	antiretroviral	ADJ
ajlm-933	181	23	experienced	experience	VERB
ajlm-933	181	24	hiv	hiv	PROPN
ajlm-933	181	25	positive	positive	ADJ
ajlm-933	181	26	patients	patient	NOUN
ajlm-933	181	27	at	at	ADP
ajlm-933	181	28	two	two	NUM
ajlm-933	181	29	hospitals	hospital	NOUN
ajlm-933	181	30	in	in	ADP
ajlm-933	181	31	ethiopia	ethiopia	PROPN
ajlm-933	181	32	.	.	PUNCT
ajlm-933	182	1	plos	plos	PROPN
ajlm-933	182	2	one	one	NUM
ajlm-933	182	3	.	.	PUNCT
ajlm-933	183	1	2013;8(10):e75585	2013;8(10):e75585	ADJ
ajlm-933	183	2	.	.	PUNCT
ajlm-933	184	1	https://doi.org/10.1371/journal.pone.0075585	https://doi.org/10.1371/journal.pone.0075585	NOUN
ajlm-933	184	2	boulware	boulware	PROPN
ajlm-933	184	3	dr	dr	PROPN
ajlm-933	184	4	,	,	PUNCT
ajlm-933	184	5	meya	meya	PROPN
ajlm-933	184	6	db	db	PROPN
ajlm-933	184	7	,	,	PUNCT
ajlm-933	184	8	muzoora	muzoora	PROPN
ajlm-933	184	9	c	c	NOUN
ajlm-933	184	10	,	,	PUNCT
ajlm-933	184	11	et	et	PROPN
ajlm-933	184	12	al	al	PROPN
ajlm-933	184	13	.	.	PUNCT
ajlm-933	184	14	timing	timing	NOUN
ajlm-933	184	15	of	of	ADP
ajlm-933	184	16	antiretroviral	antiretroviral	ADJ
ajlm-933	184	17	therapy	therapy	NOUN
ajlm-933	184	18	after	after	ADP
ajlm-933	184	19	diagnosis	diagnosis	NOUN
ajlm-933	184	20	of	of	ADP
ajlm-933	184	21	cryptococcal	cryptococcal	ADJ
ajlm-933	184	22	meningitis	meningitis	NOUN
ajlm-933	184	23	.	.	PUNCT
ajlm-933	185	1	new	new	ADJ
ajlm-933	185	2	engl	engl	PROPN
ajlm-933	185	3	j	j	PROPN
ajlm-933	185	4	med	med	PROPN
ajlm-933	185	5	.	.	PUNCT
ajlm-933	186	1	2014;370(26):2487–2498	2014;370(26):2487–2498	X
ajlm-933	186	2	.	.	PUNCT
ajlm-933	187	1	https://doi.org/10.1056/nejmoa1312884	https://doi.org/10.1056/nejmoa1312884	PROPN
ajlm-933	187	2	jarvis	jarvis	PROPN
ajlm-933	187	3	jn	jn	PROPN
ajlm-933	187	4	,	,	PUNCT
ajlm-933	187	5	harrison	harrison	PROPN
ajlm-933	187	6	ts	ts	PROPN
ajlm-933	187	7	,	,	PUNCT
ajlm-933	187	8	lawn	lawn	NOUN
ajlm-933	187	9	sd	sd	NOUN
ajlm-933	187	10	,	,	PUNCT
ajlm-933	187	11	et	et	PROPN
ajlm-933	187	12	al	al	PROPN
ajlm-933	187	13	.	.	PROPN
ajlm-933	188	1	cost	cost	NOUN
ajlm-933	188	2	effectiveness	effectiveness	NOUN
ajlm-933	188	3	of	of	ADP
ajlm-933	188	4	cryptococcal	cryptococcal	ADJ
ajlm-933	188	5	antigen	antigen	NOUN
ajlm-933	188	6	screening	screen	VERB
ajlm-933	188	7	as	as	ADP
ajlm-933	188	8	a	a	DET
ajlm-933	188	9	strategy	strategy	NOUN
ajlm-933	188	10	to	to	PART
ajlm-933	188	11	prevent	prevent	VERB
ajlm-933	188	12	hiv	hiv	PROPN
ajlm-933	188	13	-	-	PUNCT
ajlm-933	188	14	associated	associate	VERB
ajlm-933	188	15	cryptococcal	cryptococcal	ADJ
ajlm-933	188	16	meningitis	meningitis	NOUN
ajlm-933	188	17	in	in	ADP
ajlm-933	188	18	south	south	PROPN
ajlm-933	188	19	africa	africa	PROPN
ajlm-933	188	20	.	.	PUNCT
ajlm-933	189	1	plos	plos	PROPN
ajlm-933	189	2	one	one	NUM
ajlm-933	189	3	.	.	PUNCT
ajlm-933	190	1	2013;8(7):e69288	2013;8(7):e69288	X
ajlm-933	190	2	.	.	PUNCT
ajlm-933	191	1	https://doi.org/10.1371/journal.pone.0069288	https://doi.org/10.1371/journal.pone.0069288	NOUN
ajlm-933	191	2	micol	micol	NOUN
ajlm-933	191	3	r	r	NOUN
ajlm-933	191	4	,	,	PUNCT
ajlm-933	191	5	tajahmady	tajahmady	NOUN
ajlm-933	191	6	a	a	PRON
ajlm-933	191	7	,	,	PUNCT
ajlm-933	191	8	lortholary	lortholary	ADJ
ajlm-933	191	9	o	o	NOUN
ajlm-933	191	10	,	,	PUNCT
ajlm-933	191	11	et	et	PROPN
ajlm-933	191	12	al	al	PROPN
ajlm-933	191	13	.	.	PUNCT
ajlm-933	191	14	cost	cost	NOUN
ajlm-933	191	15	-	-	PUNCT
ajlm-933	191	16	effectiveness	effectiveness	NOUN
ajlm-933	191	17	of	of	ADP
ajlm-933	191	18	primary	primary	ADJ
ajlm-933	191	19	prophylaxis	prophylaxis	NOUN
ajlm-933	191	20	of	of	ADP
ajlm-933	191	21	aids	aid	NOUN
ajlm-933	191	22	associated	associate	VERB
ajlm-933	191	23	cryptococcosis	cryptococcosis	NOUN
ajlm-933	191	24	in	in	ADP
ajlm-933	191	25	cambodia	cambodia	PROPN
ajlm-933	191	26	.	.	PUNCT
ajlm-933	192	1	plos	plos	PROPN
ajlm-933	192	2	one	one	NUM
ajlm-933	192	3	.	.	PUNCT
ajlm-933	193	1	2010;5(11):e13856	2010;5(11):e13856	PROPN
ajlm-933	193	2	.	.	PUNCT
ajlm-933	194	1	https://doi.org/10.1371/journal.pone.0013856	https://doi.org/10.1371/journal.pone.0013856	PROPN
ajlm-933	194	2	mfinanga	mfinanga	NOUN
ajlm-933	194	3	s	s	PROPN
ajlm-933	194	4	,	,	PUNCT
ajlm-933	194	5	chanda	chanda	PROPN
ajlm-933	195	1	d	d	PROPN
ajlm-933	195	2	,	,	PUNCT
ajlm-933	195	3	kivuyo	kivuyo	PROPN
ajlm-933	195	4	sl	sl	PROPN
ajlm-933	195	5	,	,	PUNCT
ajlm-933	195	6	et	et	PROPN
ajlm-933	195	7	al	al	PROPN
ajlm-933	195	8	.	.	PROPN
ajlm-933	196	1	cryptococcal	cryptococcal	ADJ
ajlm-933	196	2	meningitis	meningitis	NOUN
ajlm-933	196	3	screening	screening	NOUN
ajlm-933	196	4	and	and	CCONJ
ajlm-933	196	5	community	community	NOUN
ajlm-933	196	6	-	-	PUNCT
ajlm-933	196	7	based	base	VERB
ajlm-933	196	8	early	early	ADJ
ajlm-933	196	9	adherence	adherence	NOUN
ajlm-933	196	10	support	support	NOUN
ajlm-933	196	11	in	in	ADP
ajlm-933	196	12	people	people	NOUN
ajlm-933	196	13	with	with	ADP
ajlm-933	196	14	advanced	advanced	ADJ
ajlm-933	196	15	hiv	hiv	PROPN
ajlm-933	196	16	infection	infection	NOUN
ajlm-933	196	17	starting	start	VERB
ajlm-933	196	18	antiretroviral	antiretroviral	ADJ
ajlm-933	196	19	therapy	therapy	NOUN
ajlm-933	196	20	in	in	ADP
ajlm-933	196	21	tanzania	tanzania	PROPN
ajlm-933	196	22	and	and	CCONJ
ajlm-933	196	23	zambia	zambia	PROPN
ajlm-933	196	24	:	:	PUNCT
ajlm-933	196	25	an	an	DET
ajlm-933	196	26	open	open	ADJ
ajlm-933	196	27	-	-	PUNCT
ajlm-933	196	28	label	label	NOUN
ajlm-933	196	29	,	,	PUNCT
ajlm-933	196	30	randomised	randomise	VERB
ajlm-933	196	31	controlled	control	VERB
ajlm-933	196	32	trial	trial	NOUN
ajlm-933	196	33	.	.	PUNCT
ajlm-933	197	1	lancet	lancet	PROPN
ajlm-933	197	2	.	.	PUNCT
ajlm-933	198	1	2015;385(9983):2173–2182	2015;385(9983):2173–2182	PROPN
ajlm-933	198	2	.	.	PUNCT
ajlm-933	199	1	https://doi.org/10.1016/s0140-6736(15)60164-7	https://doi.org/10.1016/s0140-6736(15)60164-7	PROPN
ajlm-933	199	2	hakim	hakim	PROPN
ajlm-933	199	3	j	j	PROPN
ajlm-933	199	4	,	,	PUNCT
ajlm-933	199	5	musiime	musiime	PROPN
ajlm-933	199	6	v	v	NOUN
ajlm-933	199	7	,	,	PUNCT
ajlm-933	199	8	szubert	szubert	PROPN
ajlm-933	199	9	aj	aj	PROPN
ajlm-933	199	10	,	,	PUNCT
ajlm-933	199	11	et	et	PROPN
ajlm-933	199	12	al	al	PROPN
ajlm-933	199	13	.	.	PROPN
ajlm-933	199	14	enhanced	enhance	VERB
ajlm-933	199	15	prophylaxis	prophylaxis	ADJ
ajlm-933	199	16	plus	plus	CCONJ
ajlm-933	199	17	antiretroviral	antiretroviral	ADJ
ajlm-933	199	18	therapy	therapy	NOUN
ajlm-933	199	19	for	for	ADP
ajlm-933	199	20	advanced	advanced	ADJ
ajlm-933	199	21	hiv	hiv	PROPN
ajlm-933	199	22	infection	infection	NOUN
ajlm-933	199	23	in	in	ADP
ajlm-933	199	24	africa	africa	PROPN
ajlm-933	199	25	.	.	PUNCT
ajlm-933	200	1	new	new	ADJ
ajlm-933	200	2	engl	engl	PROPN
ajlm-933	200	3	j	j	PROPN
ajlm-933	200	4	med	med	PROPN
ajlm-933	200	5	.	.	PUNCT
ajlm-933	201	1	2017;377(3):233–245	2017;377(3):233–245	X
ajlm-933	201	2	.	.	PUNCT
ajlm-933	201	3	https://doi.org/10.1056/nejmoa1615822	https://doi.org/10.1056/nejmoa1615822	PROPN
ajlm-933	201	4	abassi	abassi	PROPN
ajlm-933	201	5	m	m	PROPN
ajlm-933	201	6	,	,	PUNCT
ajlm-933	201	7	rhein	rhein	PROPN
ajlm-933	201	8	j	j	PROPN
ajlm-933	201	9	,	,	PUNCT
ajlm-933	201	10	meya	meya	PROPN
ajlm-933	201	11	db	db	PROPN
ajlm-933	201	12	,	,	PUNCT
ajlm-933	201	13	et	et	PROPN
ajlm-933	201	14	al	al	PROPN
ajlm-933	201	15	,	,	PUNCT
ajlm-933	201	16	editors	editor	NOUN
ajlm-933	201	17	.	.	PUNCT
ajlm-933	202	1	cryptococcal	cryptococcal	ADJ
ajlm-933	202	2	disease	disease	NOUN
ajlm-933	202	3	in	in	ADP
ajlm-933	202	4	the	the	DET
ajlm-933	202	5	era	era	NOUN
ajlm-933	202	6	of	of	ADP
ajlm-933	202	7	“	"	PUNCT
ajlm-933	202	8	test	test	NOUN
ajlm-933	202	9	and	and	CCONJ
ajlm-933	202	10	treat	treat	NOUN
ajlm-933	202	11	”	"	PUNCT
ajlm-933	202	12	:	:	PUNCT
ajlm-933	202	13	is	be	AUX
ajlm-933	202	14	there	there	PRON
ajlm-933	202	15	cause	cause	VERB
ajlm-933	202	16	for	for	ADP
ajlm-933	202	17	concern	concern	NOUN
ajlm-933	202	18	?	?	PUNCT
ajlm-933	203	1	open	open	ADJ
ajlm-933	203	2	forum	forum	VERB
ajlm-933	203	3	infectious	infectious	ADJ
ajlm-933	203	4	diseases	disease	NOUN
ajlm-933	203	5	.	.	PUNCT
ajlm-933	204	1	oxford	oxford	PROPN
ajlm-933	204	2	university	university	PROPN
ajlm-933	204	3	press	press	VERB
ajlm-933	204	4	us	we	PRON
ajlm-933	204	5	;	;	PUNCT
ajlm-933	204	6	2017	2017	NUM
ajlm-933	204	7	.	.	PUNCT
ajlm-933	205	1	joint	joint	ADJ
ajlm-933	205	2	united	united	PROPN
ajlm-933	205	3	nations	nations	PROPN
ajlm-933	205	4	programme	programme	PROPN
ajlm-933	205	5	on	on	ADP
ajlm-933	205	6	hiv	hiv	PROPN
ajlm-933	205	7	/	/	SYM
ajlm-933	205	8	aids	aids	PROPN
ajlm-933	205	9	(	(	PUNCT
ajlm-933	205	10	unaids	unaid	NOUN
ajlm-933	205	11	)	)	PUNCT
ajlm-933	205	12	.	.	PUNCT
ajlm-933	206	1	90	90	NUM
ajlm-933	206	2	-	-	SYM
ajlm-933	206	3	90	90	NUM
ajlm-933	206	4	-	-	PUNCT
ajlm-933	206	5	90	90	NUM
ajlm-933	206	6	an	an	DET
ajlm-933	206	7	ambitious	ambitious	ADJ
ajlm-933	206	8	treatment	treatment	NOUN
ajlm-933	206	9	target	target	NOUN
ajlm-933	206	10	to	to	PART
ajlm-933	206	11	help	help	VERB
ajlm-933	206	12	end	end	VERB
ajlm-933	206	13	the	the	DET
ajlm-933	206	14	aids	aids	PROPN
ajlm-933	206	15	epidemic	epidemic	NOUN
ajlm-933	207	1	[	[	X
ajlm-933	207	2	homepage	homepage	NOUN
ajlm-933	207	3	on	on	ADP
ajlm-933	207	4	the	the	DET
ajlm-933	207	5	internet	internet	NOUN
ajlm-933	207	6	]	]	PUNCT
ajlm-933	207	7	.	.	PUNCT
ajlm-933	207	8	2014	2014	NUM
ajlm-933	208	1	[	[	X
ajlm-933	208	2	cited	cite	VERB
ajlm-933	208	3	18	18	NUM
ajlm-933	208	4	may	may	PROPN
ajlm-933	208	5	2019	2019	NUM
ajlm-933	208	6	]	]	PUNCT
ajlm-933	208	7	.	.	PUNCT
ajlm-933	209	1	available	available	ADJ
ajlm-933	209	2	from	from	ADP
ajlm-933	209	3	:	:	PUNCT
ajlm-933	209	4	http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf	http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf	VERB
ajlm-933	209	5	ford	ford	PROPN
ajlm-933	209	6	n	n	CCONJ
ajlm-933	209	7	,	,	PUNCT
ajlm-933	209	8	meintjes	meintjes	ADJ
ajlm-933	209	9	g	g	NOUN
ajlm-933	209	10	,	,	PUNCT
ajlm-933	209	11	calmy	calmy	ADV
ajlm-933	209	12	a	a	PRON
ajlm-933	209	13	,	,	PUNCT
ajlm-933	209	14	et	et	PROPN
ajlm-933	209	15	al	al	PROPN
ajlm-933	209	16	.	.	PUNCT
ajlm-933	210	1	managing	manage	VERB
ajlm-933	210	2	advanced	advanced	ADJ
ajlm-933	210	3	hiv	hiv	PROPN
ajlm-933	210	4	disease	disease	NOUN
ajlm-933	210	5	in	in	ADP
ajlm-933	210	6	a	a	DET
ajlm-933	210	7	public	public	ADJ
ajlm-933	210	8	health	health	NOUN
ajlm-933	210	9	approach	approach	NOUN
ajlm-933	210	10	.	.	PUNCT
ajlm-933	211	1	clin	clin	PROPN
ajlm-933	211	2	infect	infect	PROPN
ajlm-933	211	3	dis	dis	PROPN
ajlm-933	211	4	.	.	PUNCT
ajlm-933	212	1	2018;66(suppl_2):s106	2018;66(suppl_2):s106	NUM
ajlm-933	212	2	–	–	PUNCT
ajlm-933	212	3	s110	s110	PROPN
ajlm-933	212	4	.	.	PUNCT
ajlm-933	213	1	denning	den	VERB
ajlm-933	213	2	dw	dw	NOUN
ajlm-933	213	3	.	.	PUNCT
ajlm-933	213	4	minimizing	minimize	VERB
ajlm-933	213	5	fungal	fungal	ADJ
ajlm-933	213	6	disease	disease	NOUN
ajlm-933	213	7	deaths	death	NOUN
ajlm-933	213	8	will	will	AUX
ajlm-933	213	9	allow	allow	VERB
ajlm-933	213	10	the	the	DET
ajlm-933	213	11	unaids	unaid	NOUN
ajlm-933	213	12	target	target	NOUN
ajlm-933	213	13	of	of	ADP
ajlm-933	213	14	reducing	reduce	VERB
ajlm-933	213	15	annual	annual	ADJ
ajlm-933	213	16	aids	aid	NOUN
ajlm-933	213	17	deaths	death	NOUN
ajlm-933	213	18	below	below	ADP
ajlm-933	213	19	500	500	NUM
ajlm-933	213	20	000	000	NUM
ajlm-933	213	21	by	by	ADP
ajlm-933	213	22	2020	2020	NUM
ajlm-933	213	23	to	to	PART
ajlm-933	213	24	be	be	AUX
ajlm-933	213	25	realized	realize	VERB
ajlm-933	213	26	.	.	PUNCT
ajlm-933	214	1	phil	phil	PROPN
ajlm-933	214	2	trans	trans	PROPN
ajlm-933	214	3	royal	royal	PROPN
ajlm-933	214	4	soc	soc	PROPN
ajlm-933	214	5	b	b	NOUN
ajlm-933	214	6	:	:	PUNCT
ajlm-933	214	7	biol	biol	PROPN
ajlm-933	214	8	sci	sci	PROPN
ajlm-933	214	9	.	.	PROPN
ajlm-933	214	10	2016;371(1709):20150468	2016;371(1709):20150468	NUM
ajlm-933	214	11	.	.	PUNCT
ajlm-933	215	1	https://doi.org/10.1098/rstb.2015.0468	https://doi.org/10.1098/rstb.2015.0468	PROPN
ajlm-933	215	2	ford	ford	PROPN
ajlm-933	215	3	n	n	PROPN
ajlm-933	215	4	,	,	PUNCT
ajlm-933	215	5	shubber	shubber	PROPN
ajlm-933	215	6	z	z	PROPN
ajlm-933	215	7	,	,	PUNCT
ajlm-933	215	8	jarvis	jarvis	PROPN
ajlm-933	215	9	jn	jn	PROPN
ajlm-933	215	10	,	,	PUNCT
ajlm-933	215	11	et	et	PROPN
ajlm-933	215	12	al	al	PROPN
ajlm-933	215	13	.	.	PUNCT
ajlm-933	216	1	cd4	cd4	PROPN
ajlm-933	216	2	cell	cell	NOUN
ajlm-933	216	3	count	count	NOUN
ajlm-933	216	4	threshold	threshold	NOUN
ajlm-933	216	5	for	for	ADP
ajlm-933	216	6	cryptococcal	cryptococcal	ADJ
ajlm-933	216	7	antigen	antigen	NOUN
ajlm-933	216	8	screening	screening	NOUN
ajlm-933	216	9	of	of	ADP
ajlm-933	216	10	hiv	hiv	PROPN
ajlm-933	216	11	-	-	PUNCT
ajlm-933	216	12	infected	infect	VERB
ajlm-933	216	13	individuals	individual	NOUN
ajlm-933	216	14	:	:	PUNCT
ajlm-933	216	15	a	a	DET
ajlm-933	216	16	systematic	systematic	ADJ
ajlm-933	216	17	review	review	NOUN
ajlm-933	216	18	and	and	CCONJ
ajlm-933	216	19	meta	meta	ADJ
ajlm-933	216	20	-	-	PUNCT
ajlm-933	216	21	analysis	analysis	NOUN
ajlm-933	216	22	.	.	PUNCT
ajlm-933	217	1	clin	clin	PROPN
ajlm-933	217	2	infect	infect	PROPN
ajlm-933	217	3	dis	dis	PROPN
ajlm-933	217	4	.	.	PUNCT
ajlm-933	218	1	2018;66(suppl_2):s152	2018;66(suppl_2):s152	NUM
ajlm-933	218	2	–	–	PUNCT
ajlm-933	218	3	s159	s159	NUM
ajlm-933	218	4	.	.	PUNCT
ajlm-933	218	5	https://doi.org/10.1093/cid/cix1143	https://doi.org/10.1093/cid/cix1143	PROPN
ajlm-933	218	6	magambo	magambo	PROPN
ajlm-933	218	7	ka	ka	PROPN
ajlm-933	218	8	,	,	PUNCT
ajlm-933	218	9	kalluvya	kalluvya	PROPN
ajlm-933	218	10	se	se	PROPN
ajlm-933	218	11	,	,	PUNCT
ajlm-933	218	12	kapoor	kapoor	PROPN
ajlm-933	218	13	sw	sw	PROPN
ajlm-933	218	14	,	,	PUNCT
ajlm-933	218	15	et	et	PROPN
ajlm-933	218	16	al	al	PROPN
ajlm-933	218	17	.	.	PUNCT
ajlm-933	218	18	utility	utility	NOUN
ajlm-933	218	19	of	of	ADP
ajlm-933	218	20	urine	urine	NOUN
ajlm-933	218	21	and	and	CCONJ
ajlm-933	218	22	serum	serum	VERB
ajlm-933	218	23	lateral	lateral	ADJ
ajlm-933	218	24	flow	flow	NOUN
ajlm-933	218	25	assays	assay	NOUN
ajlm-933	218	26	to	to	PART
ajlm-933	218	27	determine	determine	VERB
ajlm-933	218	28	the	the	DET
ajlm-933	218	29	prevalence	prevalence	NOUN
ajlm-933	218	30	and	and	CCONJ
ajlm-933	218	31	predictors	predictor	NOUN
ajlm-933	218	32	of	of	ADP
ajlm-933	218	33	cryptococcal	cryptococcal	ADJ
ajlm-933	218	34	antigenemia	antigenemia	NOUN
ajlm-933	218	35	in	in	ADP
ajlm-933	218	36	hiv	hiv	PROPN
ajlm-933	218	37	-	-	PUNCT
ajlm-933	218	38	positive	positive	ADJ
ajlm-933	218	39	outpatients	outpatient	NOUN
ajlm-933	218	40	beginning	begin	VERB
ajlm-933	218	41	antiretroviral	antiretroviral	ADJ
ajlm-933	218	42	therapy	therapy	NOUN
ajlm-933	218	43	in	in	ADP
ajlm-933	218	44	mwanza	mwanza	PROPN
ajlm-933	218	45	,	,	PUNCT
ajlm-933	218	46	tanzania	tanzania	PROPN
ajlm-933	218	47	.	.	PUNCT
ajlm-933	219	1	j	j	PROPN
ajlm-933	219	2	int	int	PROPN
ajlm-933	219	3	aids	aids	PROPN
ajlm-933	219	4	soc	soc	NOUN
ajlm-933	219	5	.	.	PUNCT
ajlm-933	220	1	2014;17(1):19040	2014;17(1):19040	NUM
ajlm-933	220	2	.	.	PUNCT
ajlm-933	221	1	https://doi.org/10.7448/ias.17.1.19040	https://doi.org/10.7448/ias.17.1.19040	PROPN
ajlm-933	221	2	scriven	scriven	PROPN
ajlm-933	221	3	je	je	PROPN
ajlm-933	221	4	,	,	PUNCT
ajlm-933	221	5	lalloo	lalloo	NOUN
ajlm-933	221	6	dg	dg	NOUN
ajlm-933	221	7	,	,	PUNCT
ajlm-933	221	8	meintjes	meintjes	PROPN
ajlm-933	221	9	g.	g.	PROPN
ajlm-933	221	10	changing	change	VERB
ajlm-933	221	11	epidemiology	epidemiology	NOUN
ajlm-933	221	12	of	of	ADP
ajlm-933	221	13	hiv	hiv	PROPN
ajlm-933	221	14	-	-	PUNCT
ajlm-933	221	15	associated	associate	VERB
ajlm-933	221	16	cryptococcosis	cryptococcosis	NOUN
ajlm-933	221	17	in	in	ADP
ajlm-933	221	18	sub	sub	ADJ
ajlm-933	221	19	-	-	ADJ
ajlm-933	221	20	saharan	saharan	ADJ
ajlm-933	221	21	africa	africa	PROPN
ajlm-933	221	22	.	.	PUNCT
ajlm-933	222	1	lancet	lancet	PROPN
ajlm-933	222	2	infect	infect	PROPN
ajlm-933	222	3	dis	dis	PROPN
ajlm-933	222	4	.	.	PUNCT
ajlm-933	223	1	2016;16(8):891–892	2016;16(8):891–892	X
ajlm-933	223	2	.	.	PUNCT
ajlm-933	223	3	https://doi.org/10.1016/s1473-3099(16)30145-1	https://doi.org/10.1016/s1473-3099(16)30145-1	PROPN
ajlm-933	223	4	williamson	williamson	PROPN
ajlm-933	223	5	pr	pr	PROPN
ajlm-933	223	6	.	.	PUNCT
ajlm-933	224	1	the	the	DET
ajlm-933	224	2	relentless	relentless	ADJ
ajlm-933	224	3	march	march	NOUN
ajlm-933	224	4	of	of	ADP
ajlm-933	224	5	cryptococcal	cryptococcal	ADJ
ajlm-933	224	6	meningitis	meningitis	NOUN
ajlm-933	224	7	.	.	PUNCT
ajlm-933	225	1	lancet	lancet	PROPN
ajlm-933	225	2	infect	infect	PROPN
ajlm-933	225	3	dis	dis	PROPN
ajlm-933	225	4	.	.	PUNCT
ajlm-933	226	1	2017;17(8):790–791	2017;17(8):790–791	X
ajlm-933	226	2	.	.	PUNCT
ajlm-933	227	1	https://doi.org/10.1016/s1473-3099(17)30245-1	https://doi.org/10.1016/s1473-3099(17)30245-1	PROPN
ajlm-933	227	2	who	who	PRON
ajlm-933	227	3	.	.	PUNCT
ajlm-933	228	1	rapid	rapid	ADJ
ajlm-933	228	2	advice	advice	NOUN
ajlm-933	228	3	:	:	PUNCT
ajlm-933	228	4	diagnosis	diagnosis	NOUN
ajlm-933	228	5	,	,	PUNCT
ajlm-933	228	6	prevention	prevention	NOUN
ajlm-933	228	7	and	and	CCONJ
ajlm-933	228	8	management	management	NOUN
ajlm-933	228	9	of	of	ADP
ajlm-933	228	10	cryptococcal	cryptococcal	ADJ
ajlm-933	228	11	disease	disease	NOUN
ajlm-933	228	12	in	in	ADP
ajlm-933	228	13	hiv	hiv	PROPN
ajlm-933	228	14	-	-	PUNCT
ajlm-933	228	15	infected	infect	VERB
ajlm-933	228	16	adults	adult	NOUN
ajlm-933	228	17	,	,	PUNCT
ajlm-933	228	18	adolescents	adolescent	NOUN
ajlm-933	228	19	and	and	CCONJ
ajlm-933	228	20	children	child	NOUN
ajlm-933	229	1	[	[	X
ajlm-933	229	2	homepage	homepage	NOUN
ajlm-933	229	3	on	on	ADP
ajlm-933	229	4	the	the	DET
ajlm-933	229	5	internet	internet	NOUN
ajlm-933	229	6	]	]	PUNCT
ajlm-933	229	7	.	.	PUNCT
ajlm-933	229	8	2011	2011	NUM
ajlm-933	230	1	[	[	X
ajlm-933	230	2	cited	cite	VERB
ajlm-933	230	3	2019	2019	NUM
ajlm-933	230	4	may	may	AUX
ajlm-933	230	5	17	17	NUM
ajlm-933	230	6	]	]	PUNCT
ajlm-933	230	7	.	.	PUNCT
ajlm-933	231	1	available	available	ADJ
ajlm-933	231	2	from	from	ADP
ajlm-933	231	3	:	:	PUNCT
ajlm-933	231	4	https://apps.who.int/iris/bitstream/handle/10665/44786/9789241502979_eng.pdf?sequence=1	https://apps.who.int/iris/bitstream/handle/10665/44786/9789241502979_eng.pdf?sequence=1	NOUN